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  This research work focuses on trying to elucidate the underlying mechanisms of 
chronic pain. Here CSF samples obtained from chronic pain patients were analyzed in 
two perspectives: Firstly a new simple analysis method using HPLC for amino acids 
in CSF was developed, which was then subsequently applied to quantitatively analyze 
all physiological amino acids especially the nine pain-related amino acids (asparagine, 
aspartate, GABA, glutamate, glutamine, glycine, taurine, arginine and citrulline – NO 
markers) in the CSF of pregnant women in labor pain – as a representative acute pain 
and in no pain Caesarian patients. This method was also applied to analyze CSF 
samples from chronic pain patients and the data were all compared against acute pain 
and no pain control subjects. Though the excitatory and inhibitory amino acids are 
known to be important neurotransmitters, their direct correlation to different types of 
pain has not been so far studied. The amino acid analysis data from this work throws 
light on the differential roles of these pain-related amino acids in the different pain 
states and hints on possible roles for some of these amino acids as potential 
biomarkers for various pain conditions. 
  Secondly, a pain-related peptide – 7B2-C-terminal peptide (7B2CT) was isolated 
from the CSF of chronic pain patients by applying a multiple liquid chromatographic 
strategy – very different from proteomics technology. Though earlier known, the 
extracellular pathophysiological roles for this peptide especially related to pain 
mechanisms have not been studied to date. Attempts were made to characterize this 
7B2CT peptide using animal models and in vitro binding studies. The bioactivity 
 viii
 
studies on this peptide showed mechanical allodynia – pain hypersensitivity evoked 
by innocuous stimuli characteristic to neuropathic pain, by intrathecal administration 
of this peptide in naïve mice. This allodynic response was enhanced in neuropathic 
pain mouse models. The specific binding sites for this peptide have been shown to 
exist by receptor binding studies using membrane fractions from mouse brain and 
spinal cord and the regional distribution of these binding sites in rat and mouse brain 
were also analyzed. Further, these binding sites were increased in membrane fractions 
prepared from neuropathy model mice. In addition, some structure-function analyses 
on this peptide for its pain-related activity were also performed to identify the 
sequences in this peptide responsible for its bioactivity and receptor binding 
properties. The N-terminal hexadecapeptide fragment of this peptide produced the 
same allodynia effect as 7B2CT while the C-terminal tridecapeptide fragment showed 
the binding activity of 7B2CT and also interestingly blocked the allodynia evoked by 
7B2CT. The results from these peptide studies have identified possible important 
roles for this 7B2CT peptide in chronic pain perception and have opened new 
channels of research for the development of more effective therapeutics in chronic 
pain management. 
  In a nutshell, the main scope of this study has been to analyze and explicate chronic 
pain mechanisms from two viewpoints – amino acids analysis and peptide isolation 
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1.1 Pain – the challenges. 
 
  Pain is a multidimensional, sensory experience produced by complex neuronal 
events involving interplay of multiple neurotransmitter and neuromodulator systems. 
Pain is heterogenous and may vary in intensity (mild, moderate or severe), quality 
(sharp, burning or dull), duration (transient, intermittent or persistent) and referral 
(superficial or deep, localized or diffuse) (Woolf, 2004). Multiple molecular and 
cellular mechanisms operate alone and in combination within the peripheral and 
central nervous systems to produce the different forms of pain. Consequently, pain 
treatment must be targeted not at the general symptom, the pain, or its temporal 
properties, acute or chronic, but rather at the underlying neurobiological mechanisms 
responsible (Scholz and Woolf, 2002).  
  Pain has become a major health care problem as it interferes with daily activities. A 
WHO survey among 25,916 primary care patients across 15 centres in five continents 
reports that 22% of these patients complained of persistent pain over the past year 
(Gureje et al., 1998). Acute and chronic pain are an enormous problem world wide 
and in the United States alone it costs 650 million lost work days and $65 billion a 
year (Grichnik and Ferrante, 1991). Current therapeutics for pain management is only 
partially effective and may be accompanied by distressing side effects (Sindrup and 
Jensen, 1999) or even has abuse potential.  
  The mechanisms that individually or collectively produce pain need to be seen as 
representing the targets for the rational development of novel analgesics. One of the 





the nervous system. Some of the transmitters and receptors involved in pain 
transmission or modulation, especially peptides, excitatory amino acids (EAA) and 
inhibitory amino acids (IAA) are widely distributed throughout the nervous system. 
Most of these neuroactive substances are involved in multiple physiological functions 
and sometimes many neurotransmitters are co localized in a single neuron (Besson, 
1999). Except for a few newly developed agents, target-derived, specific agents for 
pain treatment are not available because the cellular mechanisms underlying pain 
states are poorly understood. 
  The life span of human beings and the survival rates of patients with pain-inducing 
disorders have increased as the consequence of rapid advancements in disease 
prevention, diagnosis and therapeutic interventions. Hence the demands of 
mechanism-based pain medications for improving quality of life are increasing 
rapidly (Luo, 2004). Thus, studying the mechanisms of nociception and searching for 
potential targets for specific pain therapies have become two of the top priorities on 













1.2 The Physiology of Pain 
   
  The major components of the nociceptive system include the nociceptors, afferent 
fibers, spinal cord and the brain. The peripheral endings of primary sensory neurons 
called nociceptors are activated by any harmful stimuli applied to the body. Discreet 
classes of nociceptors encode distinct intensities and modalities of pain. Diverse 
receptor molecules impart these specific properties to the different classes of 
nociceptors and these receptors mediate transduction. Two classes of primary afferent 
fibers convey such nociceptive inputs from the peripheral organs to the central 
nervous system – thinly-myelinated Aδ-fibers and the unmyelinated C-fibers. The 
terminals of these fibers synapse with numerous second order neurons located in the 
superficial laminae of the spinal dorsal horn and activate them. The excitatory amino 
acid neurotransmitter glutamate serves as the primary nociceptive neurotransmitter at 
these synapses by activating several glutamate receptors such as α-amino-3-hydroxy-
5-methyl-4-isoxazole propionic acid (AMPA) receptors, N-methyl-D-aspartate 
(NMDA) receptors and metabotropic glutamate receptors (mGLURs) (Kuner, 2004). 
  Afferent input from cutaneous and visceral nociceptors converge on spinal neurons 
and projection neurons in the spinal dorsal horn project to cell nuclei in supraspinal 
areas such as the thalamus, brain stem, midbrain etc… The synaptic junctions in the 
thalamus play a vital role in the integration and modulation of spinal nociceptive 
inputs. The nociceptive inputs are finally conducted to the cortex, where the pain 
sensation is perceived. The spinal component of the nociceptive system has received 





transmission of pain to brain – the component of pain perception, can prove effective 
in treating persistent pain without affecting the other normal functions. The 
spinothalamic tract involved in pain transmission may be intervened by surgical 
sectioning or otherwise to relieve intractable pain (Afifi and Bergman, 2005). 
 
Table 1.1 Physiology of the nociceptive system 
Components Nociceptor Afferent fibers Spinal cord Brain 
Normal 
function 









   
  Further the spinal nociceptive output is strongly modulated by the descending 
inhibitory systems that originate at the supraspinal sites such as periaqueductal gray, 
rostroventromedulla and pons. Stimulation of these brain regions either electrically or 
chemically by morphines and other opiates, produces analgesia in humans. These 
inhibitory pathways utilize monoamines such as noradrenaline and serotonin as 
neurotransmitters and terminate on nociceptive neurons in the spinal cord as well as 
on spinal inhibitory interneurons which store and release opioids and exert both pre-
synaptic and post-synaptic inhibitory actions at primary afferent synapses in the 
spinal dorsal horn by activating specific opioid receptors. Thus supraspinal pathways 






1.3 Pain – Classification 
 
  Pain has been defined by the International Association for the Study of Pain as “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage or described in terms of such damage” (Merskey, 1986). 
  Pain has been broadly classified as – transient pain, acute pain and chronic pain by 
Loeser and Melzack (1999). 
 
Transient Pain 
   Transient pain is elicited by the activation of nociceptive transducers in skin or 
other tissues of the body in the absence of tissue damage. The function of such pain to 
the individual is related to its speed of onset after stimulation is applied and speed of 
offset that indicates that the offending physical disturbance is no longer impinging 
upon the body. This type of pain evolved to protect man from physical damage by the 
environment or by over stress of body tissues (Loeser and Melzack, 1999). 
 
Acute pain 
  Acute pain is defined as pain temporally related to a precipitating event (Garcia and 
Altman, 1997). It is elicited by substantial injury of body tissue and activation of 
nociceptive transducers at the site of local tissue damage. The local injury alters the 
response characteristics of the nociceptors, their central connections and the 
autonomic nervous system in the region. This pain stops long before healing is 





persists for months or years is not classified as acute. This type of pain is seen after 
trauma, surgical interventions and some diseases (Loeser and Melzack, 1999). 
 
Chronic pain 
  The International Association for the Study of Pain defines chronic pain as pain that 
persists for at least 3 months and also includes more than 200 clinical syndromes in 
the classification of chronic pain (Merskey, 1986). Chronic pains such as lower back 
pain, postherpetic neuralgia, fibromyalgia are commonly triggered by an injury or 
disease, but may be perpetuated by factors other than the cause of the pain. The 
nervous system may be damaged by the original injury in such a way as to be unable 
to restore itself to a normal state. Chronic pain is unrelenting and often not treated 
effectively. It is likely that stress, environmental and affective factors may be 
superimposed on the original damaged tissue and contribute to the intensity and 
persistence of the pain. 
  Chronic pain differs from acute pain because therapies that provide only transient 
pain relief do not resolve the underlying pathological process. Chronic pain will 
continue when the treatment stops. It is not the duration of pain that distinguishes 
acute from chronic pain but more importantly, the inability of the body to restore its 
physiological functions to normal homeostatic levels (Loeser and Melzack, 1999).  
  
Cancer pain 
  Cancer pain is more complex and can be related to a variety of etiologic factors and 





constellation of pain characteristics, physical signs and data from laboratory, 
electrodiagnostic and radiographic tests (Caraceni and Portenoy, 1999). Efforts are 
being made to obtain additional information about the cancer pain characteristics, 
syndromes and pathophysiologies to provide useful background for the interpretation 
of these complicated pain characteristics. 
 
  Woolf (2004) has classified pain into four primary types as follows based on the 
cause resulting in pain. 
 
Nociceptive pain 
  Nociceptive pain is defined as a transient pain in response to a noxious stimulus and 
is a vital physiologic sensation. This nociceptive pain system is a key early warning 
device, an alarm system that announces the presence of a potentially damaging 
stimulus. To prevent damage to tissue, we have learned to associate certain categories 
of stimuli with danger that must be avoided if at all possible. This association is 
formed by linking noxious stimuli with a sensation that is intense and unpleasant: pain. 
Nociceptive pain must be controlled only under specific clinical situations, such as 
during surgery or medical procedures that damage tissue and after trauma. 
 
Inflammatory pain 
  Inflammatory pain is defined as spontaneous pain and hypersensitivity to pain in 
response to tissue damage and inflammation. If tissue damage occurs despite the 





diseases) inflammatory pain sets in. Inflammatory pain typically decreases as the 
damage and inflammatory response resolve 
 
Neuropathic pain 
  Neuropathic pain is defined as spontaneous pain and hypersensitivity to pain in 
association with damage to or a lesion of the nervous system. Neuropathic pain may 
result from lesions to the peripheral nervous system, as in patients with diabetic or 
AIDS polyneuropathy, post-herpetic neuralgia, or lumbar radiculopathy, or to the 
central nervous system, such as in patients with spinal cord injury, multiple sclerosis, 
or stroke (Koltzenburg and Scadding, 2001).  
 
Functional pain 
  Functional pain is an evolving concept. In this form of pain sensitivity, no 
neurologic deficit or peripheral abnormality can be detected. The pain is due to an 
abnormal responsiveness or function of the nervous system, in which heightened gain 
or sensitivity of the sensory apparatus amplifies symptoms. Several common 
conditions have features that may place them this category: for example, fibromyalgia, 
irritable bowel syndrome, some forms of noncardiac chest pain, and tension-type 
headache. It is not known why the central nervous system of patients with functional 








1.4 Neurotranmitters/neuromodulators in Pain 
 
  The molecular basis underlying different pain conditions differs widely even though 
some of these pain states may exhibit similar behavioural aspects. The numerous 
transmitters and modulators involved in pain transmission are widely distributed 
through out the nervous system. They co-exist in different regions and involve in 
complex interactions to make pain perception the most complicated and the least 
understood phenomenon. The neurotransmitters or neuromodulators could be 
generally classified based on their structure as small-molecule transmitters and 
neuroactive peptides. 
 
1.4.1 Small molecule neurotransmitters – monoamines 
 
1.4.1.1 Dopamine 
  Dopamine is a member of catecholamine family and is a neurohormone. There are 
two primary dopamine receptor-types: D1 (stimulatory) and D2 (inhibitory), both of 
which act through G-proteins. Painful stimulation increases the regional cerebral 
blood flow in the human striatum. Striatal dopamine may have an important role in 
pain regulation in humans and the striatal dopamine D2 receptor has been proposed as 
an important target for the diagnosis and treatment of chronic pain (Hagelberg et al., 
2004). The striatal administration of dopamine D2 receptor agonists suppresses and 
dopamine D2 receptor antagonists enhances pain-related responses in animal 





antagonists does not influence pain-related responses (Magnusson et al., 2000). Motor 
cortex stimulation, which has proved effective in treating some painful conditions in 
humans increases release of striatal dopamine (Strafella et al., 2003).  
 
1.4.1.2 Norepinephrine 
  Norepinephrine is also a catecholamine and is a neurotransmitter in the nervous 
system where it is released from noradrenergic neurons during synaptic transmission. 
This compound along with epinephrine effects the fight-or-flight response, activating 
the sympathetic nervous system to directly increase heart rate, release energy from fat, 
and increase muscle readiness.  
Electrical stimulation of brain sites such as the periaqueductal grey or the nucleus 
raphe magnus produces analgesia via the local spinal release of endogenous serotonin 
and norepinephrine. α2-adrenoceptors in C-fiber nociceptors are implicated in the 
sensitizing action of norepinephrine in a rat model of acute or persistent inflammation 
(Sato et al., 1991). Spinal application of norepinephrine (Yaksh, 1985; Sullivan et al., 
1987) and (2) electrical stimulation of cerebral noradrenergic cell nuclei elicit robust 
antinociception (Millan, 2002). 
 
1.4.1.3 Serotonin (5-hydroxytryptamine) 
  Serotonin (5-HT) is a monoamine neurotransmitter synthesised in serotonergic 
neurons in the central nervous system (CNS). Serotonin is believed to play an 
important part of the biochemistry of depression, bipolar disorder and anxiety. It is 





majority of serotonergic fibres which innervate structures involved in pain 
modulation. It is well documented that serotonin is released in dorsal horn following 
sciatic nerves stimulation, carrageenan-induced inflammatory pain and chronic pain 
states (Palazzo et al., 2004). Higher dose of serotonin attenuates the antinociceptive 
effects induced by norepinephrine at the spinal cord level and 5-HT2 receptor might 
mediate this effect (Zhang et al., 1995). 
 
1.4.2 Small molecule neurotransmitters – amino acids 
 
1.4.2.1 Glutamate 
  Glutamate is the main EAA in the mammalian CNS and mediates most of the 
excitatory synaptic transmission. Glutamate interaction with glutamate receptors is 
fundamental to excitatory transmission in the CNS and therefore plays important 
roles in both normal and pathophysiological nociception. Glutamate is released from 
the central terminals of the nociceptive primary afferents in the spinal cord upon 
noxious stimulation, activating primarily AMPA receptors on second order neurons. 
Prolonged activation of nociceptors, e.g., resulting from tissue damage, inflammation 
or nerve injury, evokes a continuous release of glutamate, which, in combination with 
co-released neuropeptides like substance P, can cause a longer-lasting membrane 
depolarization, relieve the voltage-dependant magnesium block of NMDA receptors 
and allow their activation by glutamate. This mechanism appears to play a key role in 
pain chronification (Chizh, 2002). Glutamate is removed from the extracellular space 





excitatory amino acid transporter (EAAT) family, which have been well characterized 
(Danbolt, 2001).Animal and human studies confirm the efficacy of NMDA 
antagonists in chronic pain states, including inflammatory and neuropathic pain 
(Fisher et al., 2000; Sang, 2000). Other types of glutamate receptors – kainite 
receptors (KA) and also metabotropic glutamate receptors together with the AMPA 
and the most popular NMDA receptors (Table 1.2) can be used as targets for 
pharmacological intervention for the treatment of pain. The major limitation for the 
use of clinically available NMDA antagonists for the treatment of pain is its 
unacceptable side-effects like psychotomimesis, ataxia, sedation, etc. (Chizh, 2002). 
One of the most promising strategies to dissociate the analgesia and side-effects is the 
development of subtype-selective NMDA antagonists (Hardman and Limbird, 2001) 
better tolerated due to their lower cross-reactivity to other receptors and ion channels. 
 
1.4.2.2 Aspartate 
  Aspartate is also a potent neuronal excitant, activating the same receptors as 
glutamate and thus suggested to also act as a neurotransmitter. However, there is only 
sparse evidence for this, since aspartic acid is rarely concentrated in synaptic vesicles, 
nor is it released from nerve terminals in a calcium-dependant manner (Doble, 1999). 
In some studies (Vollenweider et al., 1990) but not all (Levi et al., 1982) a calcium-
dependant release of aspartate in the cerebellum can be evoked by depolarizing 
stimuli. The best evidence for a transmitter role for aspartate comes from studies of 
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IR – ionophore receptor, GPCR – G protein-coupled receptor 
AP5 – DL-2-amino-5-phosphonopentanoic acid 
tACPD – trans-1-aminoacyclopentane-1,3-dicarboxylic acid 
AP4 – L(+)-2-amino-4-phosphonobutyric acid 
MCPG – (RS)-alpha-methylcarboxyphenylglycine 
NBQX - 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline 






  Glycine is known to serve two contrasting roles as a neurotransmitter in the central 
nervous system.  
  Firstly, it serves as an inhibitory neurotransmitter in the spinal cord, brainstem and 
retina, where it activates a ligand-gated Cl - channel. This glycine mediated 
neurotransmission involves storage of the transmitter in synaptic vesicles (Chaudhry 
et al., 1998; Sagne et al., 1997), transmitter release following neuronal depolarization 
(Mulder and Snyder, 1974) and glycine binding to and activation of specific Cl- 
permeable, ligand-gated ionotropic receptors on the postsynaptic neuron. The 
activation of receptor generates inhibitory postsynaptic potentials as a result of 
increasing Cl- conductance that are antagonized by strychnine (Werman et al., 1967). 
The synaptic action of glycine ends by recapture of neurotransmitter by specific high-
affinity transporters located in neuronal and glial plasma membranes (Neal and 
Pickles, 1969).  
  Secondly, besides its inhibitory action, glycine exerts a positive modulation on 
excitatory glutamatergic neurotransmission through NMDA receptors in the spinal 
nociceptive processing. Glycine behaves as an obligatory co-agonist with glutamate 
and glycine binding at the NMDA receptor site interacts allosterically with other sites 
in the receptor increasing the binding of glutamate. Conversely, glutamate itself 
increases the glycine site affinity (Leeson and Iversen, 2001). This pro-nociception 
effect can be modified by intrathecal injection (i.t) of D-serine, a full agonist at the 
glycine-binding site of NMDA receptors (Ahmadi et al., 2003; Muth-Selbach et al., 





be two to three orders of magnitude higher than its affinity to the strychnine-sensitive 
glycine receptors, which mediate the anti-nociceptive effect (Becker et al., 1988; 
Muth-Selbach et al., 2004)).  On the other hand, i.t. administered glycine has been 
shown to inhibit hyperalgesia in chronic pain animals (Simpson Jr et al., 1996; 
Simpson Jr et al., 1997). Taken together, these studies have demonstrated that 
exogenously administered D-serine and glycine could lead to a change in pain 
behaviours in animal models.  
 
1.4.2.4 GABA (γ-amino butyric acid) 
  GABA is the major inhibitory neurotransmitter of the brain, occurring in 30-40% of 
all synapses. It is most highly concentrated in the substantia nigra and globus pallidus 
nuclei of the basal ganglia, followed by the hypothalamus, the periaqueductal grey 
matter and the hippocampus.  
 
Table 1.3 GABA receptors pharmacology in the central nervous system 
Transmitter Receptor subtype Selective agonists Selective antagonists 
GABAA (IR) 
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  GABAA receptors represent Cl- ionophores that serve to hyperpolarize the cell body 
by increasing Cl- conductance (Borman et al., 1987). GABAB receptors are linked by 
a Gi protein to K+ channels and may be linked to calcium channels (Holz et al., 1989). 
  A single dose of GABA has been shown to reverse the neuropathic pain induced by 
nerve injury and the mechanisms that induce such hypersensitivity and that the 
response to such an intervention is lost over time after nerve injury (Eaton MJ et al., 
1999). GABAergic neurons in the trigeminal caudalis nucleus have been reported to 
be involved in the transmission of nociceptive information in inflammatory pain and 
that the blockade of the GABAA receptor with bicuculline prevents the behavioural 
expression of the pain perception (Viggiano et al., 2004). There has been growing 
interest in other 3-alkylated GABA analogues such as pregabalin (3-isobutyl-GABA), 
the S-(+) enantiomer, which has shown greater potency in animal pain models (Field 
Et al., 1997). It has also been shown that changes in GABA neurotransmission in the 
rostral agranular insular cortex can raise or lower the pain threshold - producing 
analgesia or hyperalgesia, respectively in freely moving rats (Jasmin et al., 2003).  
 
1.4.2.5 Other amino acids 
  Taurine modulates both excitatory and inhibitory neurotransmission. Taurine has 
been shown to activate Cl- influx through GABAA receptors in cerebellar granule 
cells in vitro through a direct interaction with GABAA receptors. Also it has been 
shown that mice fed with taurine show significantly elevated levels of GABA and 
also approximately a twofold increase in the expression of both isoforms of glutamic 





downstream of glutamate receptor activation through the regulation of cytoplasmic 
and intramitochondrial calcium homeostasis thus preventing neuronal damage 
associated with excitotoxicity. (El Idrissi and Trenkner,1999). 
  Proline, one of glutamate family (Tapiero et al., 2002), may also be involved in pain 
mechanisms as one of the proline specific transporters, the proton/amino acid co-
transporter PAT2 has been shown to be expressed in the spinal cord and brain, 
especially in the NMDA subtype glutamate receptor subunit (Renick et al., 1999; 
Rubio-Aliaga et al., 2004).  
  It has also been demonstrated that the four endogenous sulfur-containing amino 
acids: L-cysteic acid, L-cysteine sulfinic acid, L-homocysteic acid and L-homocysteic 
sulfinic acid when administered i.t. into conscious animals all produced dose-
dependant increases in the amounts of time animals spent exhibiting spontaneous 
nociceptive behaviours suggesting that these endogenous sulfur containing amino 
acids may play a role in spinally mediated nociception (Osborne and Coderre, 2003). 
 
1.4.3 Small molecule neurotransmitters – others 
 
1.4.3.1 Acetylcholine 
  Acetylcholine was the first neurotransmitter discovered and is the major 
neurotransmitter in the peripheral nervous system. Nicotinic cholinergic receptors 
have an important role in the central modulation of persistent pain and inflammation. 
The spinal administration of nicotinic cholinergic receptor agonist, epibatidine, 





The nicotinic agonists, when administered i.t have been shown to be potent excitants 
of dorsal horn systems, leading to spontaneous nociceptive response and the spinal 
release of excitatory amino acids (Khan et al., 1996). 
 
1.4.3.2 Adenosine (Purine) 
  Adenosine is an important neuromodulator in the CNS and regulates neuronal and 
non-neuronal cellular function (e.g. microglia) by actions on extracellular adenosine 
A1, A2A, A2B and A3 receptors. Adenosine also regulates pain  transmission in the 
spinal cord and in the periphery, and a number of agents can alter the extracellular 
availability of adenosine and subsequently modulate pain  transmission, particularly 
by activation of adenosine A1 receptors (Sawynok et al., 2003). Release of adenosine 
from both spinal and peripheral compartments has inhibitory effects on pain  
transmission. Adenosine produces long-lasting analgesia in a model of neuropathic 
pain (Lavand’homme and Eisenach, 1999). In humans, the spinal administration of 
adenosine also produces analgesia that is selective for sensitized states (Eisenach et 
al., 2002). Studies have shown that systemic administration of adenosine kinase 
inhibitors can produce antihyperalgesic and analgesic properties in inflammatory pain 
models (Jarvis et al., 2002). 
 
1.4.3.3 Nitric Oxide (NO) 
  Early evidence for a neuromodulatory action of endogenous NO derived from 
observations that glutamate, acting through NMDA receptors, rapidly augments the 





(Garthwaite et al., 1989). NO is synthesized by nitric oxide synthase (NOS) and 
stimulates soluble isoforms of guanylate cyclase. Many of its cellular effects are the 
results of NO-induced increases in the level of cGMP. Evidence that NO may mediate 
neuronal responses to excitatory amino acids was strengthened by the purification and 
cloning of a cerebellar NOS followed by the use of an antibody to identify this NOS 
related antigens in discrete population of neurons in striatum, hypothalamus, posterior 
pituitary, midbrain, basal forebrain and cerebellum of rat (Nathan, 1992). Glutamate 
released from certain presynaptic neurons elicits a Ca2+ transient in the postsynaptic 
neuron, activating its NOS. NO diffuses from the postsynaptic neuron in retrograde 
fashion to affect the presynaptic neuron (O’Dell et al., 1991; Nathan, 1992).  
  NO biosynthesis inhibitors produced antinociceptive effects in the mouse. This 
study as well as investigations that utilized other models suggests that NO plays a role 
in promoting nociceptive processing in the spinal cord (Meller et al., 1993). It has 
been shown that spinal nitric oxide synthesis inhibition blocks NMDA-induced 
thermal hyperalgesia and generates antinociceptive effects in the formalin test in rats 
(Malmberg and Yaksh, 1992). Chronic constriction injury accompanied by tactile and 
cold allodynia has been shown to cause profound alterations of NOS in the dorsal root 
ganglia and dorsal horn of the corresponding spinal segments (Cizkova et al., 2002). 
Injection of formalin into a hind paw evokes a biphasic spinal release of NO 
metabolites, which indicates that NO is involved in the central mechanism of 
inflammatory hyperalgesia at the spinal cord level (Okuda et al., 2001). Further 
systemic and i.t. administrations of NOS inhibitors reduce nociceptive responses to 





evidences strongly support the existence of important neuromodulatory roles for NO 
in the CNS especially in spinal transmission. 
 
1.4.3.4 Prostaglandins  
  Prostaglandins (PGs) are a group of C20 carboxylic acid containing a cyclopentane 
ring and act as local hormones in a number of pathophysiological processes including 
pain. The initial two reactions of PG synthesis from arachidonic acid to PGH2 via 
PGG2, are catalyzed by the enzyme PGH synthase (COX) and these are rate-limiting 
enzymes in the arachidonate cascade and inhibition of COXs by aspiring and other 
NSAIDs is commonly accepted as the mechanism by which these agents produce 
analgesic effects (Vane, 1971).            
  Evidence for a major role of PGE2 in mediating inflammation and pain among PGs 
is derived from following experiments; (1) therapeutic effect of NSAIDs resulted 
from the inhibition of COX, (2) peripherally administered PGE2 produced 
hyperalgesia in humans and experimental animals, and (3) anti-PGE2 monoclonal 
antibodies inhibited the phenylbenzoquione-induced nociception (Mnich et al., 1995). 
Therefore, it has long been considered that PGs are produced at the site of 
inflammation in the periphery and cause hyperalgesia as a local hormone (Ito et al., 
2001). Nociceptive behaviour has been shown to be accompanied by a biphasic 
release of PGE2 in the formalin test (Malmberg and Yaksh, 1995). Subcutaneous 
injections of selective COX-2 inhibitors into the affected hind paw relieved 





neuropathic pain (Syriatowicz et al., 1999). This implies that PGE2 may also be 
involved in pain associated with neuropathy in the periphery and spinal cord.  
 
1.4.4 Opioid peptides 
   
  The existence of endogenous opioid peptides has been known for more than 25 
years. The first opioid peptides to be discovered were the enkephalins. They are 
pentapeptides and their structure constitute the minimum sequence (Tyr-Gly-Gly-
Phe-X; X= Leu or Met) required for opioid activity (Table 1.4). The enkephalin units 
reside in the majority of opioid peptides, which appear to represent C-terminal 
extensions of pentapeptide entities. Other peptides like the endomorphins (Zadina et 
al., 1997) with even shorter structures having opioid activity have been identified.         
  The opioid peptides have received attention for their modulatory action in pain 
processing.  In brain, the opioid peptides (β-endorphin, dynorphins and enkephalins) 
are widely distributed whereas in spinal cord dynorphins are present mainly in 
interneurons while the spinal enkephalins are found mainly in long descending 
pathways from midbrain to the dorsal horn (Hallberg and Nyberg, 2003). Opioid 
peptides are also produced in non-neuronal cells such as endocrine cells and cells of 
the immune system. 
  It is known that opioid peptides are effective as analgesics through a central action. 
Opioid peptides produce analgesia by interacting with spinal and supraspinal opioid 
receptors including the four major categories of known opioid receptors – mu (µ), 





microinjection techniques to examine the pharmacology of local drug action have 
shown potent antinociceptive actions to be mediated by a receptor specific action at a 
number of sites within the brain, including the periaqueductal gray (µ receptor), the 
rostral ventral medulla (µ/δ receptor), the substantia niagra (µ receptor) and within the 
spinal dorsal horn (µ/ δ /κ receptor) (Yaksh, 1997). 
 
Table 1.4 Amino acid sequences of some mammalian opioids 

















  Enkephalins induce their effects mainly through activation of δ and µ-opioid 
receptors, while the dynorphins have preference for κ-opioid receptors, β-endorphin 
appears less selective and can produce its effect through all three receptors, although 
it seems like µ-opioid receptor is preferred.  The two other endogenous peptides, 





peptides interact with opiate receptors, the neurons become hyperpolarized. They 
have been found to inhibit neuronal excitability via two mechanisms: inhibition of 
calcium conductances and enhancement of potassium conductances. The endogenous 
opioid systems have a functional role in modulating pain perception and opioid 
agonists are therefore potent analgesics. 
  The heptadecepeptide nociceptin/orphanin FQ (NCP) is an endogenous opioid-like 
compound and plays an important role in a number of physiological functions. It was 
first identified and isolated from the rat brain (Reinscheid et al., 1995) and porcine 
hypothalamus (Meunier et al., 1995) and has been characterized as an endogenous 
ligand for the opioid receptor-like orphan receptor-1 (ORL-1). This is a G protein-
coupled receptor with considerable sequence homology to the opioid receptors. 
Recently the distribution of NCP in microdissected areas of CNS of human adult 
brain was studied using radioimmunoassay (Witta et al., 2004). The highest 
concentrations were measured in the dorsal central gray matter (periaqueductal gray), 
the locus coeruleus, the ventromedial nucleus of hypothalamus, the septum and the 
dorsal horn of the spinal cord. High concentrations were also detected in other 
hypothamamic nuclei, the inferior colliculus, the ventral central gray matter, the 
pontine tegmentum, the amygdala, the reticular formation and the spinal trigeminal 
nucleus. 
  When first administered intracerebroventricularly (i.c.v.) in mice, NCP was reported 
to increase reactivity to a painful stimulus (hyperalgesia) in the hot plate assay 
(Meunier et al., 1995). NCP induced hyperalgesia in mice was also observed in the 





The i.t. administration of ≥0.5 pmol NCP induces allodynia, a pain response to non-
noxious (tactile) stimulation, in mice (Okuda-Ashitaka et al., 1996). 
  NCP has also been shown to elicit a naloxone-sensitive analgesia in rats (Rossi et al., 
1998). Experiments have also revealed no i.c.v. NCP hyperalgesia on the radiant heat 
tail withdrawal test over a dose range spanning six orders of magnitude (4 fmol-10 
nmol) (Tian et al., 1997). Such conflicting results may be the outcome of many 
factors including differences in animal species used or difference in the NCP doses 
tried. The i.c.v. administration of NCP can influence numerous neural circuits in 
various brain regions and the net behavioural effects of NCP at different sites might 
be unrelated or even antagonistic (Darland et al., 1998). In clinical studies, plasma 
levels of NCP are shown to be affected especially in patients with chronic pain 
(Anderberg et al., 1998). 





























































DAMGO – [D-Ala2,N-Me-Phe4,Gly-ol5]-Enkephalin 
PL 017 – Tyr-Pro-MePhe-D-Pro 
CTOP – D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Phe-Thr-NH2 
DPDPE – [D-Pen2,5]-Enkephalin 
DSLET - [D-Ser2,Leu5,Thr6]-Enkephalin  
U-50488 –3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide  






  1.4.5 – Neuroactive peptides – Tachykinins 
 
  Substance P (SP), neurokinin A and neurokinin B are the well recognized members 
of the tachykinin family. These neuropeptides frequently named neurokinins share the 
common homologous C-terminal Phe-X-Gly-Leu-Met-NH2, where X is either Phe as 
in SP or Val as in neurokinin A and neurokinin B (Table 1.1). The tachykinin 
receptors, also known as neurokinin receptors, are subdivided into NK1, NK2 and 
NK3, their respective preferred agonists being SP, neurokinin A and neurokinin B. 
 
Table 1.6 Amino acid sequences of some mammalian Tachykinins 
Peptide Amino acid sequence 
Substance P Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 
Neurokinin A His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2 
Neurokinin B Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2 
 
1.4.5.1 Substance P (SP) 
  There is evidence that SP plays a role in transmission of pain sensation (Jessell, 
1982) and its elaboration in the CNS. A complex behaviour in mice suggested to be 
nociceptive has been reported upon i.t. administration of SP (Hilden and Wilcox, 
1981). Evidence for role of SP in pain transmission is more convincing in the 
periphery, from sensory nerve endings to the dorsal horns of the spinal cord, less so in 





SP has been shown to abolish the facilitatory effect of ATP on spontaneous glycine 
release in the neurons of trigeminal nucleus pars caudalis and hence has been 
suggested to play a significant role in hyperalgesia or chronic pain (Wang et al., 
2001). It has also been demonstrated that the nociceptin/orphanin FQ-induced 
nociceptive response is brought about in mice by SP release from peripheral nerve 
endings of nociceptive primary afferent neurons (Inoue et al., 1998). In the absence of 
noradrenaline, substance P acting at the NK1 receptor has been reported to cause 
chronic thermal hyperalgesia, and that the reduced opioid efficacy associated with a 
lack of noradrenaline is due to increased NK1-receptor stimulation (Jasmin et al., 
2002). 
 
1.4.5.2 Neurokinins A & B 
  Neurokinin A-like immunoreactivity has been detected in the spinal dorsal horn and 
skin with a similar distribution pattern as that of substance P-like immunoreactivity 
(Dalsgaard et al., 1985). The i.t. injection of neurokinin A in mice decreased the 
latency in the tail flick assay but did not alter the reactions in the hot plate test or the 
hypertonic saline assay (Gamse and Saria, 1986). More recently electrophysiological 
studies have shown that neurokinin A could play an important role in sensory 
transmission and modulation when high intensity of stimuli or tissue/nerve injury 
occurs and it contributes to sensory synaptic transmission in the spinal dorsal horn (Li 







1.4.6 – Neuroactive peptides - Bradykinins 
 
  Bradykinin – a nonapeptide and Kallidin – a decapeptide (Table 1.2) are implicated 
in many physiological and pathological processes. They participate in inflammation, 
pain and vascular processes and are stored in neuronal elements of the CNS where 
they function as neuromediators in various cerebral functions particularly in the 
control of nociceptive information. Two major kinin receptors – the B1 and B2 
receptors have been cloned and sequenced in many species. The two receptors are 
both involved in pain and inflammation, where the B2 receptor is mainly engaged in 
the acute phase, while the B1 receptor seems to be more important in the chronic 
phase of the inflammation (Couture et al., 2001). The B1 receptor has been 
demonstrated to play an essential physiological role in the modulation of spinal cord 
plasticity a central component of pain (Pesquero et al., 2000). 
 
Table 1.7 Amino acid sequences of Bradykinin and Kallidin 












1.4.7 Other neuroactive peptides 
 
1.4.7.1 Nocistatin (NST)   
  Nocistatin (NST) is a novel bioactive peptide produced from the same precursor as 
NCP, and it plays important roles in the regulation of pain transmission and learning 
and memory processes in the central nervous system. It is widely present in the spinal 
cord and brain. NST by itself did not affect nociception. Simultaneous injection of 
NST blocks the nociceptin-induced allodynia and hyperalgesia. The carboxy-terminal 
hexapeptide of NST (Glu-Gln-Lys-Gln-Leu-Gln) is conserved in bovine, human and 
murine species and this possesses the allodynia-blocking activity and endogenous 
NST was isolated from bovine brain. (Okuda-Ashitaka et al., 1998). In addition to 
bovine NST (17-amino acid peptide), mature forms of NST (Table 1.5) with 30, 35 
and 41 residues were identified in human, rat and mouse brains respectively (Lee et 
al., 1999). NST also attenuated the allodynia and hyperalgesia evoked by 
prostaglandin E2 and the inflammatory hyperalgesia induced by formalin or 
carrageenan/kaolin and reversed the NCP-induced inhibition of morphine analgesia at 
pictogram doses. (Okuda-Ashitaka and Ito, 2000). Various studies in different animal 
models and different nociceptive tests all suggest that NST is involved in the 
modulation of pain transmission. 
 
1.4.7.2 Neurotensin 
  This tridecapeptide – neurotensin was first isolated from CNS but later found in 





were found within laminae I and II but are most densely concentrated in lamina II of 
superficial dorsal horn (Furst, 1999). Iontophoresis of neurotensin selectively excites 
spinal nociceptors. 
  It was observed that neurotensin following its administration into the CSF, produces 
dose-related antinociceptive actions using the tail immersion, hot plate and writhing 
models (Yaksh, 1981). These actions were apparently independent of the opioid 
system since naloxone failed to inhibit antinociception produced by neurotensin. 
Some invitro experiments have also suggested a possible pharmacological interaction 
between neurotensin and SP. Although this peptide has not been comprehensively 
studied, the available neuroanatomical and pharmacological data support the concept 
that neurotensin may involve in modulation of pain transmission at the spinal cord 
level (Yaksh, 1981; Furst, 1999). 
 
1.4.7.3 Somatostatin 
  Somatostatin exerts a predominantly inhibitory effect on nociceptors. Somatostatin 
and its several analogues (e.g., octreotide) administered by various routes to animals 
and humans produced analgesia, partly reversible by naloxone. However, it seems 
likely that somatostatin-induced analgesia might be produced by nonopioid 
mechanisms as well (Dray, 1992). 
 
1.4.7.4 Cholecystokinin (CCK) 
  Cholecystokinin differs from other neuropeptides because it modulates spinal 





endogenous inhibitor of opioid-mediated analgesia (Baber et al., 1989; Dray, 1992). 
Given i.t. to the spinal cord, CCK antagonizes the analgesic action of µ-receptor 
agonists, but it does not normally produce hyperalgesia itself. However, peripheral 
nerve lesions increase the expression and release of CCK, which reduces the efficacy 
of opioids. It has also been demonstrated that CCK-B neurons are expressed in a high 
percentage of dorsal root ganglion neurons at all spinal levels and that CCK may 
antagonize opiate analgesia at the level of the primary afferent neuron itself.  
(Ghilardi et al., 1992). 
 
  Thus pain transmission is polygenic in the sense that it involves expression or 
modification of multiple rather than single factors or modulators (described above) in 
the sensory pathways. It is the unique interactions of these factors or modulators that 
underlie the pathogenesis of different types of pain. To further complicate the issue, 
pain perception in individuals is affected by social, environmental, gender, age and 
genetic factors. Therefore in order to treat the different complex pain conditions 
efficiently, the need of the hour is to develop new, specific and effective analgesics 
that – (1) target the underlying mechanisms of pain perception rather than rely on 
symptom relief and (2) are free from adverse intolerable side effects, addictive 









1.5 Aim and Scope of this study 
 
  Chronic pain associated with inflammation and nerve injury is unrelenting and often 
outlasts its biological usefulness. The therapeutics developed so far for controlling 
pain (e.g. NSAIDS, opioid analgesics, COX inhibitors etc…) have proved to be only 
partially effective and have their own drawbacks. Pain perception is mediated by the 
interplay of numerous neurotransmitters and neuromodulators present in the nervous 
system especially, neuroactive peptides, and the excitatory and inhibitory amino acids. 
Cerebrospinal fluid (CSF) circulates through the subarachnoid space around the brain, 
spinal cord and through the ventricles of the brain and should contain substances 
released or secreted from the nerve cells. Therefore, its contents reflect the changes 
occurring in the central neurons. CSF analysis represents a key tool in the diagnosis 
of a variety of central nervous diseases and in understanding the status and 
functioning of our CNS. Thus a better knowledge of the neurotransmitters and 
neuromodulators in CSF, especially their structures, synthesis, concentrations and 
functions can provide further insight into the complex pain perception mechanisms. 
  This is a two pronged study on CSF samples from chronic pain patients that 
approaches pain perception from two perspectives – 
(1) Amino acids concentration in CSF  
(2) New neuroactive peptides in CSF and their function 
  Amino acids - glutamate, aspartate, glycine and GABA are widely accepted as 
neurotransmitters in the mammalian brain. In addition to these, some physiological 





involved in pain perception as neurotransmitters and/or neuromodulators. Citrulline (a 
by product of NO synthesis) especially along with arginine (substrate of NO synthesis) 
has been used as an effective NO marker. The simultaneous quantitative 
determination of excitatory and inhibitory amino acids, NO and the other 
physiological amino acids in CSF of pain patients can aid in improving our 
understanding of the pathophysiology of pain. 
  Peptide concentrations in CSF are considered to reflect neuronal activity, which 
might be correlated to CNS disorders. Our current understanding of the 
pathophysiology of chronic pain is very limited and though several classes of 
compounds, including anticonvulsants, antiarrhythmics and local anaesthetics show 
some efficacy against neuropathic pain, they are required in very high doses that elicit 
severe side effects.  The identification and characterization of CNS-related peptides in 
CSF especially from chronic pain patients is vital for studying the neurochemistry and 
pathogenesis processes of this pain syndrome. These peptides could be new, clinically 
important neuronal markers of different pain states or could be potential analgesics in 
pain management without adverse side effects or abuse tendency – the major 
drawbacks of many painkillers in use today for managing chronic pain.   
  The aim of this study is thus (i) To try and further explicate the chronic pain 
mechanisms, by analysis of physiological amino acids by a newly developed method 
in CSF of chronic pain patients in comparison with other types of pain (Chapters 2 -4) 
and (ii) Isolation and characterization of a pain related peptide from CSF of chronic 
pain patients and thus probably hint on new potential therapeutics for better and 












A SIMPLE QUANTITATIVE HPLC METHOD FOR 
















  Glutamate, glycine and GABA are widely accepted as neurotransmitters in the 
mammalian brain. Further, many other physiological amino acids are also thought to 
be putative neurotransmitters or neuromodulators. As CSF bathes the whole CNS, its 
contents reflect changes occurring in the central neurons. An increase in the 
concentration of glutamate in CSF has been correlated with neuronal damages after 
stroke or acute brain injury (Thomas, 1995; Zhang et al., 2001; Ruppel et al., 2001). 
The simultaneous determination of EAAs, IAAs and NO has improved our 
understanding of the pathophysiology of pain (Larson et al., 2000; Hsu et al., 2001; 
Gallai et al., 2003).   
  Amino acids in physiological fluids and tissues are determined by post-column 
derivatization with ninhydrin or o-phthalaldehyde (OPA) by commercially available 
amino acid analyzers. Alternatively, they can also be analyzed by pre-column 
derivatization with different reagents such as dansyl chloride, phenylisothiocyanate, 
fluorenylmethyl chloroformate, dabsyl chloride and OPA, followed by HPLC 
separation (Fuerst et al., 1990; Sarwar and Botting, 1993; Fisher et al., 2001). Pre-
column derivatization with OPA has been predominantly used for analysis of amino 
acids in CSF (Spink et al., 1986; Larson et al., 2000; Hsu et al., 2001). However, the 
method has two major drawbacks, OPA only reacts with primary amines and the 
OPA-adducts are unstable (Watanabe et al., 1992; Fuerst et al., 2000). Further, the 
reaction procedures including the CSF sample storage conditions and the pre-
treatment used for amino acids analysis in physiological fluids have not been 




standardized, making it difficult to compare the results from different laboratories 
(Sarwar and Botting, 1993; Jimenez-Jimenez et al., 1996; Rizzo et al., 1996; Levine 
et al., 2000; Mou et al., 2002). For instance, different deproteination methods have 
been used for analyzing amino acids from CSF samples; these include trichloroacetic 
acid (Fuerst et al., 1990; Rizzo et al., 1996; Gallai et al., 2003), sulfosalicylic acid 
(Jimenez-Jimenez et al., 1996), methanol (Alfredsson et al., 1998), ethanol (Davy and 
Ersser, 1990), acetonitrile (Jansen et al., 1991), and ultrafiltration (Krause et al., 1995; 
Guecueyener et al., 1999; Larson et al., 2000) while others analyzed CSF without 
deproteination (Ruppel et al., 2001). Pretreatment has been shown to adversely affect 
the quantitative results of amino acids (Krause et al., 1995; Zhang et al., 2003). 
  Chang et al first reported the use of dabsyl chloride to convert primary and 
secondary amines to their colored derivatives and subsequently separated them by 
HPLC (Chang et al., 1983). This method was then adopted and modified by Jansen et 
al (1991), Krause et al (1995) and others (Vendrell and Aviles, 1986; Watanabe et al., 
1992) for analysis of amino acids and other compounds from physiological fluids and 
tissue extracts. The application of this method to CSF samples has not been reported.  
  Pre-column derivatization with dabsyl chloride was applied to the analysis of amino 
acids and physiological compounds in CSF without any pretreatment. The roles of 
two non-ionic neutral surfactants, Triton X-100 and Tween 20 were evaluated. In 
addition, the ideal dabsylation conditions needed for efficient pre-column 
derivatization were determined. These include the ratios between different amounts of 
dabsyl chloride and CSF, effects of different pH and temperature of heating, effects 































2.2 Materials and Methods 
 
Chemicals 
  Dabsyl chloride was purchased from Pierce (Rockford, IL). Lithium hydroxide, 
potassium perchlorate, guanidine thiocyanate, morpholine, triethylamine (TEA), 
dimethylamine, Tween 20, GABA, taurine, citrulline, glutamine, asparagine and the 
amino acid standard mixture (AA-S-18) were from Sigma (St. Louis, MO). Triton X-
100 was from Bio Rad (Hercules, CA). DMF and acetonitrile (HPLC grade) were 
from Fisher Scientific (Fairlawn, NJ). Hydrochloric acid, phosphoric acid and acetone 
were from Merck (Whitehouse station, NJ). 
  
HPLC apparatus 
  Gynkotek HPLC system with P 580A HPG pump, autosampler and UV-Visible 
photodiode array detector (UVD 340S) were used. Chromeleon (Softron, ver.6.20) 
software was used for controlling the system, for peak analysis and for determining 
other relevant parameters.  
  
CSF samples 
  After obtaining approval from institutional research and ethics committee and 
informed consents from patients, 1 to 2 mL of CSF was collected during the 
application of spinal anaesthetic, from patients with chronic osteoarthritis of the knees 
undergoing joint replacement surgery. All the CSF samples were kept frozen at -80°C 




immediately after collection. The samples were thawed and aliquots were made just 
before the derivatization and analysis.  
 
Dabsylation Procedure 
  Dabsyl derivatization was carried out in the dabsylation buffer consisting of 0.15 
mol/L NaHCO3 buffer (pH 9.0) and 0.05% Triton X-100 adjusted to pH 9.0 with 1N 
NaOH. Dabsyl chloride solution was dissolved in acetone (12.35 mmol/L), aliquoted 
into 1 mL vials and subsequently stored at – 25°C, protected from light and moisture. 
The standard 23 compounds mixture (Std AA) used for this experiment was prepared 
by adding glutamine, asparagine, taurine, citrulline and GABA to the commercial 18 
amino acid standard mixture and diluting with the dabsylation buffer to achieve a 
final concentration of 1 nmol per 20 µL for each of the amino acids. Dabsylation 
buffer (20 µL) and dabsyl chloride reagent (40 µL) were added onto the Std AA (20 
µL) or CSF samples (20 µL) in 1 mL vials (see flow chart below). The vials were 
capped and sealed tightly with Parafilm (American National Can) and were incubated 
at 65 - 70ºC with intermittent mixing using a vortex-mixer at 1 minute and 5 minutes 
for an overall duration of 20 minutes. The samples were then cooled to room 
temperature and the pH was adjusted to 6.5 using 1N phosphoric acid. To stabilize the 
dabsyl derivates, 60 µL of the dilution buffer consisting of a mixture of 50 mL 
acetonitrile, 25 mL ethanol and 25 mL mobile phase A used in the HPLC process 
(Krause et al., 1995) was added to the dabsylated samples, followed by centrifugation. 
The clear supernatants obtained were then stored at -20ºC till analysis. 
 




Flow Chart – Dabsylation Procedure 
 
 
 HPLC Process 
  The dabsyl derivatives of amino acids were separated on a LiChrosphere 100 RP-18 
column (Merck, 5 µm, 2 X 250 mm) packed by ChromatoResearch (Japan). The 
column was maintained at a temperature of 50°C. The stock dabsylated samples - Std 
AA and CSF samples were filtered with Millex HN syringe filters (Millipore, 
Billerica, MA) to remove any possible precipitates and 20 µL of the solution was 
loaded on the column. The mobile phase A consisted of 9mmol/L lithium phosphate, 
4% DMF, 0.3% guanidine thiocyanate, 0.2% potassium perchlorate and pH adjusted 
to 6.5 using 1N phosphoric acid. Mobile phase B was 80% aqueous acetonitrile. The 
elution was performed at a flow rate of 0.2 mL/min by monitoring OD at 438 nm 
using a gradient system as shown in the legend of Figure 2.1. 
 
Quantitative analysis of peaks 
  The amounts of the different compounds in the CSF samples were calculated based 
on the peak areas in the HPLC run and by comparing with the corresponding peak 
areas in the Std AA, run on the same day.  To ensure the reliability and to improve the 
precision of the analysis, a Std AA run was included after every five or six runs of 
20 µL STD AA/ CSF + 20 µL Dabsylation buffer (0.15 mol/L NaHCO3 buffer  
pH 9.0 and 0.05%TritonX-100) + 40 µL Dabsyl chloride (12.35 mmol/L) 
 
                                                      Incubate at 65 -70°C for 20 min  
                                                      with intermittent mixing      
   
          Sample cooled, pH adjusted to 6.5, added  
60 µL dilution buffer (50%Ethanol + 25%Acetonitrile + 25% Mobile phase A) 




CSF samples. The result of the Std AA run closest to each of the CSF sample was 
used to measure and analyze the peak areas observed in the test sample. 
  
Statistical analysis 
  The data was subjected to linear regression analysis. The slopes, intercepts, standard 
errors of the slope and intercept and standard deviation about the regression line were 
calculated. Analysis of variance was used to compare the differences - between day 
and with-in-day and the with-in-day and between-day repeatability were estimated for 
this method. Detection limit was calculated using the concentration at a signal-to-




















Effect of Ultrafiltration 
  The effect of ultrafiltration was tested for 3 different CSF samples using the Amicon 
filters (Millipore, Billerica, MA) with a molecular weight cut-off at 3K or 30K. The 
recovery of the individual amino acid from these ultrafiltrates was calculated with 
respect to their original amounts in the corresponding unfiltered sample. When the 3K 
molecular weight cut-off filters were used, the recovery was between 35 and 50% for 
all the amino acids except serine, leucine and histidine, which achieved a higher 
recovery between 60 and 70%. When the 30K cut-off filters were used, the recovery 
was between 55 and 70% for most amino acids.  
 
Effect of Non-ionic surfactant 
  It was observed during the dabsylation experiments that the reaction mixtures 
frequently showed some precipitates or turbidity after dabsylation. A surfactant 
Triton X-100, when added to the dabsylation buffer, was able to make the reaction 
mixture clear and also increase the recovery ratios of the amino acids, especially for 
the hydrophilic amino acids such as aspartate, glutamate, asparagine, serine, threonine, 
GABA and glycine (Table 2.1). Furthermore, as shown in Table 2.2, the recovery for 
all the amino acids was between 90 and 108% when known amounts of amino acids 
were added to the CSF samples. Although another surfactant Tween 20 also showed a 
similar favourable effect, the subsequent separation of the compounds on HPLC was 
more homogenous when Triton X-100 was used. When the three concentrations, 




0.025, 0.05 and 0.1 % of Triton X-100 were studied for comparison of their efficacies, 
0.05 % gave the best results.  
 
Dabsylation conditions 
  Experiments were carried out to determine the ideal dabsylation conditions by 
varying the concentrations of dabsyl chloride, pH of the reaction mixture and the 
temperature of heating. A dabsyl chloride concentration of 6.2 mmol/L was required 
for complete derivatization of all the amino acids and other compounds of interest as 
mentioned by Krause et al (1995). Increasing the dabsyl chloride concentration by 10, 
20 and 30% did not result in further increase in yield of derivatization. However a 
decrease in the dabsyl chloride concentration below 6.2 mmol/L resulted in a 
decreased yield of dabsylation of the amino acids. The pH of the dabsylation mixture 
and the temperature of heating were important in determining the homogeneity of 
derivatization of all the amino acids. Dabsylation was carried out at pH 8.0, 8.5 and 
9.0 and heating at 65 - 70ºC with intermittent mixing at 1 minute and 5 minutes for an 
overall duration of 20 minutes. A peak corresponding to N-monodabsylated tyrosine 
derivative was observed in addition to the N,O-didabsylated tyrosine, when 
dabsylation was carried out at pH 8.0 and 8.5 or when the heating time was 
insufficient. Complete homogenous derivatization was achieved for all the amino 
acids including tyrosine at pH 9.0. A decline in the degree of derivatization was 
observed at pH higher than 9.0.  
 
 




CSF sample volume 
  CSF samples were prepared in aliquots of 10, 15, 20, 25 and 30 µL, dabsylated and 
analyzed for all the compounds of interest. All the peaks of interest were detected and 
quantified even with 10 µL of CSF sample. However, it was found that the 20 µL 
volume of CSF sample was convenient to handle and also derivatization and the 
results were more consistent and reproducible. Each 20 µL of CSF yielded 140 µL of 
dabsylated sample upon derivatization and 20 µL of this dabsylated sample was 
injected onto the column for separation by HPLC, which is equivalent to 2.86 µL of 
the original CSF sample. 
  
HPLC separation 
  Separation of the dabsyl derivatives of all the 23 compounds was achieved in a 
single chromatographic run using the chromatographic conditions as described in the 
legend of Figure 2.1. The typical chromatogram of the Std AA mixture is shown in 
Figure 2.1 A. Although seldom present in CSF, cystine was also detected as shown in 
the chromatogram. The optimal chromatographic condition was determined by 
studying the effects of varying concentrations of different salts in the mobile phase A. 
Initially, 5, 9 and 15 mmol/L of lithium, sodium and potassium phosphate buffers was 
studied. The use of 9 mmol/L of lithium phosphate buffer in place of the commonly 
used sodium buffer not only improved the homogeneity of separation of the peaks but 
also enhanced the sensitivity. There was an average of 15% increase in the peak 
heights when lithium buffer was used. The use of potassium buffer delayed the 
elution time of all peaks by 8 to 10 minutes and did not improve the separation 




compared to lithium phosphate. Changing the buffer concentrations to 5 or 15% did 
not improve the separation, thus 9mM lithium buffer was deemed to be most suitable 
for the mobile phase A. The use of varying concentrations of TEA in mobile phase A 
as suggested by Krause (1995) was able to separate most of the compounds except the 
two pairs - glutamine-citrulline and glycine- arginine. The elution orders of the later 
pair sometimes reversed depending on the concentration of TEA (Krause et al., 1995). 
Substitution of TEA with other basic amines such as trimethylamine, morpholine and 
guanidine were studied. While trimethylamine and morpholine were ineffective; 
addition of guanidine thiocyanate (0.1, 0.2, 0.3, 0.4 %) to the mobile phase A 
facilitated the separation of glutamine and citrulline. Although 0.3% guanidine 
thiocyanate gave the best separation efficiency, alanine and arginine peaks could not 
be separated clearly. Addition of 0.2% potassium perchlorate as a chaotic agent to the 
mobile phase A improved significantly the separation of alanine and arginine.  
  Similar to other reports, the concentration of glutamine in the CSF samples analyzed 
in this study was at least 10 times higher as compared to other amino acids. In order 
to confirm the efficiency of this method to separate citrulline from the high glutamine 
peak, a standard sample containing 10 times the concentration of glutamine as 
compared to citrulline was successfully separated and quantified by the method just 
described above. Similar results were obtained when 400 pmol of citrulline was 
added to 20 µL of each three CSF sample containing very high concentrations of 
glutamine (7.8~9.7 nmol). The role of DMF in the mobile phase A was explored 
using different concentrations: 0, 2, 3, 4 and 6%. All the dabsyl derivatives could be 
separated in the absence of DMF; however, the addition of DMF enhanced the 




homogeneity and the quality of separation of the peaks. 4% DMF in the mobile phase 
A seemed to be the ideal concentration (Krause et al., 1995). 
  
Stability of the dabsyl derivates 
  In the absence of dilution buffer described in the methods section, the peak areas of 
dabsyl derivatives of histidine and tyrosine decreased with time. The addition of 
dilution buffer to the dabsylated sample significantly enhanced the stability of the 
dabsyl derivatives (Krause et al., 1995). The dabsylated samples were stable up to 48 
hours when stored at room temperature protected from light and remained stable up to 





  A linear relationship between peak areas and amino acid concentrations was 
observed in the range of 5 pmol to 5000 pmol when evaluated on combined amino 
acid standards with r > 0.99. The data of regression analysis are listed in Table 2.2. 
  
Analytical recovery: 
  Recovery studies were performed by adding 2 nmol of glutamine and 400 pmol of 
each of the other 22 amino acids into 20 µL of CSF samples. Recovery studies were 
carried out on three different CSF samples and each sample was studied in triplicates. 




The results showed an average of 101.6% recovery for all the compounds with 95% 
Confidence Limits (Table 2.2).  
 
Limit of detection:  
  The average detection limit for all the dabsyl derivatives was 2.7 pmol calculated 
with a signal-to-noise ratio of 2.5. 
 
Reproducibility 
  The with-in-day average repeatability was 7.4% and the average between-day 




















  A simple quantitative method was developed for analyzing amino acids in 10 to 20 
µL of CSF without pretreatment by pre-column derivatization with dabsyl chloride 
followed by separation on reverse-phase HPLC. The wide varieties of pretreatment 
procedure applied by different laboratories to analyze CSF have yielded inconsistent 
results (Sarwar and Botting, 1993; Krause et al., 1995; Zhang et al., 2003). The acidic 
pretreatment conditions using trichloroacetic acid or sulfosalicylic acid for 
deproteination have been reported to cause an increase in glutamate and aspartate 
concentrations in CSF samples, due to hydrolysis of their corresponding amide forms 
(Spink et al., 1986; Rizzo et al., 1996; Zhang et al., 2001; Zhang et al., 2003). In 
addition, the dabsyl derivatization yield was also significantly reduced (Krause et al., 
1995). On the other hand, ultrafiltration was recommended for pretreatment by 
Krause et al (1995), however, the results from this study showed that ultrafiltration 
decreased the derivatization yield by at least 20%. The loss could be attributed to 
interaction of some amino acids with certain high molecular weight components in 
the CSF, which were retained in the filter during ultrafiltration. Although addition of 
organic solvents such as methanol (Alfredsson et al., 1988), ethanol (Davy and Ersser, 
1990) and acetonitrile (Jansen et al., 1991) could precipitate high molecular weight 
proteins, the process could also remove conjugated amino acids and also some 
amount of free amino acids mechanically during centrifugation. The adverse effects 
of pretreatment of CSF on amino acid analysis can be avoided by the addition of non-
ionic surfactants such as Triton X-100 or Tween 20 to the derivatization process. 




Addition of Triton not only enhanced the dabsylation efficiency of amino acids in 
CSF but also improved the recovery of all the compounds added into the CSF 
samples. The recovery of hydrophilic amino acids, especially glycine and GABA, 
which are well known as inhibitory neurotransmitters, was increased by 50 to 60%. 
Moreover, Triton also improves the detection of citrulline. The recovery ratio of 
citrulline in one CSF sample (CSF B) was doubled and in another sample (CSF E), 
citrulline could only be detected when dabsylation was carried out in the presence of 
Triton (Table 2.1). As citrulline is a metabolite when NO is produced from arginine, 
the amounts of citrulline can be used as an indicator of NO activity (Larson et al., 
2000). This is highly significant as these amino acids are involved in neuronal 
responses including pain transmission mechanisms. It is known that many amino 
acids are present as free and bound forms in CSF (Manyam and Tremblay, 1984; 
Ferraro and Hare, 1985). However, Triton or Tween cannot release free amino acids 
from their conjugated or chemically bound forms, they only affect the hydrophobic 
and/or the hydrogen bonding interactions between free amino acids and certain 
compounds present in CSF. To date no specific binding protein for amino acids has 
been identified in CSF. Therefore, the improved recovery of hydrophilic amino acids, 
especially glycine and GABA by Triton or Tween, may suggest interestingly the 
presence of specific binding protein in CSF. Further experiments are needed to 
confirm this hypothesis. This principle of surfactants can be applied to other pre-
column derivatization techniques including the OPA method to increase amino acid 
recovery.   




  The pH of the dabsylation mixture is critical for the yield of the derivatization 
process. Maximum dabsyl derivatization occurs at pH 9.0, which is in accordance 
with the report of Vendrell et al (1986) and the ideal incubation time was 20 minutes 
at 65-70ºC.  The relative amount of organic solvent in the reaction mixture also 
influenced the efficiency of the derivatization process. As shown in earlier studies, 
maximum dabsylation was carried out at water to acetone ratios between 1:1 and 
1:1.2 (v/v) (Vendrell et al., 1986).  As reported by Krause et al (1995), the dabsylated 
samples in the dilution buffer were stable for up to 48 hours even when stored at 
room temperature, which is adequate for manual sample preparation and subsequent 
HPLC analysis. The same CSF sample (20 µL) dabsylated once by this procedure can 
be repeatedly analyzed at least 6 times by 20 µL injection of the total 140 µL of 
dabsylated sample obtained, which should be the additional merit of this method. In 
order to minimize the variance, it is recommended to perform a duplicate analysis for 
each sample.  
  The dabsyl derivatives of all the 23 compounds including the common α-amino 
acids and the other compounds of interest were separated simultaneously in a single 
run of HPLC with reasonable homogeneity. The dabsyl peaks could be conveniently 
detected with a simple UV-visible detector. Cystine though easily oxidized, was 
efficiently dabsylated by addition of Triton and separated clearly although no 
antioxidants were added (Krause et al., 1995). The detection limit of cystine is 1.3 
pmol and recovery is 104%, which are reasonable. Methionine could also be oxidized 
to methionine sulfone and methionine sulfoxide under these conditions as mentioned 
by Krause et al (1995). Since the recovery test of cystine and methionine showed 




reasonable quantitative results as shown in Table 2.2, no antioxidants were included 
in the current protocol. 
  Lithium phosphate when used in mobile phase A for HPLC enhanced the peak areas 
as compared to sodium or potassium buffers. It is possible that the small molecular 
weight lithium ions enable the side chains of the amino acids to become more explicit 
and pronounced thus increasing the sensitivity and efficiency of the separation. The 
replacement of TEA with the combination of guanidine thiocyanate and potassium 
perchlorate ensured the elution order of the peaks was more predictable and 
reproducible. Possible interactions between the guanidine thiocyanate in the mobile 
phase A and the guanidine group in the side chain of arginine might be broken by 
potassium perchlorate. 
  A linear relationship was observed between the peak areas and the different 
concentrations of each compound (Table 2.2). The correlation coefficients for all the 
compounds analyzed was greater than 0.99. Reasonable recovery values were 
obtained for all the compounds analyzed but the correlation coefficients were slightly 
lower and detection limits were less sensitive than those reported by Krause et al 
(1995). The small difference could be attributed mainly to the different apparatus 
used. In this procedure, the samples were dabsylated manually whereas an automated 
pre-column dabsylation device was used by Krause et al (1995).  
  In conclusion, by adding a non-ionic surfactant, the pre-column derivatization of 
amino acids with dabsyl chloride was applied to the analysis of various amino acids 
and other compounds of interest in a small amount of CSF sample without any 
deproteination processes. This method is able to detect all the amino acids, including 




the well known neurotransmitters such as glutamate, aspartate, glycine, GABA and 
NO related compounds. Hence this method will be very useful to study different types 
of pain conditions and other CNS diseases. As the method of analysis for amino acids 
in CSF is not yet standardized, especially the sample collection, pretreatment, storage 
and analysis methods (Levine et al., 2000; Mou et al., 2002; Zhang et al., 2003), this 























Figure 2.1 HPLC separation of dabsyl derivatives. 
  
Chromatograms of dabsyl derivatives of all the 23 compounds in STD-AA (A) and 
CSF sample from a chronic pain patient (B) separated using – 
 
Time program: 0 – 2 min,4% B in A; 2 - 4 min,4 to 20% B linear gradient; 4 - 20 
min,20 to 27% B linear gradient; 20 - 39 min,27 to 31% B linear gradient; 39 - 43 
min,31 to 43% B linear gradient; 43 - 59 min,43 to 65% B linear gradient; 59 - 60 
min,65 to 90% B linear gradient; 60 - 69 min,90 to 96% B linear gradient; 69 - 70 
min,96 to 100% B linear gradient. 
 
Peaks: 1-aspartate; 2-glutamate; 3-asparagine; 4-glutamine; 5-citrulline; 6-serine; 7-
threonine; 8-glycine; 9-alanine; 10-arginine; 11-taurine; 12-GABA; 13-proline; 14-
valine; 15-methionine; 16-isoleucine; 17-leucine; 18-tryptophan; 19-phenylalanine; 










Table 2.1 Effect of surfactant Triton X-100 on dabsylation and quantitative analysis of CSF:  
Five CSF samples from patients with chronic pain were dabsylated with and without Triton X-100 and the amino acids were 
quantified by HPLC. 
 
        CSF A CSF B CSF C CSF D CSF E 











































Recovery±   
S.E  (%) 
 µmol/L µmol/L  µmol/L µmol/L  µmol/L µmol/L  µmol/L µmol/L  µmol/L µmol/L    
Asp 7.1 8.2 0.87 7.8 7.9 0.99 7.6 9.7 0.78 6.5 10.8 0.60 3.6 5.8 0.62 0.77 103.4 ± 1.7
Glu 0.0 0.0 0.00 3.4 5.6 0.61 4.3 6.4 0.67 2.3 3.9 0.60 3.4 4.0 0.86 0.69 105.0 ± 1.1
Asn 0.0 0.0 0.00 9.0 13.4 0.68 13.6 17.5 0.78 12.0 18.6 0.64 9.2 11.5 0.81 0.73 108.0 ± 1.6
Gln 1040.5 1397.6 0.75 965.6 986.8 0.98 1162.1 1169.0 0.99 890.6 991.8 0.90 875.9 961.3 0.91 0.91 100.5 ± 1.9
Citb 0.0 0.0 0.00 2.6 5.0 0.52 0.0 0.0 0.00 0.0 0.0 0.00 0.0 4.0 0.00 0.52
c 89.0 ± 1.9 
Ser 36.8 54.8 0.67 38.2 46.1 0.83 44.0 44.5 0.99 38.1 42.9 0.89 21.8 41.2 0.53 0.78 106.5 ± 1.0
Thr 46.2 80.1 0.58 39.2 42.3 0.93 44.4 48.6 0.91 53.7 60.8 0.88 25.8 58.7 0.44 0.75 106.6 ± 0.6
Gly 10.1 35.4 0.29 5.7 23.1 0.25 7.0 28.9 0.24 4.7 6.5 0.73 2.3 4.9 0.47 0.40 100.6 ± 1.2
Ala 48.2 54.4 0.89 37.4 38.7 0.97 34.7 35.5 0.98 28.6 30.0 0.95 30.1 33.3 0.91 0.94 101.9 ± 2.0
Arg 26.8 39.9 0.67 38.5 39.0 0.99 34.3 35.2 0.97 32.2 33.7 0.96 28.7 32.5 0.88 0.90 103.4 ± 2.9




Taub 16.4 42.9 0.38 23.0 22.5 1.02 22.9 23.2 0.99 20.3 23.3 0.87 18.2 19.5 0.94 0.84 107.9 ± 2.3
GABA 3.8 9.4 0.41 2.7 3.2 0.85 4.4 7.5 0.58 3.3 4.4 0.76 2.4 6.5 0.37 0.60 93.0 ± 2.4 
Pro 2.0 2.5 0.81 0.7 0.7 1.10 0.9 0.9 0.98 0.6 0.7 0.86 1.1 0.9 1.17 0.98 101.1 ± 0.9
Val 5.5 21.2 1.20 11.0 11.1 0.99 11.8 12.4 0.95 10.2 12.3 0.83 13.9 15.0 0.93 0.98 96.9 ± 3.4 
Met 3.8 3.9 0.99 1.7 1.7 0.99 2.8 2.8 0.99 1.5 2.2 0.67 2.8 3.7 0.75 0.88 100.2 ± 1.0
Ile 5.7 4.3 1.32 2.8 3.3 0.85 3.0 3.2 0.94 2.9 3.3 0.85 3.4 3.4 1.0 0.99 95.0 ± 2.2 
Leu 17.9 15.7 1.14 9.9 10.1 0.99 12.8 11.7 1.04 9.6 10.0 0.96 11.2 12.9 0.87 1.00 98.1 ± 2.5 
Trp 1.7 2.6 0.66 1.1 1.2 0.90 1.9 2.1 0.93 1.7 1.6 1.02 1.6 2.1 0.77 0.86 97.4 ± 1.4 
Phe 11.3 10.5 1.08 6.8 7.3 0.93 13.9 14.9 0.93 5.8 8.5 0.68 8.2 12.1 0.67 0.86 103.6 ± 2.4
Cys 0.0 0.0 0.00 0.0 0.0 0.00 0.0 0.0 0.00 0.0 0.0 0.00 0.0 0.0 0.00 0.00 104.3 ± 0.3
Lys 24.3 24.4 1.00 14.2 14.2 1.00 26.2 27.0 0.97 13.9 19.3 0.72 21.3 24.4 0.88 0.91 105.3 ± 3.7
His 15.2 25.6 0.59 19.9 19.4 1.03 23.2 23.3 1.00 16.4 16.4 1.00 17.3 20.4 0.85 0.89 104.9 ± 0.6
Tyr 4.6 8.3 0.56 4.7 4.9 0.96 10.5 10.3      1.01 4.9 7.4 0.67 7.8 10.0 0.78 0.80 104.7 ± 0.5
 
a Ratio = amount of amino acid when sample was dabsylated without Triton / amount of amino acid when sample was dabsylated with 
Triton.  
b Cit – citrulline, Tau – taurine. 
c This value is the ratio seen for CSF B only as this peak was detected in this CSF only with and without Triton.  
d Recovery test was performed for all the amino acids and other compounds of interest as explained in the text and the results of this 
experiment are included above in the last column. Three CSF samples different from the five samples (CSF A –E) used to evaluate the 
effect of Triton were used in the recovery test.  
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Table 2.2 Statistical analysis data:  



















Asp 0.045 -0.37 0.0015 0.11 0.29 0.995 2.8 
Glu 0.033 -0.23 0.0012 0.08 0.23 0.993 2.3 
Asn 0.027 -0.07 0.001 0.07 0.20 0.997 1.9 
Gln 0.022 -0.075 0.0006 0.05 0.13 0.997 7.5 
Cit 0.065 -0.54 0.0023 0.17 0.46 0.996 2.2 
Ser 0.033 -0.2 0.0012 0.08 0.24 0.994 5.6 
Thr 0.021 -0.098 0.0008 0.05 0.15 0.993 7.4 
Gly 0.072 -0.68 0.0031 0.23 0.63 0.992 3.2 
Ala 0.051 -0.33 0.0014 0.10 0.28 0.996 2.4 
Arg 0.037 -0.29 0.0014 0.1 0.27 0.991 4.8 
Tau 0.071 -0.44 0.0027 0.19 0.52 0.992 0.3 
GABA 0.065 -0.34 0.0013 0.09 0.26 0.997 0.7 
Pro 0.056 -0.22 0.0012 0.09 0.25 0.996 0.1 
Val 0.047 -0.30 0.0014 0.1 0.29 0.992 1.5 
Met 0.046 -0.34 0.0013 0.09 0.25 0.997 1.6 
Ile 0.049 -0.28 0.001 0.07 0.21 0.998 1.4 
Leu 0.047 -0.32 0.0012 0.08 0.23 0.997 1.8 
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Trp 0.045 -0.25 0.0013 0.09 0.25 0.995 1.3 
Phe 0.054 -0.35 0.086 0.0012 0.24 0.998 1.3 
Cys 0.034 -0.32 0.0013 0.09 0.25 0.993 5.1 
Lys 0.069 -0.47 0.0015 0.11 0.29 0.998 2.6 
His 0.069 -0.72 0.0024 0.17 0.48 0.995 3.7 
Tyr 0.061 -0.37 0.0011 0.08 0.22 0.998 3.1 
Average      0.995 2.8 
 
a Relation between peak area and the amount of amino acids (pmol) - for each amino 
acid 6 concentrations were chosen and each 3 samples were analyzed. 
b Standard deviation calculated about the regression line. 













AN ANALYSIS OF AMINO ACID NEUROTRANSMITTERS AND 














  Labor pain has been reported as the most intense pain and can be considered as a 
model of acute visceral pain (Melzack, 1993). Excitatory amino acids - glutamate and 
aspartate have been implicated in acute pain state by activating the NMDA receptors. 
Nitric oxide, prostaglandins and other neurotransmitters are also involved in these 
processes (Yaksh et al., 1999; Lewin et al., 2004). Descending inhibitory nervous 
systems are also known to be involved in pain perception (Gebhart, 2004). 
  Two reports have been published so far comparing the levels of glutamate, aspartate, 
NO, substance P or prostaglandin E2 in CSF between women with labor pain and 
without labor pain (Olofsson et al., 1997; Hsu et al., 2001). However, the results were 
not consistent except for an increase in CSF level of aspartate in women with labor 
pain. Other amino acids, including the IAAs - glycine, GABA and taurine were not 
analyzed by these reports. Recently, glycine, which has been considered primarily as 
an inhibitory neurotransmitter in the spinal cord and brain stem, has also been 
suggested to play a role as an excitatory neurotransmitter, as it is essential for full 
activation of the NMDA receptors (Chatterton et al., 2002; Ahmadi et al., 2003; 
Muth-Selbach et al., 2004). 
    In the present study, labor pain was chosen as an acute visceral pain model to 
reevaluate the roles of pain related amino acids and NO related amino acids, arginine 
and citrulline, in the mechanisms of pain perception. The HPLC method, recently 
developed in our laboratory (Sethuraman et al., 2004) as described in chapter 2 for 
quantitatively measuring the physiological amino acids in CSF without pretreatment 
was applied and this improved the recovery of hydrophilic amino acids, especially the 
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IAAs glycine and GABA. The amino acid levels were compared between women at 
term pregnancy with and without labor pain. The relationship between levels of 
amino acids and the intensity of the labor pain was also evaluated. The results showed 
statistically significant differences in the CSF levels of some amino acids between the 
two groups, and their levels could also be correlated with the labor pain intensity. 
This suggests that amino acid neurotransmitters and NO are involved in labor pain 
mechanisms. 
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3.2 Materials and Methods 
 
Collection of CSF samples 
  The experimental protocol was approved by the Institutional Review Board. CSF 
samples were collected from patients after written informed consent was obtained. 
This study involved two groups of patients – pregnant women who were in 
established labor (labor pain group, n = 38) and a control group comprising of 
pregnant women scheduled for elective Cesarean delivery (non-pain group, n = 30). 
Patients in the labor pain group received a combined spinal epidural (CSE) technique 
for pain relief, within 30 minutes when the woman requested for pain relief. The 
patient’s perception of her pain intensity was rated using verbal rating scales as mild, 
moderate or severe prior to the CSE procedure (Caraceni et al.,2002; Noble et 
al.,2005). Patients in the non-pain group received spinal anesthesia for their operative 
delivery. 0.5 to 1 mL of CSF was collected from the patients after successful 
subarachnoid puncture before intrathecal injection of analgesics. All the CSF samples 
were kept frozen at -80°C immediately after collection until final analysis.  
    
HPLC analysis 
  CSF analysis was performed by applying pre-column derivatization using dabsyl 
chloride (Pierce, Rockford, IL) in the presence of 0.05% of Triton X-100 (Bio Rad, 
Hercules, CA). The dabsyl derivatives were separated on a LiChrosphere 100 RP-18 
column (5 µm, 2 X 250 mm, Merck, Darmstadt, Germany) using HPLC (Gynkotek 
HPLC system, Germany) and their optical densities were monitored at 438 nm. 20 µL 
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of CSF sample was sufficient for dabsylation and quantitative analysis of twenty-
three amino acids. The dabsyl chloride derivatization procedure and the HPLC 
conditions used were as discussed in chapter 2 (Sethuraman et al., 2004). 
  A standard amino acid mixture (Std AA) of 23 compounds was prepared by adding 
glutamine, asparagine, taurine, citrulline and GABA to the commercial 18 amino acid 
standard mixture (Sigma, St. Louis, MO). This Std AA containing 1 nmol of each of 
the 23 compounds of interest was dabsylated each time with the CSF samples and 
analyzed using HPLC. After HPLC separation, the amounts of the different 
compounds in the CSF samples were calculated by comparing the peak areas in the 
HPLC run of the CSF sample with the corresponding peak areas in the dabsylated Std 
AA, which was also run on the same day. A duplicate analysis was performed for 
each CSF sample to minimize the variance. 
  
Statistical analysis 
  All amino acid concentrations are expressed as mean ± SEM. Differences of amino 
acids between groups were examined using Student’s t-test. Correlation between the 
pain intensity and amino acids concentration was evaluated using the Kendall’s tau_b 
correlation coefficient. SPSS (version 12.0, SPSS Inc., Chicago, IL) statistical 











  The typical separation of the 23 compounds of interest in the CSF from the three 
groups of patients is shown in the chromatograms in Figure 3.1. The amounts of pain 
related amino acids in CSF of both the labor pain (n = 38) and non-pain control (n = 
30) groups are shown in Table 3.1. Nine amino acids – arginine, asparagine, aspartate, 
citrulline, GABA, glutamate, glutamine, glycine and taurine were chosen for 
comparison as they are known to play a role in pain modulation. 
  Eight out of the thirty-eight patients with labor pain received intra-muscular 
Meperidine™ for pain relief at least four hours before CSF collection. In addition, ten 
patients in the same group received Prostin™ and / or Oxytocin™ for induction of 
labor and augmentation of uterine contraction. As there were no significant 
differences in the amino acid concentrations between patients who received and those 
who did not receive the drugs; their results were pooled together in the final analysis. 
 
Analysis of EAAs – aspartate, glutamate and their metabolites  
  Aspartate in the labor pain group was significantly higher (P < 0.01) than that of the 
non-pain control whereas glutamate was not significantly different between the two 
groups. Asparagine and glutamine, the respective metabolites of aspartate and 
glutamate, in the labor pain group were significantly lower (P < 0.05 and 0.001 
respectively) than the control group.   
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Analysis of IAAs – glycine, GABA and taurine 
  Glycine and GABA in the labor pain group were significantly higher (P < 0.01 and 
0.05 respectively) while taurine was significantly lower (P < 0.01) as compared to the 
control group.  
 
Analysis of citrulline – citrulline positive and negative subgroups 
  The level of citrulline (the by-product of NO formation from arginine) in the labor 
pain group was significantly raised as compared to the control group. However, only 
17 out of 38 CSF samples of the labor pain group showed an increased level of 
citrulline (2.27 to 8.79 µmol/L), which was comparable to other amino acids. 
Citrulline was undetected in the remaining 21 CSF samples. In contrast, only one out 
of 30 CSF samples in the control group showed a very small amount of citrulline 
(0.96 µmol/L). The 38 labor pain CSF samples were sub-divided into two sub-groups 
- citrulline positive (n = 17) and citrulline negative (n = 21), to study if there were any 
difference in other amino acids between these two sub-groups. 
  The sub-groups analysis (Figure 3.2) showed that the levels of GABA and taurine 
(2.56 + 0.27 µmol/L and 4.30 + 0.42 µmol/L respectively) in the citrulline positive 
sub-group were less than one third (P < 0.001) of the levels of GABA and taurine 
(8.25 + 1.00 µmol/L and 14.34 + 1.02 µmol/L respectively) in the citrulline negative 
sub-group.  Arginine which is the substrate of NO synthase was significantly higher 
in the citrulline positive compared to the citrulline negative sub-group (P < 0.01).  
 
 
Amino acids and Nitric oxide in Labor Pain 
------------------------------------------------------------------------------------------------------- 
 67
Correlation between pain related amino acids and pain intensity  
  Pain intensity which was rated as no pain (control group, n=30), mild (n = 11), 
moderate (n = 18) and severe pain (n = 9) was ranked as 0, 1, 2, and 3 respectively. 
The correlation coefficients between the concentrations of the pain related amino 
acids and their pain intensity were analyzed (Table 3.2, Figure 3.3). The levels of 
aspartate, citrulline and glycine were significantly correlated with the severity of pain 
intensity (P = 0.002), P < 0.001 and P < 0.001 respectively); whilst a significant 
negative correlation was observed between pain intensity and the levels of asparagine 
(P < 0.05), glutamine (P < 0.05) and taurine (P < 0.01). 
 
Analysis of other physiological amino acids 
  In addition to the above-mentioned nine amino acids, which are known to play a role 
in pain modulation, the levels of fourteen other physiological amino acids were also 
analyzed in both groups of patients. The results are shown in Table 3.3. Interestingly, 
the citrulline positive samples in the labor pain group did not contain cystine while 10 
out of 21 citrulline negative samples in the same labor pain group showed significant 
amount (0.76 + 0.08 µmol/L). The levels were comparable to the 0.81 + 0.13 µmol/L 
of cystine detected in 22 out of the 30 CSF samples in the control group. The levels of 
methionine, proline and tryptophan were significantly increased, and serine levels 









  It is well known that the sensation of pain is produced by complicated neuronal 
events involving both stimulatory and inhibitory mechanisms. Labor pain was chosen 
as an acute visceral pain model to study the relationship between CSF concentrations 
of various amino acids and pain perception. Although the focus was mainly on amino 
acids currently known to modulate pain, this method of analysis also allowed us to 
study many other amino acids and their yet unexplored roles in pain perception. The 
relationship between amino acids concentrations and the degrees of pain intensity 
were also analyzed using verbal rating scales. This scale is considered valid according 
to the report of the expert working group of the European Association for Palliative 
Care and is widely used in clinical situation (Caraceni et al., 2002; Noble et al., 2005). 
  This study compares the CSF from two groups of pregnant patients – one group 
before receipt of spinal anaesthetic for elective caesarean section and other group 
before receipt of spinal anaesthetic after initial onset of labor pain during vaginal 
delivery. These two groups differ not only in the pain experienced by the labor pain 
group but also in the point of delivery cycle. The labor pain group is few hours later 
in the parturition cycle as against the no pain group. Hence the observed differences 
in amino acid levels could also be the outcome of this difference but procuring CSF 
samples from pregnant women at other time points during labor and delivery is 
ethically not possible justifying our current experimental design with regards to 
subjects involved in this study. 
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Excitatory amino acids    
  Similar to the previous reports (Olofsson et al., 1997; Hsu et al., 2001), the results 
from this study also demonstrated a significant increase in aspartate (P < 0.01) in the 
labor pain group. This strongly suggests the involvement of aspartate in labor pain. 
Contrary to our expectation (Bergles et al., 1999), asparagine, the metabolite of 
aspartate was lower in the labor pain group as compared to control. There have been 7 
reports since 1995 on the level of asparagine in CSF of normal controls and the 
reported values vary from 3.0 to 9.5 µmol/L, which were lower than the values 
reported in this study. This may suggest that the physiological events of pregnancy or 
delivery might affect the metabolic pathways of aspartic acid (Maes et al., 2002). 
Glutamate has been reported as significantly increased (Hsu et al., 2001) or no 
significant change (Olofsson et al., 1997) during labor pain. The latter study 
concurred with the results in this study that glutamate might not be involved in labor 
pain. The significantly lower level of glutamine observed in the labor pain group also 
support this hypothesis. 
The current results also demonstrated a positive correlation between the concentration 
of aspartate and pain intensity, but not glutamate, this further supports the observation 
that aspartate and not glutamate might be involved in labor pain. 
 
Inhibitory amino acids  
  IAAs glycine, GABA, and taurine are well known to modulate pain perception. 
However, a dual role in pain perception has been suggested for glycine. In addition to 
being the primary inhibitory neurotransmitter in the spinal cord and brain stem, it has 
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also been shown to be an obligatory co-agonist at the excitatory glutamate receptors 
of the NMDA subtype (Chatterton et al., 2002). The affinity of glycine to the NMDA 
receptors has been shown to be higher than its affinity to the strychnine-sensitive 
glycine receptors (which mediate the anti-nociceptive effect) (Becker et al., 1988; 
Muth-Selbach et al., 2004). This suggests that synaptically released glycine might be 
detected in the CSF even though the amount released might be small. As shown in 
Table 3.1, glycine levels in the labor pain group were significantly higher than the 
control group (8.18 µmol/L vs. 4.39 µmol/L, P < 0.01). This increased glycine 
concentration in labor pain patients coupled with the significant positive correlation 
observed between the pain intensity and glycine levels (P < 0.001) suggests that 
glycine might be involved in labor pain via the excitatory glutamate receptors of the 
NMDA subtype. More than 15 reports have been published since 1995 on the levels 
of glycine in CSF and the reported values vary from 1.8 to 18.92 µmol/L, which make 
direct comparison with these results difficult. The wide range of values reported is 
probably the result of the different methods of amino acid analysis, deproteination 
and storage conditions of the CSF samples (Sethuraman et al., 2004; Zhang et al., 
2003).  
    The level of GABA in the labor pain group was higher than the control (P < 0.05). 
This result was unexpected as GABA in the cerebral cortex has been shown to 
stimulate the descending pain inhibitory system (Jasmin et al., 2003). However, a 
correlation between GABA level and pain intensity could not be seen, which suggests 
that the increase in GABA may not be related to labor pain. As this study did not 
include a group of nonpregnant women for comparison, the possibility that some of 
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the observed changes could be related to pregnancy per se cannot be ruled out. Very 
recently, Altemus et al. (2004) compared GABA and glutamate levels of CSF 
between 22 healthy nonpregnant women and 21 pregnant women and found no 
difference in glutamate levels in both groups, while GABA in the pregnant women 
(42.6 pmol/mL) was significantly lower than non-pregnant women (55.0 pmol/mL). 
The authors suggested that this might contribute to the higher incidence of anxiety 
and depression seen during later stage of pregnancy.  
  The level of taurine in the labor pain group (9.85 + 1.01 µmol/L) was significantly 
lower as compared to control (13.74 + 0.89 µmol/L). In addition, this study results 
also demonstrated a significant correlation between decreasing taurine level and 
increasing pain intensity (P = 0.01).  A significant decrease in taurine level was also 
reported in CSF from patients with headache during the acute phase of 
cerebrovascular ischemic disease (Castillo et al., 1995). Therefore, the decrease in 
taurine might enhance labor pain. 
 
Citrulline – as surrogate of NO 
  NO has been accepted as one of the neurotransmitters involved in pain perception 
(Yaksh et al., 1999; Lewin et al., 2004). However, the first study on NO production in 
labor pain analyzed the amounts of nitrate (oxidized products of NO) by high 
performance capillary electrophoresis in CSF obtained from women with labor pain, 
and reported a significantly lower NO level as compared to pregnant women not in 
labor pain (Olofsson et al., 1997). On the other hand, a second study showed that 
there was no significant difference in the total amounts of NOx (NO, NO2-, and NO3-) 
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as detected by a commercial chemiluminescence detector, in CSF obtained from 
women with labor pain compared to pregnant women without labor pain (Hsu et al., 
2001). However, in these two studies, the methods used to estimate the amount of NO 
were different. In the present study, NO was indirectly studied, by analyzing the 
amount of citrulline, a by-product of NO synthesis from arginine. A similar method 
was applied to patients with fibromyalgia (Larson et al., 2000) and it was shown that 
an increase of NO (citrulline) in these patients was proportional to their pain intensity 
(expressed as tender point index), although the amount of CSF citrulline was not 
significantly different from healthy normal controls. Similar indirect analysis of NO 
in terms of arginine and citrulline levels in CSF has been reported by Perez-Neri et al 
in patients with infections and inflammatory processes in CNS and this report 
analyses in detail the validity of analyzing NO in terms of citrulline and arginine 
levels taking into consideration the effects of other metabolic processes involving 
these compounds. They report that the citrulline level in CSF reflects the actual NO 
biosynthesis and could be applied advantageously to evaluate the roles of NO. Further 
it is ethically impossible to confirm the steady state levels of citrulline by drawing 
second collection of CSF sample from the same parturient women.  
  The results showed that there was no significant difference in the arginine level 
between the pain and the non-pain group. This concurs with a recent study by Perez-
Neri et al. (2004). They were also unable to demonstrate any difference in the CSF 
arginine levels between healthy human control and patients with infection and 
inflammatory processes in the CNS, even though both these conditions are known to 
be associated with increase NO production.  
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  Citrulline was detected in 17 out of 38 CSF samples in the labor pain group and only 
in one out of 30 control samples. This method is able to detect 2.2 pmol of citrulline 
(Sethuraman et al., 2004) and the recovery of citrulline was about 90% when 
calculated by adding known amounts of citrulline to the CSF samples. These findings 
suggest that labor pain might be caused by the interplay of two different mechanisms 
– one involving NO and another NO independent system. Hence the labor pain group 
was divided into citrulline positive and citrulline negative subgroups and compared 
the amino acids concentrations between them. The results showed that eight out of 
nine patients who rated their labor pain as ‘severe’ were citrulline (NO) positive. 
Majority of the citrulline (NO) negative patients rated their pain as mild (8 out of 11) 
and moderate (12 out of 18). The citrulline level in the non-pain group (one patient) is 
lower than previously reported values [2.1-2.3 µmol/L (Molina et al., 1997 and 1998; 
Rainesalo et al., 2004) and 8.45 µmol/L (Larson et al., 2000)] in healthy volunteers 
To our knowledge there has been no report on CSF citrulline level in pregnant women 
and hence we cannot rule out the possibility that citrulline levels might also be 
affected by pregnancy.  
  When the two labor pain subgroups were compared, the levels of GABA and taurine 
in the citrulline negative labor pain subgroup were significantly higher than those of 
the citrulline positive labor pain subgroup (P < 0.001). When the overall labor pain 
group was compared with that of no pain control, the level of GABA was higher but 
that of taurine was lower in labor pain group as compared to control.  These results 
also suggest a possible involvement of GABA and taurine in labor pain through a 
mechanism not involving NO production. The arginine levels were significantly 
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higher in the citrulline positive subgroup although there was no significant difference 
in the initial comparison between the overall labor pain and no pain control. NO is 
formed by nitric oxide synthase which oxidizes L-arginine to citrulline and NO and it 
has been shown that the reaction product NO acts as a feedback inhibitor of the 
neuronal enzyme nitric oxide synthase (Wang et al., 1994; Abu-Soud et al., 1995). 
Such a feedback inhibition by NO itself would account for the higher arginine levels 
in the citrulline positive sub-group of the labor pain patients who had relatively high 
CSF citrulline levels. As mentioned before, the first report on NO in CSF showed 
significantly lower NO in labor pain than control (Olofsson et al., 1997) and the 
second report (Hsu et al., 2001) observed no differences in NO between the two 
groups although their detection methods were different from each other and also from 
the method used in this study. Taken together, we hypothesize that two mechanisms, 
with and without the NO production, may be involved in labor pain.  
 
Other amino acids 
  It is worth mentioning that this method is able to detect cystine and proline which 
can not be determined by the most frequently used o-phthalaldehyde method. 
  Cystine was not detected in all samples in the citrulline positive subgroup while 10 
out of 21 citrulline negative and 22 out of 30 control group contained cystine. The 
cystine level (Table 3.3) of the control group (0.6 µmol/L) was comparable to a 
previously reported value of 0.7 µmol/L (Molina et al., 1997 and 1998). Sulfur 
containing amino acids such as cystine might protect against nerve cell injury by 
decomposition of potentially reactive peroxynitrite derived from NO, which is known 
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to cause cell injury (Tapiero et al., 2002; Carlo et al., 2003). In addition, the 
possibility of proline (increased in the labor pain group), one of glutamate family 
(Tapiero et al., 2002), being involved in labor pain cannot be excluded because one of 
the proline specific transporters, the proton/amino acid co-transporter PAT2 has been 
shown to be expressed in the spinal cord and brain, especially in the NMDA subtype 
glutamate receptor subunit (Rubio-Aliaga et al., 2004).  
       
  In summary, it is evident from these results that aspartate is involved in labor pain 
while glutamate is not. Two different pain mechanisms, with and without NO might 
be involved in labor pain. The hydrophilic IAAs, glycine, GABA and taurine were 
also involved in labor pain. These results provide new insight into the mechanisms of 
intense acute visceral pain and suggest that in addition to aspartate – known to be 
involved in labor pain, citrulline, GABA, glycine and taurine in CSF might also be 




















Figure 3.1 Typical chromatograms of CSF samples from the two pregnant groups 
 
Peaks: 1-aspartate; 2-glutamate; 3-asparagine; 4-glutamine; 5-citrulline; 6-serine; 7-
threonine; 8-glycine; 9-alanine; 10-arginine; 11-taurine; 12-GABA; 13-proline; 14-
valine; 15-methionine; 16-isoleucine; 17-leucine; 18-tryptophan; 19-phenylalanine; 









                
Pregnant - No Pain
Pregnant – Labor pain 
STD AA
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Age (mean ± SD) 
Highest age 
Lowest age 
Control groupa (µmol/L) 
(n = 30) 
33.4 ± 5.0 
48 
23 
Labor pain groupb(µmol/L) 
(n = 38) 
28.6 ± 4.5 
41 
                    20 
Arginine 13.34 ± 0.65 13.51 ± 0.56 
Asparagine 12.63 ± 0.79 10.19 ± 0.51* 
Aspartate 4.42 ± 0.63 6.63 ± 0.41** 
Citrulline ‡ 0.03              2.11 ± 0.42*** 
GABA 3.94 ± 0.34 5.71 ± 0.73* 
Glutamate 2.13 ± 0.22 2.48 ± 0.18 
Glutamine 981.03 ± 46.49 583.65 ± 16.36*** 
Glycine 4.39 ± 0.27 8.18 ± 1.26** 
Taurine 13.74 ± 0.89 9.85 ± 1.01** 
 
Values are expressed as mean ± SEM 
 
a Pregnant women with no labor pain 
b Pregnant women in acute labor pain 
 
* (P < 0.05) ** (P < 0.01) *** (P < 0.001) – Statistically significant when compared 
to the control group. 
 















Figure 3.2 Comparison between Pain related amino acids in CSF of Citrulline 
positive labor pain patients Vs Citrulline negative labor pain patients 
 
** (P < 0.01) *** (P < 0.001) – Statistically significant differences between the two 
groups compared 
 














































Amino acids and Nitric oxide in Labor Pain 
------------------------------------------------------------------------------------------------------- 
 79
Table 3.2 Statistical correlation between Pain intensity (PI) and the concentration of 
pain related amino acids in cerebrospinal fluid of the labor pain group as compared 




  Labor Pain group 
(n = 38) 






































PI – Pain intensity – graded as Mild (n = 11), Moderate (n = 18), Severe (n = 9)  
 
To evaluate the correlation between the pain intensity and the amino acids 
concentration - Kendall’s tau_b correlation coefficient was calculated comparing the 
three pain subgroups of labor pain group (mild, moderate and severe) and No pain 
control group (n = 30) and the P value calculated. 
 
* (P < 0.05) ** (P < 0.01) *** (P < 0.001) – Statistically significant correlation 
relative to the control group. 




















Figure 3.3 Correlation between Pain intensity (PI) and the concentration of Pain 
related amino acids in cerebrospinal fluid of the labor pain group. 
 
 






























No Pain Mild Pain Moderate Pain Severe Pain
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Table 3.3 CSF concentration of other amino acids not related to pain. 
Amino acids 
 
Age (mean ± SD) 
Control groupa (µmol/L) 
(n = 30) 
33.4 ± 5.0 
Labor pain groupb(µmol/L) 
(n = 38) 
28.6 ± 4.5 
Alanine 29.41 ± 1.33 33.41 ± 1.53 
Cystine ‡ 0.6 ± 0.12  0.2 ± 0.06** 
Histidine 14.87 ± 1.13 17.39 ± 0.84 
Isoleucine 3.77 ± 0.15 4.03 ± 0.19 
Leucine 8.56 ± 0.37 9.09 ± 0.35 
Lysine 18.72 ± 1.38 19.34 ± 1.31 
Methionine 1.85 ± 0.13 2.19 ± 0.10* 
Phenylalanine 7.26 ± 0.29 7.94 ± 0.27 
Proline 0.89 ± 0.09 1.22 ± 0.09** 
Serine 32.05 ± 1.27 24.55 ± 0.87*** 
Threonine 58.68 ± 2.73 59.94 ± 3.16 
Tryptophan 1.87 ± 0.10 2.26 ± 0.10** 
Tyrosine 3.94 ± 0.43 4.95 ± 0.44 
Valine 9.59 ± 0.50 10.02 ± 0.38 
 
 
Values are expressed as mean ± SEM 
 
a Pregnant women with no labor pain 
b Pregnant women in acute labor pain 
 
* (P < 0.05) ** (P < 0.01) *** (P < 0.001) – Statistically significant when compared 
to the control group. 











A COMPARATIVE STUDY ON THE ROLES OF AMINO ACID 
NEUROTRANSMITTERS AND NITRIC OXIDE IN CHRONIC 















  Acute pain is elicited by substantial injury of body tissue and activation of 
nociceptive transducers at the site of local tissue damage. Chronic pain although 
triggered by an injury or tissue damage, may be perpetuated by factors other than the 
cause of pain itself thus becoming out of proportion to the original injury itself 
(Loeser and Melzack, 1999).The EAAs glutamate and aspartate, IAAs glycine, 
GABA and taurine, NO, prostaglandins and other neurotransmitters play important 
roles in pain perception (Wen et al., 2003; Cronin et al., 2004; El Idrissi and Trenkner, 
2004). Continual and prolonged stimulation by these neurotransmitters can result in 
chronic persistent pain. Acute pain is biologically useful as a warning system and 
subsides as healing progresses while chronic pain is more challenging, does not 
spontaneously resolve and serves no useful biological function. 
  Though amino acid analysis studies date back to more than 50 years, there have 
been very few reports on CSF amino acid levels in pain states.  Two of them have 
analyzed only the EAAs in head ache (Castillo et al., 1995; Gallai et al., 2003). A 
third report analyzed the CSF levels of the EAAs and also glycine, taurine, arginine 
and citrulline in fibromyalgia syndrome (Larson et al., 2000) and has found 
interesting correlation between the tender point index (pain scale) in these patients 
and some of these amino acid levels. Though these amino acids are known to be 
involved in chronic pain mechanisms per se, the differential roles of these amino acid 
neurotransmitters and modulators in acute and chronic pain states have not been 
compared so far. 
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  In this study, three groups of subjects were chosen – acute pain, chronic pain and 
and no pain control to study the roles of nine pain related amino acids described in 
chapter 3 in the mechanisms of pain perception. The HPLC method, recently 
developed in our laboratory (Sethuraman et al., 2004) as described in chapter 2 for 
quantitatively measuring the physiological amino acids in CSF without pretreatment 
was applied. The levels of these neurotransmitters and modulators were quantitatively 
analyzed in the CSF of chronic pain patients and compared with their levels in the no 
pain control group and in the acute pain group to analyze which of these amino acids 
were involved in establishment of chronic persistent pain. Statistically significant 
differences in the CSF levels of some amino acids between these groups were 
observed, which suggested that amino acid neurotransmitters were differentially 
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4.2 Materials and Methods 
 
Collection of CSF samples 
  The experimental protocol was approved by the Institutional Review Board. CSF 
samples were collected from patients after written informed consent was obtained. 
Three groups of patients were involved in this study – (1) chronic pain female 
patients (n = 29) with chronic osteoarthritis of the knees undergoing joint replacement 
surgery or with chronic back ache undergoing myelogram (2) a no pain female 
control group (n =35) comprising of pregnant women scheduled for elective Cesarean 
delivery, womb removal or renal impairment patients (3) acute pain female patients 
(n = 46) comprising of acute labor pain patients and few with fractures.  
  Patients in the labor pain group received a combined spinal epidural technique for 
pain relief. Patients in the non-pain group received spinal anaesthesia for their 
operative delivery or other surgery. Patients in the chronic pain group received spinal 
anaesthesia before their joint replacement surgery or the myelogram procedure. 0.5 to 
1 mL of CSF was collected from the patients after successful subarachnoid puncture 
before intrathecal injection of analgesics. All the CSF samples were kept frozen at -
80°C immediately after collection until final analysis.  
  During collection of samples, CSF was collected from both male and female patients. 
The summary of patient details from whom the CSF samples were collected and 
analyzed are as summarized below: 
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Clinical Data of Patients 
 




No pain  
(n=60) 
Age – Mean(range) 63.2(32-87) 40.7(20-97) 50.0(23-83) 
Sex – male/female 19/29 13/46 25/35 
Clinical 
condition (no. of 
patients) 
Knee pain/OA (30) 
Back pain (6) 
Others (11) 







  The number of male subjects in all the three groups of patients was relatively lower 
than female subjects and the numbers of males in each group were not sufficient (n 
was small) to compare the data from these subjects, between the groups. Hence only 
the analysis data of female subjects were chosen for comparison. 
 
HPLC analysis 
  CSF analysis was performed following the same protocol as explained in the 
methods section of chapter 3. The dabsyl chloride derivatization procedure and the 
HPLC conditions used were as discussed in chapter 2 (Sethuraman et al., 2004). 
  A standard amino acid mixture (Std AA) was prepared as explained in chapter 3 and 
dabsylated each time with the CSF samples and analyzed using HPLC. After HPLC 
separation, the amounts of the different compounds in the CSF samples were 
calculated by comparing the peak areas in the HPLC run of the CSF sample with the 
corresponding peak areas in the dabsylated Std AA, which was also run on the same 
day. A duplicate analysis was performed for each CSF sample to minimize the 
variance. 
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 Statistical analysis 
  All amino acid concentrations were expressed as mean ± SEM.   
  Statistical comparison of amino acids concentrations in the different groups of 
patients was performed using the student’s t-test – 
   a. Labor pain vs. other acute pain 
   b. Acute male vs. acute female 
   c. Chronic pain vs. control with no pain 
   d. Chronic pain vs. acute pain  
  SPSS (version 12.0) statistical software was used. A P value of less than 0.05 was 


















   
  Although labor pain is considered as a typical acute pain (Melzack, 1993), we 
compared 38 labor pain CSF samples with the other acute female samples and found 
there were no significant differences between the corresponding amino acids except 
GABA (Table 4.1). On the other hand, there were significant differences in many 
amino acids between male and female acute pain CSF samples (Table 4.2). Therefore, 
in this study we limited to female CSF sample data for comparison and labor pain and 
other acute pain samples were pooled into the acute pain group and applied to the 
comparison study. 
  The typical separation of the 23 compounds of interest in the CSF from the three 
groups of patients is shown in the chromatograms in Figure 4.1. 
  Statistical analysis results are discussed in two groups as indicated below – 
(a) Chronic pain vs. control with no pain 
(b) Chronic pain vs. acute pain  
  The amounts of the nine pain-related amino acids (defined in chapter 3) in the CSF 
of chronic pain (n = 29), no pain control (n = 35) and acute pain (n = 46) groups are 
shown in Table 4.3.  
 
Analysis of EAAs – aspartate, glutamate and their metabolites 
(a) Aspartate and glutamate in the chronic pain group were significantly higher (P < 
0.01) than that of the no pain control. Asparagine, the metabolite of aspartate in 
the chronic pain group was also significantly higher (P < 0.01) than the control 
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group. Glutamine levels were not significantly different between the chronic 
pain and no pain groups. 
(b) Aspartate in the chronic pain group was significantly higher (P < 0.01) than that 
of the acute pain group while glutamate did not show any significant difference. 
Asparagine and glutamine, the respective metabolites of aspartate and glutamate, 
in the chronic pain group were also significantly higher (P < 0.001) than the 
acute pain group. 
 
Analysis of IAAs – glycine, GABA and taurine 
(a) Glycine in the chronic pain group was significantly higher (P < 0.01) while the 
levels of taurine and GABA, though lower in chronic pain, were not significantly 
different as compared to the control group.  
(b) GABA in the chronic pain group was significantly decreased (P < 0.05) as 
compared to the acute pain group while taurine and glycine were not 
significantly different between the two groups.  
 
Analysis of citrulline and arginine (NO indicators) 
(a) The level of citrulline, which is the by-product of NO formation from arginine, 
in the chronic pain group was significantly higher (P< 0.001) as compared to 
the no pain control group. Citrulline was detected in 17 out of the 29 chronic 
pain CSF samples (1.65 ± 0.36 µmol/L) and only 3 out of 35 CSF samples in 
the no pain control group showed very small amount of citrulline. Arginine, 
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which is the substrate of NO synthase was also significantly higher in the 
chronic pain group as compared to the control group (P < 0.001).  
(b) No significant differences were observed in the concentrations of citrulline 
between the chronic pain and acute pain group. CSF arginine levels were 
significantly higher in chronic pain group as compared to the acute pain group 























  Acute and chronic pains though initiated by tissue damage or injury, are very 
different from each other. Chronic pain is more challenging and unrelenting. 
Prolonged activation of nociceptors evokes continuous release of EAAs, which in 
combination with co-released neuropeptides like substance P etc… play a pivotal role 
in the chronification of pain (Chizh, 2002). The levels of various amino acids were 
determined in CSF of chronic pain group and compared with no pain control group to 
evaluate the role of these compounds in chronic pain per se. Then by comparing the 
concentrations of these amino acids in chronic pain group with their levels in the 
acute pain group, the differential roles of these amino acids in these two types of pain 
were evaluated.  The focus in this work was mainly on the amino acids, known to 
modulate pain. 
  In our pursuit to quantitatively analyze physiological amino acids in CSF, a number 
of samples from chronic pain, acute pain and no pain groups including both male and 
female subjects have been analyzed. Previous studies on the effect of gender on CSF 
amino acids concentrations, reported that only the arginine and tyrosine levels in CSF 
of males are significantly higher than in females (Ferraro and Hare, 1985) while 
Kornhuber et al (1988) stated that there was no consistent relation between gender 
and CSF amino acid levels. Before choosing the data for this comparative study, the 
samples in the different groups were separated based on their gender and statistically 
compared. Statistically significant differences in many amino acids were observed 
between male and female samples in both acute pain and no pain control group. 
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Hence to nullify the impact of gender from our study, it was decided to choose only 
the female subjects from both acute and no pain groups to compare with the chronic 
pain group also comprising of only female subjects. 
  The acute pain group in our study had both labor pain patients and other non 
pregnant patients similar to our no pain group. Hence another comparison was 
performed between the amino acid levels in acute labor pain and other acute pain 
patient groups and since no statistically significant differences were seen between 
these groups except for GABA, it was decided to pool the labor pain and other acute 
pain samples.  
  The next concern was the age differences between the different groups. The chronic 
pain group in our study were all elderly patients as compared to the other two groups 
(Table 4.3). The influence of age on CSF amino acids was investigated by different 
studies (Gjessing et al., 1974; Goodnick et al., 1980; Ferraro and Hare, 1985). All 
these three studies have consistently reported a positive correlation between age and 
CSF concentrations of aspartate, isoleucine, leucine, phenylalanine and valine. These 
amino acids were all reported to be significantly increased in CSF of elderly patients 
(Ferraro and Hare, 1985). In addition, Ferraro and Hare suggested that GABA and 
serine in CSF significantly decreased in elderly patients. Hence when evaluating the 
differential roles of these amino acids in chronic and acute pain states, the influence 




Amino acid neurotransmitters and nitric oxide in Chronic and Acute Pain 
------------------------------------------------------------------------------------------------------- 
 93
Excitatory amino acids    
  The EAAs aspartate and glutamate were significantly higher in the chronic pain 
group (P < 0.01) as compared to the no pain group. This suggests the involvement of 
the EAAs, aspartate and glutamate in chronic pain mechanisms. Asparagine, the 
metabolite of aspartate was also higher (P < 0.01) in the chronic pain group as 
compared to control. This is justified as asparagine concentration is projected to be 
higher in pain group (Bergles et al., 1999) and further supports the involvement of 
aspartate in chronic pain. However, glutamine concentration was not significantly 
different between the two groups. 
  In chronic pain, aspartate (P < 0.01) was significantly higher than in acute pain 
suggesting aspartate may have important contributions in the establishment of 
persistent chronic pain state. In chronic pain syndromes, the intensity of pain is out of 
proportion to the original injury or tissue damage (Loeser and Melzack, 1999) unlike 
acute pain and hence the observed higher aspartate in chronic pain patients should 
have stimulatory effects on the pain processing pathway. The chronic pain group 
consisted of elderly patients as compared to the acute labor pain group and aspartate 
levels have been reported to increase in CSF with age of the patients but glutamate, 
glutamine and asparagine levels were not influenced by age of the subjects (Ferraro 
and Hare, 1985). Though the increase in aspartate observed in chronic pain patients 
could also be the effect of age, the significant increase observed in asparagine (P < 
0.001) – the metabolite of aspartate in chronic pain group further supports the 
hypothesis that aspartate levels are increased due to the chronic pain condition itself. 
Glutamate levels though higher in chronic pain group as compared to acute pain (4.42 
Amino acid neurotransmitters and nitric oxide in Chronic and Acute Pain 
------------------------------------------------------------------------------------------------------- 
 94
µmol/L vs. 2.86 µmol/L); this difference was not statistically significant. This could 
also be due to insufficient numbers (n = 29) in chronic pain group. The glutamine 
levels however were significantly higher in chronic pain group as against the acute 
pain group (P < 0.001) which hints that the glutamate levels could be significantly 
higher with increase in number of samples. 
  Taken together, the above two sets of comparison indicate, the EAAs aspartate and 
glutamate have vital roles in chronic pain mechanisms. Aspartate in particular is 
important in chronification of pain states. 
   
Inhibitory amino acids  
  IAAs glycine, GABA, and taurine are also known to modulate pain perception. 
However, a dual role has been suggested for glycine in pain perception. In addition to 
being the primary inhibitory neurotransmitter in the spinal cord and brain stem, it has 
been shown to be an obligatory coagonist at the excitatory glutamate receptors of the 
NMDA subtype (Chatterton et al., 2002, Ahmadi et al., 2003) and the affinity of 
glycine to the NMDA receptors is much higher than its affinity to the strychnine-
sensitive glycine receptors, which mediate the anti-nociceptive effect (Becker et al., 
1988). As discussed earlier in the discussion section of chapter 3, synaptically 
released glycine might be detected in the CSF. Therefore, CSF glycine levels were 
determined to analyze if extracellular glycine in the CSF might reflect pain status 
clinically.  
  As shown in Table 4.3, glycine level in the chronic pain group was significantly 
higher than the non-pain control group (10.80 µmol/L vs. 4.86 µmol/L, P < 0.01). 
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This suggested the involvement of glycine in chronic pain via the NMDA subtype 
excitatory glutamate receptors.  
Though there was some increase in glycine in the chronic pain group as compared to 
acute pain group, the increase was not statistically significant (10.50 µmol/L vs. 8.18 
µmol/L). As already shown in the previous Chapter, glycine is involved in acute pain 
mechanism. However, higher glycine levels sustained in chronic pain group as 
compared to acute pain patients suggested glycine might contribute in acute pain 
becoming chronic pain states. 
  The level of GABA was not significantly different between the chronic pain and the 
control group. In the second comparison between the chronic and acute pain groups, 
GABA levels were significantly lower (P < 0.05) in the chronic pain group. As 
mentioned earlier, in the comparison between labour pain and other acute pain, 
GABA was different between these groups. Also as discussed in chapter 3, GABA 
might be affected by pregnancy and also age of the patients (Ferraro and Hare, 1985). 
Hence the GABA levels in the chronic and acute pain groups in this study cannot be 
compared. 
  Taurine levels were not different in both the comparisons – chronic pain vs. no pain 
control and chronic pain vs. acute pain group. This suggests taurine may not have 
important implications in chronic pain mechanisms. 
 
Citrulline – surrogate of NO 
  NO has been accepted as one of the neurotransmitters involved in pain perception 
(Yaksh et al., 1999; Lewin et al., 2004). NO was analyzed indirectly in this study too, 
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by analyzing the amount of citrulline, a byproduct of NO synthesis from arginine. 
Similar method was applied to patients with fibromyalgia (Larson et al., 2000) and 
similarly Perez-Neri et al. (2004) reported that the citrulline levels in CSF reflected 
actual NO biosynthesis. The citrulline and arginine levels in chronic pain patients 
were both significantly higher than the control no pain group (P < 0.001). As 
discussed in chapter 3, NO is formed by nitric oxide synthase which oxidizes L-
arginine to citrulline and NO and it has been shown that the reaction product NO acts 
as a feedback inhibitor of the neuronal enzyme nitric oxide synthase (Wang et al., 
1994; Abu-Soud et al., 1995). Such a feedback inhibition by NO itself would account 
for the higher arginine levels in addition to high citrulline in chronic pain patients. 
This suggests NO is involved in the mechanism of pain perception in these patients. 
  Citrulline levels in chronic pain patients were not significantly different from those 
in acute pain group although the chronic pain patients had significantly high levels of 
arginine as compared to the acute pain group (P < 0.001). Citrulline and arginine 
levels in CSF were not influenced by the age of the subjects. Arginine  transport and 
biosynthesis are both stimulated by cytokines such as interleukin-1 and interferon-γ 
(Simmons et al., 1996; Perez-Neri et al., 2004), so its concentration is expected to 
increase during any immune response. Also arginine levels are regulated by a number 
of other mechanisms, such as metabolic consumption and efflux transport across the 
blood-brain barrier (Wiesinger, 2001). Since there were no significant differences in 
citrulline levels in this comparison, only the arginine increase cannot be taken as an 
indicator of NO involvement in chronic pain state. Hence NO, though involved in 
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pain perception, may not contribute in the development of persistent, chronic pain 
state.  
  In summary, the EAAs – aspartate and glutamate, NO and Glycine are involved in 
the mechanism of chronic pain perception. Aspartate in particular seems to have a 
vital role in the establishment of persistent, chronic pain state from acute pain. 
Glutamate and NO though involved in pain perception may not directly contribute to 
pain chronification. The other IAAs GABA and taurine are not the major contributors 
to chronic pain mechanism. These results highlight the important role of aspartate in 
the unrelenting chronic pain and thus could possibly be a signal for chronification of 
pain conditions. Hence this amino acid could also be a possible chronic pain indicator 
and thus support the role of NMDA receptor antagonists as reasonable targets for 
















Table 4.1 Comparison of concentration of pain-related amino acids in CSF – Acute 
labor pain Vs other acute pain group. 
 
Amino acids Acute labor paina 
(µmol/L) 
(n = 38) 
Other acute painb 
(µmol/L) 
(n = 8) 
Arginine 13.51 ± 0.56 23.64 ± 4.69 
Asparagine 10.19 ± 0.51 13.89 ± 1.73 
Aspartate 6.63 ± 0.41 7.78 ± 2.91 
Citrulline 2.11 ± 0.42 1.52 ± 0.68 
GABA 5.71 ± 0.73* 2.46 ± 0.86 
Glutamate 2.48 ± 0.18 4.69 ± 2.54 
Glutamine 583.65 ± 16.36 663.22 ± 103.08 
Glycine 8.18 ± 1.26 8.17 ± 2.34 
Taurine 9.85 ± 1.01 10.15 ± 2.76 
 
Values are expressed as mean ± SEM 
 
a Women with acute labor pain 
b Women in other acute pain 
 









Table 4.2 Comparison of concentration of pain-related amino acids in CSF – Acute 
pain MALE Vs Acute pain FEMALE group. 
 
Amino acids Acute pain MALEa 
(µmol/L) 
(n = 13) 
Acute pain FEMALEb 
(µmol/L) 
(n = 46) 
Arginine 15.27 ± 1.07** 33.22 ± 4.62 
Asparagine 10.84 ± 0.55* 18.21 ± 2.38 
Aspartate 6.83 ± 0.59 6.12 ± 1.56 
Citrulline 2.00 ± 0.37 1.34 ± 0.44 
GABA 5.14 ± 0.64 3.35 ± 0.64 
Glutamate 2.86 ± 0.46 5.31 ± 1.32 
Glutamine 597.49 ± 22.12*** 1141.59 ± 115.89 
Glycine 8.18 ± 1.11 10.50 ± 1.55 
Taurine 9.90 ± 0.95* 18.26 ± 2.87 
 
Values are expressed as mean ± SEM 
 
a Male with acute pain 
b Female in acute pain 
 












Figure 4.1 Chromatograms of CSF samples from the three patient groups 
 
Peaks: 1-aspartate; 2-glutamate; 3-asparagine; 4-glutamine; 5-citrulline; 6-serine; 7-
threonine; 8-glycine; 9-alanine; 10-arginine; 11-taurine; 12-GABA; 13-proline; 14-
valine; 15-methionine; 16-isoleucine; 17-leucine; 18-tryptophan; 19-phenylalanine; 









Table 4.3 Concentration of pain-related amino acids in CSF – Chronic pain Vs 





Age (mean ± SD) 
Controla  
(µmol/L) 
(n = 35) 
37.6 ± 12.2 
Chronic painb 
(µmol/L) 
(n = 29) 
64.7 ± 12 
Acute painc 
(µmol/L) 
(n = 46) 
36.8 ± 19.1 
Arginine 15.52 ± 1.21*** 32.32 ± 2.70 15.27 ± 1.07‡‡‡ 
Asparagine 13.28 ± 0.99** 21.22 ± 1.90 10.84 ± 0.55‡‡‡ 
Aspartate 4.94 ± 0.69*** 12.05 ± 1.69 6.83 ± 0.59‡‡ 
Citrulline¥ 0.13 ± 0.08*** 1.65 ± 0.36 2.00 ± 0.37 
GABA 4.20 ± 0.37 3.37 ± 0.60 5.14 ± 0.64‡ 
Glutamate 2.27 ± 0.23** 4.42 ± 0.68 2.86 ± 0.46 
Glutamine 1010.27 ± 49.01 994.7 ± 91.31 597.49 ± 22.12‡‡‡
Glycine 4.86 ± 0.34** 10.50 ± 1.42 8.18 ± 1.11 
Taurine 13.95 ± 0.85 12.51 ± 1.85 9.90 ± 0.95 
 
Values are expressed as mean ± SEM 
 
a Women with no pain 
b Women in chronic pain 
c Women with acute pain 
 
*, ‡ (P < 0.05) **, ‡‡ (P < 0.01) ***, ‡‡‡ (P < 0.001) – Statistically significant when 
compared to the chronic pain group. 
¥ Citrulline detected in only 3 out of 35 control CSF, 17 out of 29 chronic pain CSF 
and 22 out of 46 acute pain CSF. 
 








Figure 4.2 Comparison between Pain related amino acids in CSF of Chronic pain and 
Acute pain patients - Differential roles for these amino acids in the two types of Pain 
states 
 
* (P < 0.05) ** (P < 0.01) *** (P < 0.001) – Statistically significant differences 
between the two groups compared 
 








































PURIFICATION OF PEPTIDES FROM CEREBROSPINAL 
















  CSF is distributed between the subarachnoid space surrounding the brain, the spinal 
cord and the interstitial space encircling the cells in the CNS. Metabolites from 
various tissues within the brain are secreted into the interstitial space and up in the 
CSF. Hence CSF reflects the metabolic state of the brain under healthy as well as 
diseased conditions. Many pathogenic processes especially CNS diseases are 
reflected by characteristic changes in the contents of CSF. Peptides, such as hormones, 
cytokines and growth factors play a central role in biological processes. These 
peptides, being degradation products or processed forms of larger proteins form a part 
of the protein turnover (Heine et al., 2002). Peptide concentrations in CSF reflect 
neuronal activity and can be correlated to CNS disorders. Conventionally 
concentration of peptides in CSF or nervous system such as the opioid peptides has 
been studied by radioimmunoassay (RIA). RIA, though highly sensitive and specific 
for detection of peptides, has the disadvantage that peptides with similar structures or 
the precursors and metabolites of the same peptide may cross-react with the specific 
antibodies and also the presence of proteins and salts in biological samples like CSF 
may interfere with the RIA procedure (Liu et al., 2000).  
  The proteomics approach based on two-dimensional (2-D) gel electrophoresis is 
very popular for protein markers identification and analysis of protein content in 
different systems but this approach has short-comings especially in peptides analysis. 
Resolution of low-molecular weight peptide mixtures using 2-D gels is not 
satisfactory. Also staining of short peptides gives much lower intensities than protein 
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staining. Recovery of peptides from 2-D gels is often cumbersome resulting in lower 
recovery and often requires in-gel digestion (Schulz-Knappe et al., 2001). This 
approach is thus restricted to the analysis of proteins with higher molecular masses 
(>10KDa). An approach different from proteomics involving multiple column 
chromatography steps were applied to CSF for isolation of new peptides with special 
focus on peptides between 1 and 15KDa. This method had the definite advantage that 
the peptides remained in liquid phase during the various processing steps and were in 
unchanged molecular forms, thus improving the recovery.  
  The concentration of neuropeptides in CSF is generally very low except for 
albumins and globulin and their levels may increase or decrease depending on the 
CNS status. In this work, the above strategy was applied to purify new peptides from 
CSF of chronic pain patients. Chronic pain, being unrelenting is more challenging and 
no effective therapeutics are available for treating chronic pain. In chronic pain 
patients’ CSF, the levels of some pain related peptides, their precursors or processed 
forms may be up or down regulated. These peptides purified from CSF could be 
potential markers for chronic pain and could hint on pain mechanisms or could be 
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5.2 Materials and Methods 
 
Materials: 
  All chemicals and solvents used were of HPLC or analytical grade. Acetonitrile and 
methanol (HPLC grade) and hydrochloric acid were from Merck (Whitehouse station, 
NJ) and trifluoroacetic acid (TFA) was from Pierce (Rockford, IL). All the HPLC 
columns were from Phenomenex (Torrance, CA). CT peptide was synthesized and 
obtained from Peptide Institute Inc. Japan. The ultrafiltration filters with molecular 
weight cut-off at 3K and 30K were from Amicon (Millipore, Billerica, MA). Tween-
20 was from SIGMA (St. Louis, MO).  
 
CSF samples: 
  1 to 2 mL of CSF per patient was collected at lumbar puncture during spinal 
anaesthesia in patients with chronic osteoarthritis of the knee undergoing joint 
replacement surgery and during myelogram in patients with chronic backache. CSF 
samples were collected from patients after written informed consents were obtained. 
The experimental protocol was approved by the Institutional Review Board. Since 
neuropeptides concentration in CSF is reported to be in femtomole range, it was 
required to pool samples from few patients. 25 mL CSF was obtained by pooling 
several lumbar puncture samples. All the CSF samples were kept frozen individually 
at -80°C immediately after collection and pooled just before the purification process.  
 
 




  The preparative and analytical purification procedures were carried out using a 
Shimadzu HPLC system (Kyoto, Japan) with LC10ADVP pump, SPD10AVP UV-
Visible detector and SCL10AVP system controller and using Class-VP (version 5.03) 
software for system control and peak analysis.  
  For microbore purification, Gynkotek HPLC system (Germany) with P 580A HPG 
pump, auto sampler and UV-Visible photodiode array detector (UVD 340S) were 
used. Chromeleon (Softron, version 6.20) software was used for controlling the 
system, for peak analysis and for determining other relevant parameters.  
 
Methods: 
  A new approach based on multiple column chromatography steps including an 
ultrafiltration step for removal of high molecular weight proteins was developed and 
applied to CSF for purification of peptides. The overall methodology is as indicated 
























  The pooled CSF samples from chronic pain patients (25 mL) were diluted 2X with 
milli Q distilled water. The pH of the diluted sample was adjusted below 3.0 with 1N 
hydrochloric acid and then loaded directly on a Nucleosil C18 column (250 x 10.0 
mm, 10 µm particle size) equilibrated with the solvent system of 1% acetonitrile, 
0.1% TFA in water at a flow rate of 4 mL/min. Absorbance was monitored at 214 nm 
and 280 nm. After a stable base line was established, the sample was eluted in three 
steps using three different solvents from the column. First elution from the column 
was performed using the same solvent system of 1% acetonitrile, 0.1% TFA in water, 
the second elution was performed using the solvent system comprising of 80% 
acetonitrile, 0.1% TFA in water and the final elution was with methanol. The three 
eluted fractions were individually collected and labelled Fraction A, B and C 
respectively and separately lyophilized. 
 
Ultra filtration 
  The lyophilized powder of Fraction B (16 mg) obtained from the above preparative 
HPLC procedure was dissolved in 1 mL of the solvent 1% acetonitrile, 0.1% Tween-
20 in water and centrifuged in 30K molecular weight cut-off amicon filters at 12,000 
x g for 20 minutes. The residue (molecular weight > 30K) was recovered from the 
filter using 0.5 mL of 10% acetonitrile, 0.1% TFA in water, lyophilized and kept 
aside. The filtrate (molecular weight <30K) was mixed with 10% the net volume of 
1% acetonitrile, 1% Tween-20 in water and then centrifuged in 3K molecular weight 
cut-off amicon filters at 12,000 x g for 50 minutes. The filtrate (molecular weight < 
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3K) was lyophilized and kept aside. The residue is our fraction of interest as this 
consists of the components of CSF with molecular weight between 3K and 30K. This 
was carefully recovered from the filter unit using 0.5 mL of 10% acetonitrile, 0.1% 
TFA in water, the pH of this solution was adjusted below 3.0 with 1N hydrochloric 
acid and then stored at -80°C until further purification procedures. 
 
Analytical HPLC fractionation and Protein Staining 
  The fraction with molecular weight between 3K and 30K obtained from ultra 
filtration was next loaded on the analytical HPLC column Jupiter C18 (250 x 4.6 mm, 
5 µm particle size) using a Shimadzu HPLC instrument. The solvent system consisted 
of 10% acetonitrile, 0.1% TFA in water (solvent A) and 80% acetonitrile, 0.1% TFA 
in water (solvent B). Elution was performed at a flow rate of 1 mL/min and 
absorbance monitored at 214 nm. After sample injection, 100% solvent A was used 
for elution for 10 minutes till the baseline stabilized, followed by a gradient of 0-
100% solvent B over 45 minutes. 1 minute fractions were collected using a fraction 
collector. Peak calibration was done using the Class-VP software and the amounts 
were calculated based on the peak areas using previous calibration curves plotted by 
running known amounts of peptide nocistatin-30 on the same HPLC using similar 
conditions. The fractions corresponding to various peaks were all lyophilized 
individually. 
  The above lyophilized fractions were then reconstituted in the solvent 10% 
acetonitrile, 0.1% TFA in water to a concentration of about <5pmol/2 µl. Then 
depending on each peak amounts, 1 to 5 pmol of each peak/fraction was spotted on 
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nitrocellulose membrane (Bio-Rad, Hercules, CA) and stained using colloidal gold 
total protein stain followed by gold enhancement staining from Bio-Rad for 
identification of protein/peptides in the fractions. The peaks/fractions that stained 
positive in the above procedure were individually chosen, lyophilized and stored for 
final purification at -80°C. 
 
Final purification – microbore 
  Fractions collected at 28th, 30th and 31st minutes in the above analytical HPLC 
fractionation step were confirmed by enhanced colloidal gold total protein staining to 
contain protein/peptides. These three lyophilized fractions (597.6 pmol) were 
reconstituted in 40 µL of the solvent 5% acetonitrile, 0.02% TFA, and 0.1% Tween-
20 in water, pooled and injected onto a Luna Phenyl Hexyl (150 x 2.0 mm, 3 µm 
particle size) microbore column using the Gynkotek HPLC system auto sampler. The 
solvent system consisted of 5% acetonitrile, 0.02% TFA in water (solvent A) and 
80% acetonitrile, 0.02% TFA in water (solvent B). The flow rate was maintained at 
0.15 mL/min and absorbance monitored at 214 nm. After sample injection, 10% 
solvent B was used for elution for 10 minutes till the baseline stabilized, followed by 
a gradient of 10-80% solvent B over 45 minutes. Fractions were collected manually. 
 
Mass spectrometry - sequencing 
  The molecular weight (M.W.) of the pure peaks were estimated by MALDI TOF 
mass (Shimazdu AXIMA) and subsequently sequenced by MALDI TOF/TOF mass 
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(Applied Biosystems 4700, Foster city, CA) following trypsin (Roche Diagnostics, 
Tokyo, Japan) digestion.  
 
Co-elution experiments 
  In order to confirm the sequence of the isolated peptide from CSF, the estimated 
sequence was synthesized by the general solid-phase method (Peptide Institute Inc. 
Japan) and its structure was confirmed by mass spectrometry and amino acid analysis. 
  The purified peptide isolated from CSF of chronic pain patients was run on HPLC 
using two different conditions and the peak was collected manually. To this collected 
peak, known fixed amount of the synthetic peptide was added and pooled. This 
sample was next loaded on the same microbore column and performed the HPLC run 

















The chromatograms of the analytical and microbore HPLC purification steps are 
shown in Figure 5.1- A and B respectively. After the final purification step on 
microbore HPLC, three sharp peaks stained positive for peptides. These peaks are 
indicated as Peaks 1, 2 and 3 in the chromatogram (Figure 5.1 B). The staining results 
of these three peaks are as seen in Figure 5.2. 
 
Isolation of 7B2CT peptide: 
  The Peak 1 in the microbore purification chromatogram (Figure 5.1 – B) was 
collected manually and lyophilized for mass analysis. The M.W. of this highest peak 
1 was estimated as 3512.96 (H+) by MALDI TOF mass (Shimadzu AXIMA-CFR 
plus) and subsequently sequenced by MALDI TOF/TOF mass (Applied Biosystems 
4700, Foster City, CA, USA)) after trypsin (Roche Diagnostics, Tokyo, Japan) 
digestion. The sequences of the two trypsin fragments are shown in Figure 5.3 -A as 
trypsin-1 and 2. The peak 1 was identified as the C-terminal 31 amino acid peptide 
(7B2CT) of the neuroendocrine protein 7B2 precursor.  
  The concentration of this 7B2CT peptide in human CSF calculated based on the 
peak area in the final HPLC purification step was found to be 6.3 pmol/mL of CSF.  
Co-elution experiments: The estimated sequence of the peak 1 was synthesized by 
the general solid-phase method (Peptide Institute Inc. Japan) and its structure was 
confirmed by mass spectrometry and amino acid analysis. The synthetic peptide was 
used to confirm the sequence of the peptide isolated from CSF by performing co-
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elution experiments on HPLC. The retention time of the synthetic peptide coincided 
with that of the natural peptide isolated from CSF in two HPLC conditions (Figure 
5.4).  
 
Isolation of a Chromogranin A fragment and its oxidized form: 
  The Peaks 2 and 3 in the microbore purification chromatogram (Figure 5.1 – B) 
were collected and subjected to mass analysis. The M.W. of these peaks 2 and 3 were 
estimated as 3923.51 (H+) and 3906.28 (H+) by MALDI TOF mass (Shimadzu 
AXIMA-CFR plus) and subsequently sequenced by MALDI TOF/TOF mass 
(Applied Biosystems 4700, Foster City, CA, USA)) after trypsin (Roche Diagnostics, 
Tokyo, Japan) digestion. The peak 3 was identified as a fragment of chromogranin A 
precursor, covering positions 97-131 of the original protein. The peak 2 mass was 
found to be around 16 Da higher than that of peak 3. The trypsin digest of peak 2 
yielded similar fragment as the fragment trypsin-1 of peak 3 (Figure 5.3 B). The 
peaks were then subjected to Edman sequencing and correlation of these results with 
the mass data of the two peaks indicated that this peak 2 was the methionine oxidized 
form of peak 3. The sequences of the trypsin digest fragments of the peak 3 are 
shown in Figure 5.3 – B. The concentrations of this Chromogranin A fragment 
peptide and its oxidized form in human CSF were calculated as explained for 7B2CT 
and were found to be 5.9 and 5.4 pmol/mL of CSF respectively. 
Co-elution experiments: The estimated sequence of the peak 3 was also synthesized 
by the general solid-phase method (Peptide Institute Inc. Japan) and the synthetic 
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peptide was used to confirm the sequence of this peptide isolated from CSF as 



























  A strategy different from proteomics was developed for purification of low 
molecular weight peptides from CSF. A multiple column chromatography protocol 
using reverse phase HPLC was applied along with an ultra filtration step, which 
facilitated the separation of high molecular weight proteins and other components 
from the targeted peptides. The peaks and fractions obtained from each HPLC 
procedure were all systematically screened for presence of peptides/proteins by a 
staining protocol as described in methods section. After the ultra filtration step, when 
analytical HPLC run was performed, many fractions with small peaks confirmed to 
be peptides by staining were obtained. Three such fractions were pooled and purified 
successfully by this method to get three peptides and their structures were confirmed 
by MS MS sequencing. These peptides were identified as (1) the 31 amino acid 
7B2CT of neuroendocrine secretory protein 7B2 precursor, a granin family protein 
and (2) a fragment of chromogranin A precursor protein from positions 97-131 of the 
original protein sequence. The oxidized form of this peptide fragment of 
chromogranin A precursor was also isolated from human CSF by this method. This 
chromogranin A fragment was synthesized as explained in structure confirmation 
experiments for this peptide and this synthetic peptide when dissolved and run on 
HPLC the same day showed one single peak in the chromatogram (Figure 5.6 – A). 
When the dissolved synthetic peptide was stored overnight at -30°C in the freezer and 
run using same HPLC conditions the following day, showed two peaks – one 
corresponding to the original peak (retention time – 28.40) and another small peak 
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(retention time – 26.79) as shown in Figure 5.6 – B. This shows the peptide is very 
much prone to oxidation. Stark et al (2001) isolated these peptides from human CSF 
but their purification strategy involving phase separation was very different from the 
one developed in this study. 
  The neuroendocrine protein 7B2 precursor Pro7B2 is cleaved into N-terminal 
mature 7B2 protein also called secretogranin V (Taupenot et al., 2003) and 7B2CT 
peptide during transportation from Golgi apparatus into the secretory granules. 7B2 
protein or mRNA has been reported to be found in tissues that are primarily neuronal 
(brain, adrenal medulla) or endocrine (pituitary, thyroid, pancreas) or are known to 
carry a sub-population of neuroendocrine cells (gastrointestinal tract) and its 
intracellular function has been established as the specific chaperone for the proprotein 
convertase 2 (PC2) enzyme. It prevents the premature activation of PC2 zymogen. 
The 7B2CT peptide has also been shown to strongly inhibit PC2 activity in in vitro 
experiments (Van Horssen et al., 1995; Zhu et al., 1996; Mbikay et al., 2001).  
  This 7B2CT and the other peptide isolated from CSF – a chromogranin A fragment 
covering positions 97-131 and its oxidized form are all fragments of proteins that 
belong to the granin family. Granins are a unique group of acidic, soluble secretory 
proteins and are ubiquitously distributed in neuroendocrine and nervous system 
tissues. Owing to the presence of numerous paired basic amino acids in granins, they 
function as prohormones, giving rise to bioactive peptides by post-translational 
proteolytic processing. Peptides derived in this fashion from chromogranin A, 
chromogranin B and secretogranin II have autocrine, paracrine and endocrine 
activities (Taupenot et al., 2003). Though clinically granins themselves have been 
Purification of peptides from CSF 
------------------------------------------------------------------------------------------------------- 
 117
shown to be useful neoplasm markers, no extracellular functions have so far been 
assigned to many peptides derived from these granins especially the two peptides 
isolated in this study. Also no unique receptors have been identified for all these 
granin fragments (Taupenot et al., 2003). A characteristic feature of these two 
peptides isolated in this study is their high content of acidic amino acids and it is 
probable that this high content of aspartate and glutamate residues in these peptides 
may have a physiological function or significance. 
  In conclusion, here two peptides that are fragments of two such members of granin 
family (secretogranin V and chromogranin A) were isolated from CSF of chronic pain 
patients. Hence these peptides are hypothesized to have additional important 
extracellular, pathophysiological roles unexplored so far, especially related to chronic 
pain perception mechanisms.  
  These unique extracellular bioactivities of 7B2CT, which might cause chronic pain, 
have been explored in the following chapters of this work. 
   
 
   
   















Figure 5.1 Chromatograms of the Analytical HPLC purification step (A) and the 
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Figure 5.3 Sequences of the trypsin digestion fragments obtained from Peak 1 (A) 
and Peak 3 (B) during MS MS sequencing  
 
 
 +ve control  Peak 1    Peak 2     Peak 3       
A 
                                                  1                                10                                 20                                 30                                       
Human 7B2CT             SVNPYLQGQRLDNVVAKKSVPHFSDEDKDPE               PEAK 1 
Trypsin-1 Trypsin-2
                                                        1                             10                                 20                               30               35 
Chromogranin A          HSGFEDELSEVLENQSSQAELKEAVEEPSSKDVME         PEAK 3 
Precursor fragment
B 
           Trypsin-1                                              Trypsin-2       











Figure 5.4 Co-elution experiment chromatograms – (A) 9 pmol of 7B2CT peptide 
isolated from human CSF, (B) Co-elution of 9 pmol of 7B2CT peptide collected from 
run A with 30 pmol of synthetic 7B2CT peptide – both eluting together when purified 
















Figure 5.5 Structure confirmation experiment chromatograms – (A) Chromogranin-A 
fragment peptide isolated from human CSF, (B) The Synthetic peptide run using 
same condition on HPLC – Both eluting at the same retention times on HPLC run 






















Figure 5.6 Evidence for Oxidation tendency of the Chromogranin A fragment – 
(A) The synthetic chromogranin A fragment peptide dissolved and run immediately 
on HPLC (B) The synthetic peptide after overnight storage in freezer, run on HPLC 














































   
  The 31 amino acid C-terminal peptide (7B2CT) of neuroendocrine secretory protein 
7B2 precursor (Pro7B2), a granin family protein was isolated from the CSF of 
chronic pain patients (Chapter 5). The intracellular physiological function of Pro7B2 
has been established as the regulator of PC2 by inhibition of its enzyme activity and 
7B2CT shows strong inhibitory activity against PC2 in in vitro experiments (Mbikay 
et al., 2001). Further, plasma and CSF are well known to contain 7B2-like 
immunoreactivity in relatively high concentration of 40-140 pM in plasma and 10-
times higher than these values in CSF, which are thought to be useful markers for 
neuroendocrine carcinomas (Mbikay et al., 2001; Taupenot et al., 2003). However, 
the antibodies so far used could not recognize 7B2CT because the antibodies were 
raised against 7B2 sequences (Iguchi et al., 1987).  Extracellular pathophysiological 
roles of Pro7B2 or 7B2 and its C-terminal possibly processed peptides have not been 
well studied to date. Since this peptide was isolated from the CSF in circulation of 
chronic pain patients, it was decided to check the bioactivity of this peptide especially 
related to pain perception mechanisms. 
 
Measurement of Pain in animals: 
  Chronic pain especially a persistent neuropathic pain condition is characterized by 
spontaneous, burning pain, allodynia commonly defined as pain responses to non-
noxious stimuli and hyperalgesia, which is exaggerated pain responses to noxious 
stimuli (Malmberg and Basbaum, 1998). Development of increasingly sophisticated 
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animal models have aided the progress in pain research and the models of acute 
nociception such as the tail-flick, hot-plate and writhing tests were used to develop all 
the classic analgesic drugs (Walker et al., 1999).  
 
  The tail-flick and hot-plate models use direct thermal stimulus to elicit a flick of the 
tail or paw licking at noxious (unpleasant) intensities of thermal stimulation (45 - 
52°C). These methods can detect hyperalgesia and characterize the effects of 
analgesic and anti-hyperalgesic drugs. Allodynia can be measured by the use of von 
Frey filaments, which are used to apply slight pressure to the skin. In presence of 
allodynia, this slight pressure becomes unpleasant and the animal moves the affected 
limb. This mechanical allodynia is one of the most common symptoms in clinical 
conditions such as neuropathic pain (Walker et al., 1999).  
 
  To evaluate the pain related bioactivities of the 7B2CT peptide, hyperalgesia and 
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6.2 Materials and Methods 
 
Materials 
  The 7B2CT peptide was synthesized by the general solid-phase method (Peptide 
Institute Inc. Japan) and its structures were confirmed by mass spectrometry and 
amino acid analysis.  
 
Methods 
  The allodynia assays in this chapter were performed in the laboratory of our 
collaborator – Prof. T. Minami, Department of Anesthesiology, Osaka Medical 
College, Japan. 
 
Allodynia assay  
  Mechanical allodynia was carried out with ddY mice weighing 22 ± 2 g (Shizuoka 
Laboratory Center, Hamamatsu, Japan) according to the previously described method 
(Minami et al., 2000).  Allodynia was assessed once every 5 min for 50 min by light 
stroking of the flank of the naive mice with a paintbrush.  The mechanical allodynic 
response was ranked as follows: 0, no response; 1, mild squeaking with attempts to 
move away from the stroking probe; 2, vigorous squeaking evoked by the stroking 
probe, biting at the probe, or strong efforts to escape. The maximum possible scores 
for mechanical allodynia of 6 mice were 2 x 6 = 12 in any 5-min period and 2 x 6 x 
10 = 120 for 50 min and they were taken as 100%. 
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  Mechanical allodynia was also studied in the inflammation model mice prepared by 
the method described by Muratani et al. (2002) and in neuropathic pain model, which 
was made by L5 spinal nerve transection (Mabuchi et al., 2003) with a slight 
modification of the method described by Kim and Chung (1992). Mice weighing 25 ± 
2 g were anesthetized by intraperitoneal administration of sodium pentobarbital (50 
mg/kg) and the left L5 spinal nerve was isolated, tightly ligated with 4-0 silk thread at 
two locations (5-mm apart), and transected between ligatures. On day 7 after nerve 
transection, the mice were placed individually on an elevated metal grid covered with 
a clear plastic cage and withdrawal responses to punctuate mechanical stimulation 
were determined using calibrated von Frey filaments (UGO Basil).  The filaments 
were once applied to the paw at an increasing force until the mouse withdrew its hind 
limb. Paw withdrawal thresholds were determined before and after a single i.t. 
injection of 7B2CT into 6 mice/group using up-down paradigm of Chaplan et al. 
(1994). 
 
Thermal hyperalgesia assay 
  Thermal hyperalgesia was assessed by the latency to withdrawal from a radiant heat 
stimulus using the plantar test (UGO Basil, model 7370). The i.t. administration of 
the peptide 7B2CT was performed into ddY mice as explained in allodynia assay at 









Allodynia and hyperalgesia assay 
  As shown in Figure 6.1, 3 pmol of 7B2CT evoked strong allodynic responses in 
naïve mice that sustained more than 50 min and showed a bell-shape dose-response 
curve (Figure 6.2). 
  Mechanical allodynia assay in neuropathic pain models showed the mean threshold 
in grams was 9.84 + 1.33 g in non-injured sides while it decreased to 1.87 + 1.87 g in 
injured sides. By i.t. injection of 7B2CT the threshold in non-injured sides was not 
significantly changed (7.65 + 2.03 g) while in injured sides it further decreased 
significantly to 0.48 + 0.21 g at a dose of 285 pmol in a dose related manner (Figure 
6.3). On the contrary to neuropathic pain models, allodynia was not evoked by i.t. 
injection of 7B2CT at both inflammation phases - stage 1 and 2 in formalin induced 
inflammation models.  
  However, thermal hyperalgesia assessed by the latency to withdrawal from a radiant 
heat stimulus using the plantar test was not observed by i.t. injection of the peptide 











  As discussed in chapter 5, three peptides were purified from CSF of chronic pain 
patients – the 7B2CT peptide, a chromogranin A fragment covering positions 97-131 
and its oxidized form. The CNS effect of both these peptides – 7B2CT and the 
chromogranin A fragment were tested initially by i.c.v. administration of these 
peptides into Swiss albino mice using the locomotor activity monitoring system (NS-
AS01 activity monitoring system, Neuroscience Inc., Tokyo, Japan) by our colleagues 
in our laboratory. The 7B2CT peptide exhibited a dose related suppression of 
locomotor activity, which was statistically significant. On the contrary, the 
chromogranin A fragment did not show any significant effect on the locomotion when 
tested by i.c.v. administration in mice (data not shown). Further pain related 
bioactivity experiments performed for the 7B2CT peptide were motivated by this 
interesting CNS effect of this peptide.   
  
  The i.t. administration of 7B2CT evoked strong allodynic responses that lasted more 
than 50 minutes. It also showed a bell-shape dose-response curve. Such mechanical 
allodynia being the most common symptom in neuropathic pain (Walker et al., 1999) 
suggests the 7B2CT peptide might be involved in pain perception mechanisms. 
Further experiments were performed to assess the mechanical allodynia induced by 
7B2CT administration in inflammation and neuropathic pain model mice. In 
neuropathic pain mice, a dose related allodynic response was evoked by the i.t. 
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administration of 7B2CT in the injured sites (Figure 6.3) while allodynia was not 
evoked by i.t. injection of 7B2CT at both inflammation phases 1 and 2.  
    The allodynic threshold for non-injured side was 9.84 + 1.33 g  force while for the 
injured side of the neuropathic pain model mice the allodynic threshold was 
decreased to 1.87 + 1.87 g force as seen in figure 6.3. The injection of 2.85 pmol of 
7B2CT (close to 3 pmol dose used in allodynia assay in figure 6.1) further reduced 
the allodynic threshold at the injured site as shown in figure 6.3. At the dose of 285 
pmol of 7B2CT, the allodynic threshold at the injured site was significantly reduced 
to 0.48 + 0.21 g. This peptide seems specifically involved in neuropathic pain. 
 
    In summary, the i.t. administration of 7B2CT did not produce thermal hyperalgesia 
in naive mice but evoked significant mechanical allodynia, pain hypersensitivity 
produced by innocuous stimuli, in neuropathic models. In this study allodynia 
characteristic to chronic pain patients was shown by 7B2CT administration, an 
interesting evidence for nociceptive activities of 7B2CT unexplored so far. Thus this 

















Figure 6.1 7B2CT (3 pmol) evoked allodynic response sustained even after 50 
minutes. 

















Figure 6.2 Bell-shaped dose response curve for 7B2CT in allodynia assay (3 pmol to 
300 pmol). At high doses of 7B2CT, the animals behaved normally and showed no 
allodynia. 
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Figure 6.3 Mechanical allodynia assays in neuropathic pain models – i.t. 
administration of 285 pmol of 7B2CT significantly decreased allodynic threshold in 
injured sites in neuropathic pain mice in dose related manner. 






















CHARACTERIZATION OF 7B2CT PEPTIDE ISOLATED FROM 














   
  7B2CT peptide is cleaved from Pro7B2 after the five-basic-residue sequence 
(RRKRR) to generate the mature 7B2 protein. Most regulatory peptides like 
hormones, growth factors and neuromodulators are derived from specific proteolysis 
of large precursor proteins, most often at pairs of basic amino acids (Paquet et al., 
1991). As explained in chapter 4, this 7B2CT peptide was isolated from CSF of 
chronic pain patients and also as discussed in chapter 6, this peptide was found to 
have interesting nociceptive effects when administered by i.c.v. or i.t. injection into 
mice. Such bioactivities produced by i.t. and i.c.v. injection of 7B2CT, if confirmed to 
be through specific receptors or binding sites in CNS, would be substantial evidence 
for the extracellular activities of this peptide.  
  In vitro receptor binding assay using radioactive ligands has been used for the study 
of the interaction between neurotransmitters and membrane bound receptors in the 
CNS. Though the most attractive feature of receptor binding assay appears to be its 
simplicity as it involves direct incubation of tissues with radio labelled ligand, 
numerous factors such as time, temperature, pH of binding, tissue and radioligand 
concentration are reported to influence the kinetic properties and possibly the 
specificity of a binding assay (Yamamura et al., 1978). These receptor binding assays 
take advantage of the highly selective interaction between the receptor and its ligand.  
  The study of peptide receptors binding is unique as compared to other 
neurotransmitters as: (1) most peptides can be relatively easily labelled to high 
specific activity (2) peptides are more subject to tissue degradation through brain 
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peptidase activity than most commonly used ligands (3) peptides tend to be stickier 
than most other ligands and hence can result in losses (Burt et al., 1980). One of the 
common receptor assays performed for confirmation of binding sites of peptides in 
CNS is by the saturation binding experiments. 
Saturation binding experiments: Constant amounts of receptors are incubated with 
increasing concentrations of labelled ligand and the binding sites will be occupied by 
the labelled ligand until at a high concentration of the labelled ligand, all receptors are 
saturated. Specific binding is defined as the difference between binding in absence 
and presence of the cold unlabelled peptide. From this experiment the affinity (Kd) of 
the ligand and the maximum amount of binding sites (Bmax) can be determined.  
The functional role of many neuropeptides and their receptors in the CNS has been 
investigated like the angiotensin, somatostatin, CGRP, kinin receptors etc... The 
identification of receptors for neuropeptides and the development of specific 
neuropeptide-related molecules will help to get a better understanding of its receptor 
physiology and neuronal distribution and may lead to innovative treatments in a 
variety of CNS disorders. 7B2CT peptide is a fragment of a larger protein belonging 
to the granin family and it is interesting that no unique receptors have so far been 
identified for most granin fragments (Taupenot et al., 2003). Therefore, the next part 
of the study was planned targeting the possible binding sites for the peptide 7B2CT in 
the CNS.  
  The main scope of this study is (1) to identify the binding sites for 7B2CT in mouse 
brain and thus substantiate the existence of possible extracellular roles for this peptide 
(2) to study the regional distribution of these receptors in the CNS and (3) to analyze 
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the correlation if any between these receptor distribution or numbers in brain and 
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7.2 Materials and Methods 
 
Materials: 
  All chemicals and solvents used were of HPLC or analytical grade. Acetonitrile and 
hydrochloric acid were from Merck (Whitehouse station, NJ, USA) and 
trifluoroacetic acid (TFA) was from Pierce (Rockford, IL, USA). The 0.45 µ 
centrifugal filters used for filtration was from Millipore and the GF/B glass 
microfibre filters used in receptor binding procedures were from Whatman 
(Middlesex, UK). Biogel P-4 column material was from Bio Rad (Hercules, CA, 
USA), the protease inhibitor Phenyl Methyl sulfonyl fluoride (PMSF), Bovine serum 




Radiolabelling of 7B2CT peptide: 
  The Iodogen method was applied for labeling (Salacinski et al., 1981). 7B2CT 
peptide (2 nmol) and Iodogen (2 µg) were dissolved in 50mM sodium phosphate 
buffer pH 7.4 and 2 MCi of Na125I (New England Nuclear, Boston, MA) was added. 
The iodination was carried out for 15 min at room temperature and terminated by 
addition of 470 µL of the same phosphate buffer. After 15 min, the mixture was 
acidified by addition of 30 µL 1N HCl and applied to a Sep-Pak C18 cartridge 
(Waters, Milford, MA) for purification. The cartridge was washed stepwise with DW 
containing 0.1 % TFA and 1 %, 10%, 20% acetonitrile. The bound labelled material 
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was eluted with 40 % acetonitrile containing 0.1 % TFA. The iodinated peptide was 
then purified using a disposable 10 mL injection syringe packed with Biogel P-4. The 
syringe column was eluted with 50 mM Tris buffer, pH 7.4 used for binding studies. 
0.5 mL fractions were collected and the radioactivity was determined by a γ counter 
(Perkin Elmer Wizard 1470 automatic gamma counter).  
  The purity of the tracer was confirmed by thin layer chromatography (TLC) system 
from ChromatoResearch, Japan. The purified radioactive material eluted from the 
Biogel column was diluted in methanol and spotted on TLC plates (Merck, RP-18, 10 
x 20cm). After drying the spots, the plate was developed in the solvent system 
comprising of 50 % acetonitrile containing 1 % TFA in water. Then film 
autoradiography was performed to visualize the spots. The corresponding region in 
the TLC plate was scraped off and the pure radioactive material was extracted from 
the powder using 60 % acetonitrile and 0.1 % TFA in water. The radioactivity in this 
material was measured and the radio-purity, calculated as the ratio between the spot 
area and the residuals was found to be 60 to 80% with specific radioactivity between 
2-20 x 1012 Bq/mmol. This biogel purified tracer was used for all experiments except 
in the vital saturation binding experiment in mice brain, for which highly pure HPLC 
purified tracer was used. Since the facility to purify radioactive materials using HPLC 
was not available in our laboratory, small amount of this highly pure radioactive 
material to confirm the saturation binding was kindly prepared by our collaborator in 
his laboratory in Japan as explained below.  
  In order to confirm the saturation binding in mice brain, 7B2CT peptide was labelled 
by lactoperoxidase method (Takei et al., 1992). The labelled peptide was further 
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purified by HPLC with an ODS-120T column (0.46 x 250 mm, Tosoh, Tokyo, Japan) 
with a linear gradient of acetonitrile - 0.1% TFA from 15 to 40% for 40 min at a flow 
rate of 1 mL/min. The specific radioactivity of the pure monoiodinated peptide of 
7B2CT thus obtained was calculated as 2.33 x 1012 Bq/mmol.   
 
Preparation of membrane fractions from endogenous tissues: 
Mice brain and spinal cord:  
  The protocol used for synaptosomal membrane preparation from brain and spinal 
cord tissues was as reported by Wong et al. (1989). Whole brain (except the stem and 
cerebellum) and spinal cord from Swiss albino mice (male, 25g) were homogenized 
in 20 volume of 0.32 M sucrose in a Teflon-glass homogenizer. The sucrose 
homogenate was centrifuged at 1,000 g for 10 min and the nuclear fraction was 
discarded. The supernatant was centrifuged at 30,000 g for 20 min for the 
synaptosomal (P2) fraction, which was then resuspended in 50 mM Tris buffer, pH 
7.4 and synaptosomes were thoroughly disrupted with a Heidolph tissue homogenizer 
(speed setting 4, 20 sec). To the resultant synaptosomal membranes, Triton X-100 
was added to a final concentration of 0.1 % and incubated at 37°C for 20 min. After 
incubation, the membrane preparation was cooled and then centrifuged at 30,000 g 
for 20 min. The pellet was washed 2 or 3 more times using 40 volume of the 50 mM 
Tris buffer, disrupted as explained above using homogenizer and centrifuged at 
30,000 g for 20 min each time. The final pellet was resuspended in 40 vol of 50 mM 
Tris buffer. All the above procedures were conducted strictly at 4°C unless specified. 
After preparation the tissues were kept frozen at -80°C till the assay. 
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Mice and rat brain regional tissue: 
  For the regional tissue preparation, the brain from Swiss albino mice (male, 25g) 
and Sprague-Dawley rats (male, 250g) were dissected and divided into 7 major 
regions – stem, cerebellum, midbrain, thalamus and hypothalamus, hippocampus, 
striatum and cortex. These regional tissues were individually weighed out and 
separately homogenized in 20 volume 0.32 M sucrose using the Teflon homogenizer 
and subsequent membrane preparation steps were similar to those described for whole 
brain and spinal cord tissues earlier. 
 
Pain models and tissue preparation: 
  For preparation of neuropathic and inflammatory pain models, Swiss albino mice 
(male, 25g) were used. 
Neuropathic pain model: Injury to a peripheral nerve often results in persistent 
neuropathic pain condition. Several peripheral nerve injury models have been 
developed to study the underlying mechanisms of neuropathic pain. The partial sciatic 
nerve ligation model as reported by Malmberg and Basbaum (1998) was adapted. A 
partial nerve injury was generated by tying a ligature with catgut suture around 
approximately 1/3 to 1/2 the diameter of the sciatic nerve. After the nerve injury, the 
mice were observed for the visible, physiological signs of neuropathic pain and they 
were sacrificed to dissect the brain tissues after 13 days. 
 
Inflammatory pain model: Most inflammatory pain models induce hyperalgesia by 
the subcutaneous injection of inflammatory agents into the hind paw of rats or mice 
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(Walker et al., 1999). Inflammatory pain models in mice were prepared by injecting 
20 µl of 5% formalin and the procedure used was similar to that reported by Hunskaar 
et al. (1985). After formalin injection, these mice were observed for swelling and 
inflammation on the injected paw and were sacrificed after 13 days to isolate the 
brain tissues. 
  When the brain tissues were isolated from both these pain model mice, 
synaptosomal membrane fractions were prepared from these brain tissues individually 
following the same protocol as explained earlier for normal whole brain and spinal 
cord tissues. 
 
Radiolabelled 7B2CT peptide binding and protein assays 
Saturation Binding experiments: 
  All binding assays were performed in 0.5 mL of buffer containing the protease 
inhibitor PMSF (50 mM Tris buffer, pH 7.4 containing 0.1 % BSA and 100 µM 
PMSF). The membrane tissues 300 µL was incubated with various fixed counts of 
125I-labelled peptide for 60 min at room temperature (25°C) and filtered over glass 
microfibre GF/B filters. Specific binding was defined as the difference between 
binding in absence and presence of the cold peptide (1 nmol). In saturation studies, 
the specific binding was calculated at different concentrations of 125I-labelled peptide 
and corrected based on mg protein which was estimated by Bio-Rad Protein Assay kit 
with BSA as the standard protein. A saturation curve was plotted and the receptor 
density (Bmax) and affinity (Kd) were calculated using the GraphPad Prism software 
(version 2.01, GraphPad Software Inc., San Diego, CA).  
Receptor binding studies of 7B2CT peptide 
------------------------------------------------------------------------------------------------------- 
 143
  Saturation experiments were also performed for membrane fractions prepared from 
mouse spinal cord.  
 
 Regional distribution studies: 
  The regional distribution studies for the binding sites of 7B2CT were carried out 
with membrane fractions prepared from the seven regions of mice and rat brains as 
explained earlier. The binding assay protocol was quite similar to that used for whole 
brain. The individual regional membrane preparations (300 µL) were incubated with 
4 x 105 cpm of the 125I-labelled peptide at room temperature (25°C) for 60 min in the 
same binding assay buffer containing the protease inhibitor PMSF and filtered over 
glass microfibre GF/B filters. The specific binding was calculated as difference in 
bound counts in the presence and absence of cold peptide (1 nmol). The binding sites 
localization in different regions was all expressed as specific binding counts per mg 
protein content of the respective tissues. 
 
Regulation of binding sites in Pain models: 
   The effect of different types of pain – inflammatory and neuropathic on the 
numbers of these binding sites was also evaluated. Inflammation and neuropathic pain 
model mice were prepared; synaptosome membrane fractions were prepared from 
their brain tissues as discussed before. Binding assay protocol was similar to that 
explained for brain tissues saturation experiment and was performed individually for 
the two pain models and the control tissues. The specific binding at different tracer 
concentrations were expressed in terms of the protein content of the corresponding 
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tissues as counts per mg and were individually compared between the normal and the 
neuropathic or inflammatory pain tissues. Statistical comparisons were also done in 
two groups – neuropathic vs. normal and inflammatory vs. normal by independent 

























  As shown in Figure 7.1, a saturation curve for brain membrane fractions was 
observed and the receptor density was calculated to be Bmax  = 139 + 27 fmol/mg 
protein and the affinity (Kd) = 0.373 + 0.17 nM. Membrane fractions from spinal cord 
also showed a similar saturation curve (Figure 7.2). These data clearly show that CNS 
has specific binding sites for 7B2CT. The numbers of the binding sites in spinal cord 
were significantly higher than those in brain based on counts/mg protein. 
  The regional distribution studies were carried out with membrane fractions prepared 
from mouse and rat brains dissected and separated into 7 different regions as 
discussed earlier.  
The regional localization of the 7B2CT binding sites in mice brain was as shown in 
Table 7.1 and their concentrations followed the trend: 
striatum = cortex > cerebellum > thalamus/hypothalamus > hippocampus. The 
midbrain and stem regions exhibited very weak specific binding. 
In rat brain tissues, the results were as shown in Table 7.2 and the trend was as 
follows: 
thalamus/hypothalamus >> cortex  > cerebellum > striatum > hippocampus. Binding 
was very weak in midbrain and stem.  
  The receptor levels were found to be differentially regulated in various pain states. 
Figure 7.3 shows three saturation curves of 125I-labeled peptide binding to membrane 
fractions obtained from brain of normal control, inflammation and neuropathic mice. 
The most interesting observation was that the binding curve of the tracer to the 
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inflammation brain membranes exactly coincided with that of intact normal mice 
brain membranes while the binding counts to the neuropathic pain mice brain 
significantly increased. Statistical comparisons also confirmed significant increase in 
the receptor levels in neuropathic pain mice as against the naïve, normal mice. The 
observed P values in the statistical comparison between neuropathic and the control 
group and the specific binding per mg protein expressed as counts per mg protein in 






















   Binding studies for 7B2CT peptide were carried out and the specific binding sites 
were identified. No difference in binding was observed when the assay was 
performed at 4°C and at room temperature. Although we did not compare enzyme 
inhibitor cocktail with usage of only PMSF, PMSF alone allowed us to get 
reproducible and stable binding counts. Similar use of PMSF alone to inhibit 
peptidase activity in binding assay of nociceptin has been previously reported 
(Dooley et al., 1997). 
   This study clearly demonstrates the presence of specific binding sites in mice brain 
synaptosomal membrane fractions for the 7B2CT peptide. The saturation curve 
shown in Figure 7.1 was performed using the HPLC purified labeled material. The 
confirmation of the presence of specific binding sites for 7B2CT in mice brain further 
strengthens the hypothesis that this peptide 7B2CT in addition to its well known 
intracellular function of PC2 regulation should have additional extracellular roles. 
These binding results together with the bioactivity results discussed in chapter 6 
suggest possible roles for this 7B2CT peptide in chronic pain mechanisms. 
  A similar binding experiment using spinal cord tissues also exhibited saturation and 
a comparative binding experiment was performed in both mouse brain and spinal cord 
membrane fractions simultaneously using our Biogel P-4 purified tracer. As shown in 
Figure 7.2, the concentration of binding sites seems relatively higher in spinal cord 
than in brain synaptosomes.  The interneurons of the dorsal horn of spinal cord play a 
key role in exogenous and endogenous modulation of the spinal pain paths (Young 
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and Young, 1997). Hence this higher concentration of 7B2CT binding sites in spinal 
cord may suggest some vital roles for this peptide in local regulation of pain 
transmission and processing.  
  Localization studies on peptides and their specific binding sites provide a better 
understanding of the functional importance of these compounds and also their 
pharmacology. Hence the anatomical distribution study of 7B2CT binding sites were 
performed in both rat and mouse brain synaptosomes. Rat brain membrane 
preparations (Table 7.2) showed the highest concentration of specific binding sites in 
the thalamus/hypothalamus region. The thalamus is known to receive and process all 
nociceptive information destined to reach the cortex. The thalamus has a role in pain 
perception and in the pathophysiology of central pain and other types of chronic pain 
(Afifi AK and Bergman RA, 2005). Hence the highest concentration of the binding 
sites in this region further supports the possible role for this peptide in pain perception. 
The binding sites for 7B2CT were also moderately localized in the rat cortex and 
striatum regions. The somasthetic area of the cerebral cortex receives nerve fibers 
from the thalamus, which convey general sensory (touch, pain, temperature) 
information. The somasthetic area is an important cortical locus for the conscious 
perception of noxious stimuli. Neurons in these cortical sensory areas are known to be 
sensitive to pain (Afifi AK and Bergman RA, 2005). Striatum is the main site of 
cortical input and receives inputs from all cortical areas and its output is GABAergic 
(inhibitory). The striatum together as the basal ganglia is well established to control 
cognitive functions and is also involved in the reward pathway. Hence the 7B2CT 
binding sites in this region may suggest possible additional roles for this peptide. 
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Cerebellum had moderate levels of 7B2CT binding sites while the hippocampus 
exhibited lower levels of binding. These results are broadly comparable to NCP 
receptor (ORL1) distribution data where high expression of ORL1 mRNA and 
receptors was detected in most of the hypothalamic nuclei, hypothalamic-related 
areas, several nuclei of the thalamus and also in the rat cerebrocortical slices 
(Mollereau and Mouledous, 2000). NCP ligand-binding studies in human brain have 
reported strong expression of functional ORL1 receptors in the cerebral cortex and 
only moderate signals in cerebellum followed by the hippocampus. Also strong 
binding was reported in the human striatum (Berthele et al., 2003).  
  There were some differences and similarities between the 7B2CT binding sites 
distribution data in the rat and mouse brain membranes. In rat brain, 
thalamus/hypothalamus region had clearly very high levels of 7B2CT binding sites as 
compared to cortex and striatum (about 2 times higher) while in mice brain the cortex 
and striatum showed similar higher levels of 7B2CT binding sites but closely 
followed by the thalamus/hypothalamus region (Table 7.1). Since this peptide was 
isolated from the CSF of chronic pain patients, this study focuses on the roles of this 
peptide in pain mechanisms. However, additional unexplored roles for this 7B2CT 
peptide cannot be overruled. In both rat and mice brains the hippocampus region had 
the least binding sites. Also almost no significant binding could be detected in the 
midbrain and stem regions of both rat and mice brain.  
  The concentration of binding sites in rat spinal cord could not be confirmed because 
of technical problems in rapid and efficient isolation of whole rat spinal cord tissue. It 
was observed in these experiments that faster the isolation of spinal cord tissue, more 
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the binding. The delay in spinal cord isolation procedure probably irreversibly 
damaged or affected the binding sites numbers.  So the binding assay data with rat 
spinal cord were not reproducible and showed higher variations (data not shown). 
  In order to analyze if the levels of 7B2CT binding sites in brain were differentially 
regulated under various pain conditions, saturation binding experiments were 
performed with synaptosomes prepared from normal, naive mice, inflammatory pain 
model mice and neuropathic mice.  As shown in Figure 7.3, three saturation curves of 
125I-labeled peptide binding to membrane fractions prepared from the three types of 
mice were obtained. The specific binding per mg protein content observed for the 
inflammatory pain model membranes at different counts of the labelled material 
added exactly matched with those for naive control mice brain membranes. In case of 
neuropathic pain model membranes, the specific binding increased as compared to the 
naive control. Statistical analysis of the data confirmed a significant increase in the 
specific binding (P < 0.05) at all the counts of labelled peptide added in the 
neuropathic pain model as against the control (Table 7.3).  These binding results 
exactly accorded with the animal experiment results discussed in Chapter 6 that 
mechanical allodynia was produced in the neuropathic mice but not in inflammation 
and normal control mice.  
  In summary, these binding studies demonstrate the presence of specific binding sites 
for this peptide 7B2CT in CNS and their relative distribution in different regions of 
the brain. There is an up regulation of these binding sites in neuropathic pain 
suggesting 7B2CT may have specific vital roles in neuropathic pain mechanisms and 
not in pain related to inflammation. 







































Figure 7.1 Saturation curve for binding of HPLC purified 125I-labelled 7B2CT to 
mouse brain synaptosome membranes. Each point is the mean ± SEM of n = 5 sets of 
experiments. 
Specific Binding on Y-axis expressed as x 10-3cpm/mg protein 
 
HPLC purified tracer for this experiment - Courtesy:  Prof. S. Hirose, Department of 






Bmax = 139 ± 27 fmol/mg protein 
Kd  =  0.373 ± 0.17 nM 



































Figure 7.2 Comparison of saturation binding of Biogel P-4 column purified 125I-
labelled 7B2CT to synaptosome membranes prepared from mouse brain and spinal 
cord showing a higher localization of binding sites in the spinal cord. Counts added 










Table 7.1 Regional distribution data of 7B2CT binding sites in mice brain 
 
No. Brain region Specific binding / mg protein 
(counts/mg protein) 
1 Cortex 30363 
2 Striatum  30070 
3 Cerebellum 28055 
4 Thalamus/hypothalamus 22277 
5 Hippocampus 15118 

















Table 7.2 Regional distribution data of 7B2CT binding sites in rat brain 
 
No. Brain region Specific binding / mg protein 
(counts/mg protein) 
1 Thalamus/hypothalamus 87406.91 
2 Cortex 43482.67 
3 Cerebellum 40669.19 
4 Striatum 35843.25 
5 Hippocampus 24863.70 
 
Rat spinal cord could not be effectively isolated with out damage and hence the 













































Figure 7.3 Specific binding sites in neuropathic and inflammation pain model mice 
brain as compared to the normal control mice. Each point on the graph is mean ± 











Table 7.3 Specific binding sites of 7B2CT in neuropathic and inflammation mice as 
compared to normal control mouse brain tissues. 
 
 
Specific binding x 10-3 per mg protein (counts/mg protein)125I 7B2CT added x 10-3 
(counts) Control Inflammation Neuropathy 
750 28.98 30.07 
 
54.48 
P = 0.02 
400 28.6 29.68 
 
53.76 
P = 0.026 
200 20.53 20.08 
 
31.93 
P = 0.02 
120 6.32 4.36 
 
22.91 
P = 0.002 
60 4.75 3.51 
 
8.41 
P = 0.03 
30 2.71 1.72 
 
3.94 
P = 0.01 
 
The specific binding at different tracer concentrations expressed as counts per mg 
were compared statistically between the normal and the neuropathic pain tissues by 
independent samples t test using the SPSS statistical software and the P values are as 







































  The structure-activity relationships of the intracellular inhibitory activity of 7B2CT 
against PC2 have been well studied. In the middle of the 7B2CT sequence (see 
below), there is one basic amino acid pair, Lys17-Lys18, which may be considered as a 
putative processing signal.          
                                                        
 
 
  It has been reported that atleast one of the lysine residue of this Lys-Lys basic pair is 
essential for the PC2 inhibitory activity. The N-terminal hexadecapeptide (7B2CT-N) 
does not have any inhibitory activity against PC2. (Van Horssen et al., 1995; Zhu et 
al., 1996; Apletalina et al., 2000).  
  In this study, additional extracellular roles for this 7B2CT peptide were hypothesed 
and the bioactivity results discussed in chapter 6 together with the binding assay 
results of chapter 7 strongly support this hypothesis. The 7B2CT-N (hexadecapeptide) 
and 7B2CT-C (tridecapeptide) terminal fragments of the peptide, before and after the 
Lys17-Lys18 pair were synthesized to compare the structural features of the peptide 
already known to be responsible for its intracellular activity of PC2 inhibition with 
those features responsible for its pain related extracellular roles. For this purpose, the 
two 7B2CT fragments (7B2CT-N and 7B2CT-C) were similarly analyzed for 
bioactivity as explained in chapter 6 for the original peptide. Next the sequences 
                                               1                                10                                 20                                 30                                       





necessary for the binding of 7B2CT to its specific binding sites in brain were 

























8.2 Materials and Methods 
 
Materials: 
  7B2CT peptide and its C and N terminal fragments were from Peptide Institute Inc. 
The protease inhibitor Phenyl Methyl sulfonyl fluoride (PMSF), Bovine serum 
albumin (BSA) and Tris were from SIGMA (St. Louis, MO, USA). The GF/B glass 
microfibre filters used in receptor binding procedures were from Whatman 




Allodynia assay for 7B2CT-N and 7B2CT-C fragments: 
  Mechanical allodynia assay was carried out in ddY mice weighing 22 ± 2 g 
according to the previously described method (Minami et al., 2000).  Allodynia was 
assessed once every 5 min for 50 min by light stroking of the flank of the mice with a 
paintbrush. The allodynic response was ranked as previously explained in methods 
section of chapter 6 for the 7B2CT peptide bioactivity. 
 
Radiolabelling of 7B2CT and Preparation of synaptosomal membrane fractions 
from mouse brain: 
  The 7B2CT peptide was labelled by the Iodogen method and purified using a Biogel 




were prepared from Swiss albino mice brain tissues also using the procedure 
described in chapter 7. 
 
Binding replacement studies: 
  The ability of the cold 7B2CT peptide and its C-terminal and N-terminal fragments 
to replace the binding of [125I]7B2CT peptide to mouse brain membranes in a 
concentration dependant manner was tested. This assay was also carried out in 0.5 ml 
of the same binding assay buffer - 50 mM Tris buffer, pH 7.4 containing 0.1 % BSA 
and 100 µM PMSF. Mouse brain membrane tissue (300 µL) was incubated with 4 x 
105 cpm of 125I-labelled 7B2CT and incubated for 15 min at room temperature 
(25°C). Then different concentrations of the cold 7B2CT peptide (1, 10, 100, 1000, 
10000 pmol) were individually added, incubated for a further 45 min at room 
temperature (25°C) and then filtered over glass microfibre GF/B filters. Similarly 
replacement trials were carried out for four different concentrations of 7B2CT-N and 
7B2CT-C fragments (10, 100, 1000, 10000 pmol) 
  The replacement ability of the target peptides (here refers to either 7B2CT-N or 
7B2CT-C fragments) was expressed in percentage as B1/B0 where B1 is the bound 
counts with the target peptide in each added concentration and B0 is the binding 
without the target peptide and was plotted against the log concentration of target 
peptide added in µM. The peptide concentrations required for 50% replacement (IC50) 
were calculated for each of the peptides. 
 




Allodynia assay - Co injection of 7B2CT and 7B2CT-C: 
  The allodynia assay was carried out as described for the 7B2CT peptide in chapter 6 
using the ddY mice. 10 ng (2.85 pmol) of 7B2CT was chosen as the sub-maximal 
dose for inducing mechanical allodynia and administered simultaneously with four 
doses of 7B2CT-C by i.t. injections into naïve mice. Allodynia response was assessed 























Allodynia assay for 7B2CT-N and 7B2CT-C fragments: 
  The i.t. administration of 7B2CT-N evoked mechanical allodynia in naive mice with 
almost the same potency as that of the original 7B2CT (Figure 8.1) and lasted more 
than 1 hr (Figure 8.2). On the contrary, the C-terminal tridecapeptide (7B2CT-C) did 
not induce any allodynia (Figures 8.1 and 8.2). 
 
Binding assay – Replacement studies: 
  As shown in Figure 8.3, the replacement curve for the displacement of the binding 
of 125I-labeled 7B2CT to mouse brain membranes by cold 7B2CT was obtained. The 
7B2CT-C fragment could replace the binding of 125I-labeled 7B2CT to mouse brain 
membranes while the N-terminal fragment showed very weak displacement activity. 
The peptide concentration needed for 50% replacement (IC50) was calculated and the 
IC50 for 7B2CT-C was 1.52 µM while that of the original 7B2CT was 0.48 µM. The 
7B2CT-N replacement activity was very weak that only at a concentration as high as 
80 µM, it showed around 50% replacement of labelled peptide.  
 
Co-injection of 7B2CT and 7B2CT-C fragment – Allodynia assay: 
   As expected, the tridecapeptide (7B2CT-C) blocked the allodynia produced by the 
7B2CT peptide in a dose-related manner. At the dose of 100 ng (66.58 pmol) the 







  The 7B2CT-N fragment was found to have bioactivity very similar to that of the 
original 7B2CT peptide. It evoked strong allodynia in a dose-related manner and this 
allodynic response lasted beyond 50 minutes. The 7B2CT-C fragment did not 
generate allodynia (Figure 8.1, 8.2). The 7B2CT-N was found to possess pain related 
bioactivity similar to that of the original 7B2CT peptide itself while this 7B2CT-N 
has earlier been reported not to have the intracellular PC2 inhibitory activity. 
Therefore, the pain related bioactivities of 7B2CT-N are completely independent of 
the intracellular PC2 inhibitory activity of 7B2CT. The extracellular pain related 
activities of 7B2CT thus reside in the N-terminal sequences and are displayed through 
the specific binding sites demonstrated in chapter 7. 
  In addition to the saturation binding experiments described in chapter 7, the 
replacement studies were performed with 7B2CT peptide and the dose related 
replacement of the 125I-labeled 7B2CT binding to the mouse brain synaptosomes by 
the cold peptide (Figure 8.3) provide additional evidence for the existence of specific 
binding sites for this 7B2CT peptide. The 125I-labeled 7B2CT binding to mouse brain 
membranes could be replaced also in a dose related manner by the C-terminal 
fragment (7B2CT-C) of the original peptide while the 7B2CT-N exhibited very weak 
replacement. The 7B2CT-C replacement ability was about three times weaker than 
that of the original peptide itself as indicated by their IC50 values (1.52 vs. 0.48 µM). 
Hence sequences required for binding to the specific binding sites reside in the C-




  These results that the active site (N-terminal part) and the binding site (C-terminal 
part) resided separately in the relatively small 31 amino acids peptide 7B2CT, 
prompted the idea whether the binding 7B2CT-C could antagonize the activity of 
7B2CT at the same receptors. When tested by co injection and allodynia assay 
(Figure 8.4) the results confirmed the antagonizing activity of 7B2CT-C. This further 
supports the existence of additional extracellular activities for 7B2CT effected 
through their specific binding sites or receptors in CNS.  
  The fact that N-terminal peptide by itself induced strong allodynia in mice suggested 
that an additional binding site should exist in the N-terminal sequences but this 
seemed to be weaker than the C-terminal binding site (Figure 8.3). Further, in the 
replacement experiments 7B2CT iodinated at the tyrosine in the 5th position was used, 
which might interfere in the binding results of 7B2CT-N to the specific binding sites. 
Since 7B2CT seems to have vital roles in neuropathic pain mechanisms as a 
pronociceptive factor, the C-terminal peptide should be a very important and useful 
prototype compound for designing new therapeutics for the management of 

















Figure 8.1 7B2CT-N (N) evoked strong allodynic response similar to the original 
7B2CT peptide – 3 pmol (CT peptide) which sustained even after 50 minutes. The 
7B2CT-C fragment (C) did not evoke any allodynia. 
 
































Figure 8.2 Bell-shaped dose response curve for 7B2CT-N in allodynia assay similar 
to 7B2CT peptide. 7B2CT-C does not evoke allodynic response. 
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Figure 8.3 Replacement curves for the displacement of 125I-labeled 7B2CT binding to 
mouse brain synaptosomes by 7B2CT peptide, 7B2CT-C (C-terminal fragment) and 















Figure 8.4 Allodynia responses for 7B2CT peptide (2.85 pmol) antagonized by co-
injection with different doses of 7B2CT-C (C-terminal fragment). At 100 ng (66.58 
pmol) of 7B2CT-C, the allodynia responses of 7B2CT is completely antagonized. 
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  Chronic pain is a major health care challenge owing to its high prevalence and 
significant negative impact on daily life and work performance. Most of the currently 
available therapeutics (opiates, salicylic acid, tricyclic antidepressants and 
anticonvulsants, etc…) is only partially effective in chronic pain and some are 
accompanied by distressing side effects or have abuse potential. Rational treatment of 
pain requires identification of pain mechanisms as targets of drug therapy (Woolf, 
2004). In this pursuit to unravel the complex multidimensional sensory mechanisms 
of pain, this study focussed on the role of neurotransmitter amino acids in chronic 
pain perception mechanisms and also on isolation and characterization of new 
peptides involved in chronic pain. By this two dimensional approach, this present 
work sought to highlight the role of these neurotransmitter amino acids and novel 
peptides in pain perception to enable a better understanding and thus facilitate better 
management of chronic unrelenting pain. The outcome of this work can thus be 
classified and discussed in the following two categories: 
 
Amino acid neurotransmitters in Pain: 
  The excitatory amino acids – glutamate and aspartate, inhibitory amino acids – 
glycine, GABA and taurine and Nitric oxide play important roles in pain perception 
(Wen et al., 2003; Cronin et al., 2004; El Idrissi and Trenkner, 2004). Continual and 
prolonged stimulation by these neurotransmitters can result in chronic persistent pain. 
A simultaneous determination of these compounds can help improve our 
understanding of the pathophysiology of pain. Amino acid analysis methods in CSF 
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suffer from a variety of shortcomings since the reaction procedures including the CSF 
sample storage conditions and pre-treatment used for amino acids analysis have not 
been standardized. Pretreatment has been shown to adversely affect the quantitative 
results of amino acids (Krause et al., 1995; Zhang et al., 2003). These factors have 
induced huge variations in the analysis data thus making it difficult to compare the 
results from different laboratories (Sarwar and Botting, 1993; Jimenez-Jimenez et al., 
1996; Rizzo et al., 1996; Levine et al., 2000; Mou et al., 2002). Hence a new HPLC 
method based on pre-column derivatization with dabsyl chloride was developed to 
analyze the amino acids and other pain related physiological compounds in CSF 
without any pre-treatment procedures. This method could also detect cystine and 
proline, which cannot be detected by the most commonly used OPA method for 
amino acid analysis. By addition of a non-ionic surfactant Triton X-100, this method 
improved the recovery of hydrophilic amino acids, especially the IAAs glycine and 
GABA. The correlation coefficient for all the compounds analyzed by this method 
was greater than 0.99 and reasonable recovery values were obtained for all the 
compounds analyzed (Sethuraman et al., 2004).  
  Amino acid analysis in CSF of pregnant women with and without labor pain by 
applying this method suggested important roles for the EAA – aspartate, IAA – 
glycine, GABA and taurine and the NO marker – citrulline in labor pain mechanisms 
and some of these compounds could be potential indicators of acute pain. Also there 
could be two possible mechanisms of labor pain perception – NO dependent and 
independent. A similar amino acid analysis study in CSF of chronic pain patients and 
some no pain subjects showed that EAAs – aspartate and glutamate, glycine and NO 
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are involved in chronic pain perception mechanisms. A further comparison between 
these chronic pain and acute pain CSF amino acids analysis data strongly supported a 
vital role for the EAA – aspartate in the establishment of persistent, chronic pain state 
from acute pain. The IAAs - especially glycine and NO though involved in pain 
perception, do not seem to be important players in the adaptive responses of the 
nervous system associated with chronic pain.  
  A simple quantitative method to quantitatively evaluate amino acids in CSF has 
been set up here and application of this method to evaluate the roles of these amino 
acids in pain has been analyzed. Though this method can be advantageously and 
reliably applied to CSF analysis without any laborious pre-treatment procedures, the 
limitation of our study on pain patient samples is that we could not procure age-
matched subjects and those with well defined pain conditions due to ethical 
constraints. Hence some of the conclusions drawn from these studies, though 
encouraging calls for further investigations. 
 
Conclusion: The outcome of these amino acids analyses in CSF is very promising. 
These amino acid analysis studies if continued using samples from extended number 
of subjects (increase “n”)with well defined and distinct type of pain and with better 
age-matched comparison groups, some of these pain related compounds could be 
confirmed as potential biomarkers for the different types of pain states. The new 
HPLC method developed in this work and its principle could also be advantageously 
applied to improve and simplify the existing sample pretreatment procedures in CSF 
analysis, thus making the amino acid analysis data more consistent and comparable.   
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Isolation and Characterization of 7B2CT peptide from chronic pain CSF: 
  A strategy different from proteomics, based on multiple liquid chromatography steps 
was developed and applied to CSF from chronic pain patients and three peptides were 
successfully purified and their sequences were confirmed in this work. One of these 
peptides identified as 7B2CT peptide, which exhibited interesting CNS effect in mice 
tested for spontaneous locomotion activity was chosen for further characterization 
studies. The i.t. administration of this peptide evoked significant mechanical 
allodynia in naïve mice that was enhanced in neuropathic pain models but did not 
produce thermal hyperalgesia in naive and inflammation model mice. 
  Receptor binding studies confirmed specific binding in a saturable manner in 
membrane fractions prepared from mouse brain and spinal cord using the 125I-labeled 
peptide. The binding sites significantly increased in neuropathic mice model but not 
in inflammation model mice. Also these binding sites were abundant in mouse spinal 
cord than brain. Studies on the structure-activity relationships revealed the N-terminal 
hexadecapeptide exhibited similar activity as 7B2CT while the C-terminal 
tridecapeptide exhibited its binding capability. The 7B2CT-C fragment also blocked 
the allodynia produced by the original peptide as a receptor antagonist.  
  A novel approach based on multiple column chromatography steps was applied to 
isolate small peptides in CSF and one of these peptides has been shown to be 
associated with chronic pain mechanisms by allodynia assay – a typical assay for 
chronic pain and existence of specific binding sites for this peptide has also been 
shown in CNS. This study though pioneering, suffers from the practical constraints 
posed by limitations to studies conducted in human subjects but this is the first step in 
Overall Discussion and Conclusions 
------------------------------------------------------------------------------------------------------- 
 175
a long journey to understand the potential implications of this peptide in chronic pain 
mechanisms. This study is a beginning for identification of many more such active 
peptides in CSF and in studying their physiological roles and application in chronic 
pain management. 
  
Conclusion: This 7B2CT peptide though already known, the pathophysiological roles 
of this peptide as a neuropeptide especially related to pain perception and bioactivities 
have not been studied to date. 7B2CT peptide is a C-terminal processed fragment of 
Pro7B2 – a granin family protein. No receptors have been identified for any of such 
granin fragments so far (Taupenot et al., 2003) although many possible processed 
neuropeptides have been suggested to be produced from granins due to the presence 
of many basic amino acid sequences in these granins. 
. The isolation of this 7B2CT peptide, the bioactivity studies on this peptide showing 
allodynia characteristic to neuropathic pain and the identification of the existence of 
specific binding sites for this peptide in mice brain and spinal cord all together 
suggest important pronociceptive roles for this peptide, which may cause chronic pain 
in humans. The 7B2CT-C fragment antagonized the 7B2CT evoked allodynia, which 
is suggestive of immense potential for this peptide fragment in development of novel 




























Abu-Soud HM, Wang J, Rousseau DL, Fukuto JM, Ignarro LJ, Stuehr DJ. Neuronal 
nitric oxide synthase self-inactivates by forming a ferrous-nitrosyl complex during 
aerobic catalysis. J Biol Chem 1995;270:22997–3006. 
Afifi AK, Bergman RA. (2005) Nogueira I, Foltin J, Malley J, Sheinis LA (eds) 
Functional neuroanatomy. McGraw-Hill, New York. 
Ahmadi S, Muth-Selbach U, Lauterbach A, Lipfert P, Neuhuber WL, Zeilhofer HU. 
Facilitation of spinal NMDA receptor currents by spillover of synaptically released 
glycine. Science 2003;300:2094-7. 
Alfredsson G, Wiesel FA, Lindberg M. Glutamate and glutamine in cerebrospinal 
fluid and serum from healthy volunteers -- analytical aspects. J Chromatogr 
1988;424:378-84. 
Alt A, Weiss B, Ogden AM, Knauss JL, Oler J, Ho K, Large TH, Bleakman D. 
Pharmacological characterization of glutamatergic agonists and antagonists at 
recombinant human homomeric and heteromeric kainite receptors in vitro. 
Neuropharmacol 2004;46:793-806. 
Altemus M, Fong J, Yang R, Damast S, Luine V, Ferguson D. Changes in 
cerebrospinal fluid neurochemistry during pregnancy. Biol Psychiatry 2004;56:386-
92. 
Apletalina EV, Juliano MA, Juliano L, Lindberg I. Structure-function analysis of the 
7B2 CT peptide. Biochem Biophys Res Commun 2000;267:940-2. 
Baber NS, Dourish CT, Hill DR. The role of CCK, coerulein and CCK antagonists in 




Becker CM, Hoch W, Betz H.  Glycine receptor heterogeneity in rat spinal cord 
during post natal development. EMBO J 1988;7:3717-26. 
Bergles DE, Diamond JS, Jar CE. Clearance of glutamate inside the synapse and 
beyond. Curr. Opinion Neurobiol 1999;9:293-98. 
Berthele A, Platzer S, Dworzak D, Schadrack J, Mahal B, Buttner A, Abmus HP, 
Wurster K, Zieglgansberger W, Conrad B, Tolle TR. [3h]-nociceptin ligand-binding 
and nociceptin opioid receptor mrna expression in the human brain. Neurosci 
2003;121:629-40. 
Besson JM. The neurobiology of pain. Lancet 1999;353:1610-15. 
Bleakman D, Lodge D. Neuropharmacology of AMPA and Kainate receptors. 
Neuropharmacol 1998;37:1187-204. 
Borman J, Hamill OP, Sakmann, B. Mechanism of anion permeability through 
channels gated by glycine and gamma-aminobutyric acid in mouse cultured spinal 
neurons. J Physiol 1987;385:243–86. 
Burt DR, Rossie SS, Miller RJ. (1980) Peptide receptor methodology. In: Short 
course syllabus Receptor binding techniques. Society for neuroscience, Ohio, pp 150-
67.  
Caraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L, De Konno F, 
the Steering Committee of the EAPC Research Network. Pain Measurement Tools 
and Methods in Clinical Research in Palliative Care: Recommendations of an Expert 
Working Group of the European Association of Palliative Care. J Pain Symptom 




Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and 
syndromes. IASP Task Force on Cancer Pain. International Association for the Study 
of Pain. Pain 1999;82:263-74. 
Carlo MD Jr, Loeser RF. Increased oxidative stress with aging reduces chondrocyte 
survival: correlation with intracellular glutathione levels. Arthritis Rheum 
2003;48:3419-30. 
Castillo J, Martinez F, Corredera E, Aldrey JM, Noya M. Amino acid transmitters in 
patients with headache during the acute phase of cerebrovascular ischemic disease. 
Stroke 1995;26: 2035-39.   
Chang J Y, Knecht R, Braun D G. Amino acid analysis in the picomole range by 
precolumn derivatization and high-performance liquid chromatography. Methods 
Enzymol 1983;91:41-8. 
Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of 
tactile allodynia in the rat paw. J Neurosci Methods 1994;53:55-63. 
Chatterton JE, Awobuluyl M, Premkumar LS, Takahashi H, Talantova M, Shin Y, 
Cui J, Tu S, Sevarino KA, Nakanishi N, Tong G, Lipton SA, Zhang D. Excitatory 
glycine receptors containing the NR3 family of NMDA receptor subunits. Nature 
2002;415:793-8.  
Chaudhry FA, Reimer RJ, Bellocchio EE, Danbolt NC, Osen KK, Edwards RH, 
Storm-Mathisen J. the vesicular GABA transporter, VGAT, localizes to synaptic 





Chizh BA. Novel approaches to targeting glutamate receptors for the treatment of 
chronic pain: Review article. Amino Acids 2002;23:169-76. 
Cizkova D, Lukacova N, Marsala M, Marsala J. Neuropathic pain is associated with 
alterations of nitric oxide synthase immunoreactivity and catalytic activity in dorsal 
root ganglia and spinal dorsal horn. Brain Res Bull 2002;58:161-71. 
Couture R, Harrisson M, Vianna RM, Cloutier F. Kinin receptors in pain and 
inflammation. Eur J Pharmacol 2001;429:161-76. 
Cronin JN, Bradbury EJ, Lidierth M. Laminar distribution of GABAA- and glycine-
receptor mediated tonic inhibition in the dorsal horn of the rat lumbar spinal cord: 
effects of picrotoxin and strychnine on expression of Fos-like immunoreactivity. Pain 
2004;112:156-63. 
Dalsgaard CJ, Haegerstrand A, Theodorsson-Norheim E, Brodin E, Hokfelt T. 
Neurokinin A-like immunoreactivity in rat primary sensory neurons; co-existence 
with substance P. Histochem Cell Biol 1985;83:37-9. 
Danbolt NC. Glutamate uptake. Prog Neurobiol 2001;35:1-105. 
Davy JF, Ersser R. Amino acid analysis of physiological fluid by high-performance 
liquid chromatography with phenylisothiocyanate derivatization and comparison with 
ion-exchange chromatography. J Chromatogr B 1990;528:9-23. 
Doble A. The role of excitotoxicity in neurodegenerative disease: Implications for 
therapy. Pharmacol Ther 1999;81:163-221. 
Dooley CT, Spaeth CG, Berzetei-Gurske IP, Craymer K, Adapa ID, Brandt SR, 




formthe nociceptin/orphanin FQ receptor ORL1. J Pharmacol Exp Ther. 
1997;283:735-41. 
Dray A. Mechanism of action of capsaicin-like molecules on sensory neurons. Life 
Sci 1992;51:1759–65. 
Eaton MJ, Martinez MA, Karmally S. A single intrathecal injection of GABA 
permanently reverses neuropathic pain after nerve injury. Brain Res 1999;835:334-9. 
Eisenach JC, Hood DD, Curry R. Preliminary efficacy assessment of intrathecal 
injection of an American formulation of adenosine in humans. Anesthesiology 
2002;96:29-34. 
El Idrissi A, Trenkner E. Growth factors and taurine protect against excitotoxicity by 
stabilizing calcium homeostasis and energy metabolism. J Neurosci 1999;19:9459-68. 
El Idrissi A, Trenkner E. Taurine as a modulator of excitatory and inhibitory 
neurotransmission. Neurochem Res 2004;29:189-97. 
Ferraro TN, Hare TA. Free and conjugated amino acids in human CSF: Influence of 
age and sex. Brain Res 1985;338:53-60. 
Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L. Gabapentin (neurontin) 
and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. 
Br J Pharmacol 1997;121:1513-22. 
Fisher GH, Arias I, Quesada I, D’Aniello S, Errico F, Di Fiore MM, D’Aniello A. A 
fast and sensitive method for measuring picomole levels of total free amino acids in 




Fisher K, Coderre TJ, Hagen NA. Targeting the N-Methyl-D-Aspartate receptor for 
chronic pain management: Preclinical animal studies, recent clinical experience and 
future research directions. J Pain Symptom Manage 2000;20:358-73. 
Fuerst P, Pollack TA, Graser TA, Godel H, Stehle P. Appraisal of four pre-column 
derivatization methods for the high-performance liquid chromatographic 
determination of free amino acids in biological materials. J Chromatogr 
1990;499:557-69. 
Furst S. Transmitters involved in antinociception in spinal cord. Brain Res Bull 
1999;48:129-41. 
Gallai V, Alberti A, Gallai B, Coppola F, Floridi A, Sarchielli P. Glutamate and nitric 
oxide pathway in chronic daily headache: evidence from cerebrospinal fluid. 
Cephalalgia 2003;23:166-74. 
Gamse R, Saria A. Nociceptive behaviour after intrathecal injections of substance P, 
neurokinin A and calcitonin gene-related peptide in mice. Neurosci Lett 1986;70:143-
7. 
Garcia J, Altman RD. Chronic pain states: Pathophysiology and medical therapy.  
Semin Arthritis Rheum 1997;27:1-16.  
Garthwaite J, Garthwaite G, Palmer RM, Moncada S. NMDA receptor activation 
induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol 
1989;172:413-6. 
Ghilardi JR, Allen CJ, Vigna SR, McVey DC, Mantyh PW. Trigeminal and dorsal 
root ganglion neurons express CCK receptor binding sites in the rat, rabbit, and 




Gjessing LR, Gjesdahl P, Dietrichson P, Presthus J. Free amino acids in the 
cerebrospinal fluid in old age and in Parkinson’s disease. Europ Neurol 1974;12:33-7. 
Goodnick PJ, Evans HE, Dunner DL, Fieve RR. Amino acid concentrations in 
cerebrospinal fluid: effects of aging, depression and probenecid. Biol Psychiatry 
1980;15:557-63. 
Grichnik KP, Ferrante FM. The difference between acute and chronic pain. Mt Sinai J 
Med 1991;58:217-20. 
Guecueyener K, Atalay Y, Aral YZ, Hasanoglu A, Tuerkyilmaz C, Biberoglu G. 
Excitatory amino acids taurine levels in cerebrospinal fluid of hypoxic ischemic 
encephalopathy in newborn. Clin Neurol Neurosurg 1999;101:171-74. 
Guruje O, Von Korff M, Simon G, Gater R. Persistent Pain and Well-being: a World 
Health Organization study in primary care. JAMA 1998;280:147-51. 
Hagelberg N, Jaaskelainen SK, Martikainen IK, Mansikka H, Forssell H, Scheinin H, 
Hietala J, Pertovaara A. Striatal dopamine D2 receptors in modulation of pain in 
humans: a review. Eur J Pharmacol 2004;500:187-92. 
Haley TJ, McCormick WG. Pharmacological effects produced by intracerebral 
injection of drugs in the conscious mouse. Br J Pharmacol 1957;12:12-5. 
Hallberg M, Nyberg F. Neuropeptide conversion to bioactive fragments – An 
important pathway in neuromodulation. Curr Protein Pept Sci 2003;4:31-44. 
Hardman JG, Limbird LE. (2001). Drugs acting in the central nervous system. In: 
Goodman & Gilman’s The pharmacological basics of therapeutics, 10th Edition, 




Heine G, Zucht HD, Schuhmann MU, Burger K, Jurgens M, Zumkeller M, 
Schneekloth CG,  Hampel H, Schulz-Knappe P, Selle H. High-resolution peptide 
mapping of cerebrospinal fluid: a novel concept for diagnosis and research in central 
nervous system diseases. J Chromatogr B 2002;782:353-61. 
Holz IV GG, Kream RM, Spiegel A, Dunlap KG. Proteins couple alpha-adrenergic 
and GABA b receptors to inhibition of peptide secretion from peripheral sensory 
neurons. J Neurosci 1989;9:657–66. 
Hsu M-M, Chou Y-Y, Chang Y-C, Chou T-C, Wong CS. An analysis of excitatory 
amino acids, nitric oxide and prostaglandin E2 in the cerebrospinal fluid of pregnant 
women: the effect on labor pain. Anesth Analg 2001;93:1293-6. 
Hunskaar S, Fasmer OB, Hole K. Formalin test in mice, a useful technique for 
evaluating mild analgesics. J Neurosci Methods 1985;14:69-76. 
Hylden JLK, Wilcox GL. Intrathecal substance P elicits a caudally-directed biting and 
scratching behaviour in mice. Brain Res 1981;217:212-5. 
Iguchi H, Chan JS, Seidah NG, Chretien M. Evidence for a novel pituitary protein 
(7B2) in human brain concentrations in controls and patients with Alzheimer’s 
disease. Peptides 1987;8:593-8. 
Inoue M, Kobayashi M, Kozaki S, Zimmer A, Ueda H. Nociceptin/orphanin FQ-
induced nociceptive responses through substance P release from peripheral nerve 
endings in mice. Proc Natl Acad Sci USA 1998;95:10949-53. 
Ito S, Okuda-Ashitaka E, Minami T. Central and peripheral roles of prostaglandins in 
pain and their interactions with novel neuropeptides nociceptin and nocistatin. 




Jansen EHJM, Van den berg RH, Both-Miedema R, Doorn L. Advantages and 
limitations of pre-column derivatization of amino acids with dabsyl chloride. 
J.Chromatogr 1991;553:123-33. 
Jarvis MF, Mikusa J, Chu KL, Wismer CT, Honore P, Kowaluk EA, McGaraughty S. 
Comparison of the ability of adenosine kinase inhibitors and adenosine receptor 
agonists to attenuate thermal hyperalgesia and reduce motor performance in rats. 
Pharmacol Biochem Behav 2002;73:573–81. 
Jasmin L, Rabkin SD, Granato A, Boudah A, Ohara PT. Analgesia and hyperalgesia 
from GABA-mediated modulation of the cerebral cortex. Nature 2003;424:316-20. 
Jasmin L, Tien D, Weinshenker D, Palmiter RD, Green PG, Janni G, Ohara PT. The 
NK1 receptor mediates both the hyperalgesia and the resistance to morphine in mice 
lacking noradrenaline. Proc Natl Acad Sci USA 2002;99:549-51. 
Jessell TM. Substance P in nociceptive sensory neurons. Ciba Found. Symp. 
1982;91:225–48. 
Jimenez-Jimenez FJ, Molina JA, Vargas C, Gomez P, Navarro JA, Benito-Leon J, 
Orti-Pareja M, Gasalla T, Cisneros E, Arenas J. Neurotransmitter amino acids in 
cerebrospinal fluid of patients with Parkinson's disease. J Neurol Sci 1996;141:39-44. 
Khan IM, Marsala M, Printz MP, Taylor P, Yaksh TL. Intrathecal nicotinic agonist-
elicited release of excitatory amino acids as measured by in vivo spinal microdialysis 
in rats. J Pharmacol Exp Ther 1996;278:97-106. 
Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by 




Kimura H, Okamoto K, Sakai Y. Pharmacological evidence for L-aspartate as the 
neurotransmitter of cerebellar climbing fibres in the guinea pig. J Physiol 
1985;365:103-19. 
Koltzenburg M, Scadding J. Neuropathic pain. Curr Opin Neurol 2001;14:641-7. 
Kornhuber J, Kornhuber ME, Hartmann GM, Kornhuber AW. In vivo influences on 
cerebrospinal fluid amino acid levels. Neurochem Int 1988;12:25-31. 
Krause I, Bockhardt A, Neckermann H, Henle T, Klostermeyer H. Simultaneous 
determination of amino acids and biogenic amines by reversed-phase high-
performance liquid chromatography of the dabsyl derivatives. J. Chromatogr A 
1995;715:67-79. 
Kuner R. (2004) Nociception. In: Offermanns S, Rosenthal W (eds.) Encyclopedic 
Reference of Molecular Pharmacology. Springer, Germany. 
Kuraishi Y, Nanayama T, Ohno H, Minami M, Satoh M. Antinociception induced in 
rats by intrathecal administration of antiserum against calcitonin gene-related peptide. 
Neurosci Lett 1988;92:325-9. 
Lada MW, Vickroy TW, Kennedy RT. Evidence for neuronal origin and 
metabotropic receptor-mediated regulation of extracellular glutamate and aspartate in 
rat striatum in vivo following electrical stimulation of the prefrontal cortex. J 
Neurochem 1998;70:617-25. 
Larson A, Giovengo SL, Russell IJ, Michalek JE. Changes in the concentrations of 
amino acids in the cerebrospinal fluid that correlate with pain in patients with 




Lavand’homme PM, Eisenach JC. Exogenous and endogenous adenosine enhance the 
spinal antiallodynic effects of morphine in a rat model of neuropathic pain. Pain 
1999;80:31-6. 
Lawand NB, Lu Y, Westlund KN. Nicotinic cholinergic receptors: potential targets 
for inflammatory pain relief. Pain 1999;80:291-9. 
Lea PM, Movsesyan VA, Faden AI. Neuroprotective activity of the mGluR5 
antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect 
actions at mGluR5 receptors. Br J Pharmacol 2005;145:527-34. 
Lee TL, Fung FMY, Chen FG, Chou N, Okuda-Ashitaka E, Ito S, Nishiuchi Y, 
Kimura T, Tachibana S. Identification of human, rat and mouse nocistatin in brain 
and human nocistatin in brain and human cerebrospinal fluid. Neuroreport 
1999;10:1537-41. 
Leeson PD, Iversen LL. The glycine site on the NMDA receptor: structure-activity 
relationships and therapeutic potential. J Med Chem 2001;37:4053-67. 
Levi G, Gordon RD, Gallo V, WIlkin GP, Balazs R. Putative acidic amino acid 
transmitters in the cerebellum I. Depolarization-induced release. Brain Res 
1982;239:425-45. 
Levine J, Panchalingam K, McClure J, Gershon S, Pettegrew JW. Stability of CSF 
metabolites measured by proton NMR. J Neural Transm. 2000;107:843-48. 
Lewin GR, Lu Y, Park J. A plethora of painful molecules. Curr Opin Neurobiol 
2004;14:443-9. 
Li P, Zhuo M. Substance P and neurokinin A mediate sensory synaptic transmission 




Liu Z, Welin M, Bragee B, Nyberg F. A high-recovery procedure for quantitative 
analysis of substance P and opioid peptides in human cerebrospinal fluid. Peptides 
2000;21:853-60. 
Loeser JD, Melzack R. Pain: an overview. Lancet 1999;353:1607-9. 
Luo ZD. (2004) Pain Research Methods and Protocols. In: Walker JM (ed) Methods 
in molecular medicine. Humana press, New Jersey, pp1-10. 
Mabuchi T, Matsumura S, Okuda-Ashitaka E, Kitano T, Kojima H, Nagano T, 
Minami T, Ito S. Attenuation of neuropathic pain by the nociceptin/orphanin FQ 
antagonist JYC-801 is mediated by inhibition of nitric oxide production. Eur J 
Neurosci 2003;17:1384-92. 
Maes M, Verkerk  R, Bonaccorso S, Ombelet W, Bosmans E, Scharpe S. Depressive 
and anxiety symptoms in the early puerperium are related to increased degradation of 
tryptophan into kynurenine, a phenomenon which is related to immune activation. 
Life Sci 2002;71:1837-48. 
Magnusson JE, Fisher K. The involvement of dopamine in nociception: the role of D1 
and D2 receptors in the dorsolateral striatum. Brain Res 2000;855:260-6. 
Malmberg AB, Basbaum AI. Partial sciatic nerve injury in the mouse as a model of 
neuropathic pain: behavioral and neuroanatomical correlates. Pain 1998;76:215-22. 
Malmberg AB, Yaksh TL. Cyclooxygenase inhibition and the spinal release of 
prostaglandin E2 and amino acids evoked by paw formalin injection: a microdialysis 




Malmberg AB, Yaksh TL. Spinal nitric oxide synthesis inhibition blocks NMDA-
induced thermal hyperalgesia and produces antinociception in the formalin test in rats. 
Pain 1993;54:291-300. 
Manyam BV, Tremblay RD. Free and conjugated GABA in human cerebrospinal 
fluid: effect of degenerative neurologic diseases and isoniazid. Brain Res 
1984;307:217-23. 
Mbikay M, Seidah NG, Chretien M. Neuroendocrine secretory protein 7B2: structure, 
expression and functions. Biochem J 2001;357:329-42. 
Meller ST, Gebhart GF. Nitric oxide (NO) and nociceptive processing in the spinal 
cord. Pain 1993;52:127–36. 
Melzack R. Labor pain as a model of acute pain. Pain 1993;53:117-20. 
Merskey HM. Classification of chronic pain syndromes [abstract]. Pain 1986;Suppl 
3:S217. 
Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour JL, 
Guillemot JC, Ferrara P, Monsarrat B, Mazarguil H, Vassart G, Parmentier M, 
Costentin J. Isolation and structure of the endogenous agonist of opioid receptor-like 
ORL-1 receptor. Nature 1995;377:532-5. 
Millan MJ. Descending control of pain. Prog Neurobiol 2002;66:355-474. 
Minami T, Okuda-Ashitaka E, Mori H, Sakimura K, Watanabe M. Characterization 
of nociceptin/orphanin FQ-induced pain responses in conscious mice: neonatal 
capsaicin treatment and N-methyl-D-aspartate receptor GluRepsilon subunit 




Mnich SJ, Veenhuizen AW, Monahan JB, Sheehan KCF, Lynch KR, Isakson PC, 
Portanova JP. Characterization of a monoclonal antibody that neutralizes the activity 
of prostaglandin E2. J Immunol 1995;155:4437–44. 
Molina JA, Jimenez-Jimenez FJ, Gomez P, Vargas C, Navarro JA, Orti-Pareja M, 
Gasalla T, ito-Leon J, Bermejo F, Arenas J. Decreased cerebrospinal fluid levels of 
neutral and basic amino acids in patients with Parkinson’s disease. J Neurol Sci 
1997;150:123-7. 
Molina JA, Jimenez-Jimenez FJ, Vargas C, Gomez P, de Bustos F, Orti-Pareja M, 
Tallon-Barranco A, ito-Leon J, Arenas J, Enriquez-de-Salamanca R. Cerebrospinal 
fluid levels of non-neurotransmitter amino acids in patients with Alzheimer’s disease.  
J Neural Transm 1998;105:279-86. 
Mollereau C, Mouledous L. Tissue distribution of the opioid receptor-like (ORL1) 
receptor. Peptides 2000;21:907-17. 
Mou S, Ding X, Liu Y. Separation methods for taurine analysis in biological samples. 
J Chromatogr B 2002;781:251-67.  
Mulder AH, Snyder SH. Potassium-induced release of amino acids from cerebral 
cortex and spinal cord slices of the rat. Brain Res 1974;76:297-308. 
Muratani T, Minami T, Enomoto U, Sakai M, Okuda-Ashitaka E, Kiyokane K, Mori 
H, Ito S. Characterization of nociceptin/orphanin FQ-induced pain responses by the 
novel receptor antagonist N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethyl 





Muth-Selbach U, Dybek E, Kollosche K, Stegmann JU, Holthusen H, Lipfert P, 
Zeilhofer HU. The spinal antinociceptive effect of nocistatin in neuropathic rats is 
blocked by D-serine. Anesthesiology 2004;101:753-8. 
Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 
1992;6:3051-64. 
Neal MJ, Pickles HG. Uptake of 14C glycine by spinal cord. Nature 1969;222:679-80.  
Noble B, Clark D, Meldrum M, Have H, Seymour J, Winslow M, Paz S. The 
measurement of pain 1945-2000. J Pain Symptom Manage 2005; 29:14–21. 
O’Dell TJ, Hawkins RD, Kandel ER, Arancio O. Tests of the roles of two diffusible 
substances in long term potentiation: evidence for nitric oxide as an early retrograde 
messenger. Proc Natl Acad Sci USA 1991;88:11285-9. 
Okuda K, Sakurada C, Takahashi M, Yamada T, Sakurada T. Characterization of 
nociceptive responses and spinal releases of nitric oxide metabolites and glutamate 
evoked by different concentrations of formalin in rats. Pain 2001;92:107–15. 
Okuda-Ashitaka E, Ito S. Nocistatin: a novel neuropeptide encoded by the gene for 
the nociceptin/orphanin FQ precursor. Peptides 2000;21:1101-9. 
Okuda-Ashitaka E, Minami T, Tachibana S, Yoshihara Y, Nishiuchi Y, Kimura T, Ito 
S. Nocistatin, a peptide that blocks nociceptin action in pain transmission. Nature 
1998;392:286-9. 
Okuda-Ashitaka E, Tachibana S, Houtani T, Minami T, Masu Y, Nishi M, Takeshima 
H, Sugimoto T, Ito S. Identification and characterization of an endogenous ligand for 
opioid receptor homologue ROR-C : its involvement in allodynic response to 




Olofsson C, Ekblom A, Ekman-Ordeberg G, Irestedt L, Nyberg F, Ungerstedt U, 
Wiklund P. Increased cerebrospinal fluid concentration of aspartate but decreased 
concentration of nitric oxide breakdown products in women experiencing visceral 
pain during active labor. Neuroreport 1997;8:995-8. 
Osborne MG, Coderre TJ. Nociceptive effects of intrathecal administration of sulfur-
containing amino acids. Behav Brain Res 2003;144:105-10. 
Palazzo E, Genovese R, Mariani L, Siniscalco D, Marabese I, Novellis V, Rossi F, 
Maione S. Metabotropic glutamate receptor 5 and dorsal raphe serotonin release in 
inflammatory pain in rat. Eur J Pharmacol 2004;492:169-76. 
Palmada M, Centelles JJ. Excitatory amino acid neurotransmission, pathways for 
metabolism, storage and reuptake of glutamate in brain. Front Biosci 1998;3:d701-18. 
Paquet L, Rondeau N, Seidah NG, Lazure C, Chretien M, Mbikay M. Immunological 
identification and sequence characterization of a peptide derived from the processing 
of neuroendocrine protein 7B2. FEBS Lett 1991;294:23-6. 
Perez-Neri I, Montes S, Boll MC, Ramirez-Bermudez J, Rios C. Liquid 
chromatographic-fluorimetric method for the estimation of nitric oxide biosynthesis 
in the central nervous system. J chromatogr B 2004;806:133-9. 
Pesquero JB, Araujo RC, Heppenstall PA, Stucky CL, Silva JA Jr, Walther T, 
Oliveira SM, Pesquero JL, Paiva AC, Calixto JB, Lewin GR, Bader M. Hypoalgesia 
and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl 
Acad Sci U S A 2000;97:8140-5. 
Rainesalo S, Keranen T, Palmio J, Peltola J, Oja SS, Saransaari P. Plasma and 




Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, 
Grandy DK, Langen H, Monsma FJ Jr, Civelli O. Orphanin FQ: a neuropeptide that 
activates an opioid like G protein-coupled receptor. Science 1995;270:792-4. 
Renick SE, Kleven DT, Chan J, Stenius K, Milner TA, Pickel VM, Fremeau Jr RT. 
The mammalian brain high-affinity L-proline transporter is enriched preferentially in 
synaptic vesicles in a subpopulation of excitatory nerve terminals in rat forebrain. J 
Neurosci 1999;19:21-33. 
Rizzo V, Anesi A, Montalbetti L, Bellantoni G, Trotti R, Melzi d’Eril GV. Reference 
values of neuroactive amino acids in the cerebrospinal fluid by high-performance 
liquid chromatography with electrochemical detection and fluorescence detection. J 
Chromatogr A 1996;729:181-88. 
Rossi GC, Perlmutter M, Leventhal L, Talatti A, Pasternak GW. Orphanin 
FQ/nociceptin analgesia in the rat. Brain Res 1998;792:327-30. 
Rubio-Aliaga I, Boll M, Vogt Weisenhorn DM, Foltz M, Kottra G, Daniel H. The 
proton/amino acid cotransporter PAT2 is expressed in neurons with a different 
subcellular localization than its paralog PAT1. J Biol Chem 2004;279:2754-60. 
Ruppel RA, Kochanek PM, Adelson PD, Rose ME, Wisniewski SR, Bell MJ, Clark 
RS, Marion DW, Graham SH. Excitatory amino acid concentrations in ventricular 
cerebrospinal fluid after severe traumatic brain injury in infants and children: the role 
of child abuse. J Pediatr 2001;138:18-25. 
Sagne C, El Mestikawy S, Isambert MF, Hamon M, Henry JP, Giros B, Gasnier B. 
Cloning of a functional vesicular GABA and glycine transporter by screening of 




Sakurada T, Sugiyama A, Sakurada C, Tan-No K, Sakurada S, Kisara K, Hara A, 
Abiko Y. Involvement of nitric oxide in spinally mediated capsaicin- and glutamate-
induced behavioural responses in the mouse. Neurochem Int 1996;29:271–8. 
Salacinski PRP, McLean C, Sykes JEC, Clement-Jones VV, Lowry PJ. Iodination of 
proteins, glycoproteins and peptides using a solid-phase oxidizing agent, 1,3,4,6-
tetrachloro-3α,6α-diphenyl glycoluril (Iodogen). Anal Biochem 1981;117:136-46. 
Sang CN. NMDA-receptor antagonists in neuropathic pain: experimental methods to 
clinical trials. J Pain Symptom Manage 2000;19 Suppl 1:S21-S25. 
Sarwar G, Botting HG. Evaluation of liquid chromatographic analysis of nutritionally 
important amino acids in food and physiological samples. J Chromatogr B 
1993;615:1-22. 
Sato J, Perl ER. Adrenergic excitation of cutaneous pain receptors induced by 
peripheral nerve injury. Science 1991;251:1608-10. 
Sawynok J, Liu XJ. Adenosine in the spinal cord and periphery: release and 
regulation of pain. Prog Neurobiol 2003;69:313-40. 
Scholz J, Woolf CJ. Can we conquer pain? Nat Neurosci 2002;5 Suppl:1062-7. 
Schulz-Knappe P,  Zucht HD, Heine G, Jurgens M, Hess R, Schrader M. Peptidomics: 
The comprehensive Analysis of peptides in complex biological mixtures. Comb 
Chem High Throughput Screen 2001;4:207-17. 
Sethuraman R, Lee TL, Tachibana S. Simple quantitative HPLC method for 





Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V. The 
Tachykinin peptide family. Pharmacol Rev 2002;54:285-322. 
Simmons WW, Closs EI, Cunningham JM, Smith TW, Kelly RA. Cytokines and 
insulin induce cationic amino acid transporter (CAT) expression in cardiac myocytes. 
Regulation of L-arginine transport and NO production by CAT-1, CAT-2A and CAT-
2B. J Biol Chem 1996;271:11694-702. 
Simpson Jr. RK, Gondo M, Robertson C, Goodman JC. Reduction in the 
mechanonociceptive response by intrathecal administration of glycine and related 
compounds. Neurochem Res 1996;21:1221-6. 
Simpson Jr. RK, Gondo M, Robertson C, Goodman JC. Reduction in thermal 
hyperalgesia by intrathecal administration of glycine and related compounds. 
Neurochem Res 1997;22:75-9.      
Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: 
an update and effect related to mechanism of drug action. Pain 1999;83:389-400. 
Smith JB, Ogonowski AA. Behavioral effects of NMDA receptor agonists and 
antagonists in combination with nitric oxide – related compounds. Eur J Pharmacol 
2003;471:121-8. 
Spink DC, Swann JW, Snead OC, Waniewski RA, Martin DL. Analysis of aspartate 
and glutamate in human cerebrospinal fluid by high-performance liquid 





Stark M, Danielsson O, Griffiths WJ, Jornvall H, Johansson J. Peptide repertoire of 
human cerebrospinal fluid: novel proteolytic fragments of neuroendocrine proteins. J 
Chromatogr B 2001;754:357-67. 
Strafella AP, Paus T, Fraraccio M, Dagher A. Striatal dopamine release induced by 
repetitive transcranial magnetic stimulation of the human motor cortex. Brain 
2003;126:2609-12. 
Sullivan AF, Dashwood MR, Dickenson AH. α2-Adrenoceptor modulation of 
nociception in rat spinal cord: location, effecrs and interactions with morphine. Eur J 
Pharmacol 1987;138:169-77. 
Syriatowicz JP, Hu D, Walker JS, Tracey DJ. Hyperalgesia due to nerve injury: role 
of prostaglandins. Neuroscience 1999;94:587–94. 
Takei Y, Ando K, Kawakami M. Atrial natriuretic peptide in eel plasma, heart and 
brain characterized by homologous radioimmunoassay. J Endocrinol 1992;135:325-
31. 
Tapiero H, Mathe G, Couvereur P, Tew KD. Free amino acids in human health and 
pathologies. II Glutamine and glutamate. Biomed Pharmacother 2002;56:446-57. 
Tapiero H, Mathe G, Couvereur P, Tew KD. Free amino acids in human health and 
pathologies. I Arginine. Biomed Pharmacother 2002;56:439-45. 
Taupenot L, Harper KL, O’Connor DT. The chromogranin-secretogranin family. N 
Engl J Med 2003;348:1134-49. 





Tian JH, Fang Y, Mogil JS, Grisel JE, Grandy DK, Han JS. Bidirectional modulatory 
effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and 
potentiation in spinal cord of rat. Br J Pharmacol 1997;120:676–80. 
Ulus IH, Wurtman RJ. Metabotropic glutamate receptor agonists increase release of 
soluble amyloid precursor protein derivatives from rat brain cortical and hippocampal 
slices. J Pharmacol Exp Ther 1996;281:149-54. 
Van Horssen AM, Van den Hurk WH, Bailyes EM, Hutton JC, Martens GJM, 
Lindberg I. Identification of the region within the neuroendocrine polypeptide 7B2 
responsible for the inhibition of prohormone convertase PC2. J Biol Chem 
1995;270:14292-96. 
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-
like drugs. Nat New Biol 1971;231:232–5. 
Vendrell J, Aviles FX. Complete amino acid analysis of proteins by dabsyl 
derivatization and reversed-phase liquid chromatography. J. Chromatogr 
1986;358:401-13. 
Viggiano A, Monda M, Viggiano A, Chiefari M, Aurilio C, De Luca B. Evidence that 
GABAergic neurons in the spinal trigeminal nucleus are involved in the transmission 
of inflammatory pain in the rat : a microdialysis and pharmacological study. Eur J 
Pharmacol 2004;496:87-92. 
Vollenweider FX, Cuenod M, Do KQ. Effect of climbing fiber deprivation on release 
of endogenous aspartate, glutamate and homocysteate in slices of rat cerebellar 




Walker K, Fox AJ, Urban LA. Animal models for pain research. Mol Med Today 
1999;5:319-21. 
Wang J, Rousseau DL, Abu-Soud HM, Stuehr DJ. Heme coordination of NO in NO 
synthase. Proc Natl Acad Sci USA 1994;91:10512–16. 
Wang ZM, Katsurabayashi S, Rhee JS, Brodwick M, Akaike N. Substance P 
abolishes the facilitatory effect of ATP on spontaneous glycine release in neurons of 
the trigeminal nucleus pars caudalis. J Neurosci 2001;21:2983-91. 
Watanabe A, Semba J, Kurumaji A, Kumashiro S, Toru M. Measurement of 
glutamate, aspartate and glycine and its potential precursors in human brain using 
high-performance liquid chromatography by pre-column derivatization with 
diethylaminoazobenzene sulphonylchloride [Short communication]. J.Chromatogr 
1992;583:241-5. 
Wen ZH, Yang LC, Wang JJ, Chang YC, Hsing CH, Chen JY, Wong CS. Intrathecal 
pertussis toxin induces thermal hyperalgesia: involvement of excitatory and inhibitory 
amino acids. Neurosci 2003;116:871-78. 
Werman R, Davidoff RA, Aprison MH. Inhibition of motoneurons by ionotophoresis 
of glycine. Nature 1967;214:681-3. 
Wiesinger H. Arginine metabolism and the synthesis of nitric oxide in the nervous 
system. Prog Neurobiol 2001;64:365-91. 
Witta J, Palkovits M, Rosenberger J, Cox BM. Distribution of nociceptin/orphanin 
FQ in adult human brain. Brain Res 2004;997:24-9. 
Wong PTH, Lee HS, Tan CH, Teo WL. Specific [3H]Tryptophan binding sites in rat 




Woolf CJ. Pain: Moving from symptom control toward mechanism-specific 
pharmacologic management. Ann Intern Med 2004;140:441-51. 
Yaksh TL, Hua XY, Kalcheva I, Nozaki-Taguchi N, Marsala M. The spinal biology 
in humans and animals of pain states generated by persistent small afferent input. 
Proc. Natl. Acad. Sci. USA 1999;96:7680-6. 
Yaksh TL. Pharmacology and mechanisms of opioid analgesic activity. Acta 
Anaesthesiol Scand 1997;41:94-111.  
Yaksh TL. Pharmacology of spinal adrenergic systems which modulate spinal 
nociceptive processing. Pharmacol Biochem Behav 1985;22:845-58. 
Yaksh TL. Spinal opiate analgesia: Characteristics and principles of action. Pain 
1981;11:293–346. 
Yamamoto T, Shimoyama N, Mizuguchi T. Nitric oxide synthase inhibitor blocks 
spinal sensitization induced by formalin injection into the rat paw. Anesth Analg 
1993;77:886–90. 
Yamamura HI, Enna SJ, Kuhar MJ. (1978) Neurotransmitter receptor binding. Eds., 
Raven Press, New York. 
Ye ZC, Sontheimer H. Metabotropic glutamate receptor agonists reduce glutamate 
release from cultured astrocytes. Glia 1999;25:270-81. 
Young AP, Young HP. (1997) Velker J (ed) Basic clinical neuroanatomy. Williams & 
Wilkins, Maryland, pp 128 –51. 
Zadina JE, Hackler L, Ge LJ, Kastin AJ. A potent and selective endogenous agonist 




Zhang H, Zhai S D, Li Y M, Chen L R. Effect of different sample pretreatment 
methods on the concentrations of excitatory amino acids in cerebrospinal fluid 
determined by high-performance liquid chromatography. J Chromatogr B 
2003;784:131-5. 
Zhang H, Zhang X, Zhang T, Chen L. Excitatory amino acids in cerebrospinal fluid 
of patients with acute head injuries. Clin Chem 2001;47:1458-62. 
Zhang ZH, Yang SW, Chen JY, Xie YF, Qiao JT, Dafny N. Interaction of serotonin 
and norepinephrine in spinal antinociception. Brain Res Bull 1995;38:167-71.  
Zhu X, Rouille Y, Lamango NS, Steiner DF, Lindberg I. Internal cleavage of the 
inhibitory 7B2 carboxyl-terminal peptide by PC2 : A potential mechanism for its 
inactivation. Proc. Natl. Acad. Sci. USA 1996;93:4919-24. 
 
 
 
 
 
